0001638833-24-00014710-Q Surgery Partners, Inc. 20241112202411121618571857161857161857 0 0001638833-24-000147 10-Q 69 20240930 20241112 20241112 Surgery Partners, Inc. 0001638833 8062 473620923 DE 1231 10-Q 34 001-37576 241448521 310 SEVEN SPRINGS WAY SUITE 500 BRENTWOOD TN 37027 615-234-5900 310 SEVEN SPRINGS WAY SUITE 500 BRENTWOOD TN 37027 10-Q 1 sgry-20240930.htm 10-Q sgry-20240930000016388332024Q3False12/31http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNetxbrli:sharesiso4217:USDiso4217:USDxbrli:sharessgry:facilitysgry:statexbrli:puresgry:physician_practicesgry:surgical_facilitysgry:de_novo_su01-012024-09-300001638833 2024-11-05 0001638833 2024-09-30 0001638833 2023-12-31 0001638833 2024-07-01 2024-09-30 0001638833 2023-07-01 2023-09-30 0001638833 2023-01-01 2023-09-30 0001638833us-gaap:CommonStockMember 2023-12-31 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001638833us-gaap:RetainedEarningsMember 2023-12-31 0001638833us-gaap:NoncontrollingInterestMember 2023-12-31 0001638833us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001638833us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001638833 2024-01-01 2024-03-31 0001638833us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001638833us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001638833us-gaap:CommonStockMember 2024-03-31 0001638833us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001638833us-gaap:RetainedEarningsMember 2024-03-31 0001638833us-gaap:NoncontrollingInterestMember 2024-03-31 0001638833 2024-03-31 0001638833us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001638833us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001638833 2024-04-01 2024-06-30 0001638833us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-04-01 2024-06-30 0001638833us-gaap:CommonStockMember 2024-06-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-06-30 0001638833us-gaap:RetainedEarningsMember 2024-06-30 0001638833us-gaap:NoncontrollingInterestMember 2024-06-30 0001638833 2024-06-30 0001638833us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001638833us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001638833us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-07-01 2024-09-30 0001638833us-gaap:CommonStockMember 2024-09-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0001638833us-gaap:RetainedEarningsMember 2024-09-30 0001638833us-gaap:NoncontrollingInterestMember 2024-09-30 0001638833us-gaap:CommonStockMember 2022-12-31 0001638833us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001638833us-gaap:RetainedEarningsMember 2022-12-31 0001638833us-gaap:NoncontrollingInterestMember 2022-12-31 0001638833 2022-12-31 0001638833us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001638833us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001638833 2023-01-01 2023-03-31 0001638833us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001638833us-gaap:CommonStockMember 2023-03-31 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001638833us-gaap:RetainedEarningsMember 2023-03-31 0001638833us-gaap:NoncontrollingInterestMember 2023-03-31 0001638833 2023-03-31 0001638833us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001638833us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001638833 2023-04-01 2023-06-30 0001638833us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0001638833us-gaap:CommonStockMember 2023-06-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001638833us-gaap:RetainedEarningsMember 2023-06-30 0001638833us-gaap:NoncontrollingInterestMember 2023-06-30 0001638833 2023-06-30 0001638833us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001638833us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001638833us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2023-09-30 0001638833us-gaap:CommonStockMember 2023-09-30 0001638833us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001638833us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0001638833us-gaap:RetainedEarningsMember 2023-09-30 0001638833us-gaap:NoncontrollingInterestMember 2023-09-30 0001638833 2023-09-30 0001638833sgry:FacilitiesAmbulatorySurgeryCentersMember 2024-09-30 0001638833sgry:FacilitiesSurgicalHospitalsMember 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:SurgicalFacilityServicesMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:SurgicalFacilityServicesMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:SurgicalFacilityServicesMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:SurgicalFacilityServicesMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:AncillaryServicesMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:AncillaryServicesMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:AncillaryServicesMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:AncillaryServicesMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:OtherServicesMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:OtherServicesMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:OtherServicesMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMembersgry:OtherServicesMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833sgry:PrivateInsuranceMember 2024-07-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:PrivateInsuranceMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833sgry:PrivateInsuranceMember 2023-07-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:PrivateInsuranceMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833sgry:GovernmentRevenueMember 2024-07-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:GovernmentRevenueMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833sgry:GovernmentRevenueMember 2023-07-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:GovernmentRevenueMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833sgry:SelfPayRevenueMember 2024-07-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:SelfPayRevenueMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833sgry:SelfPayRevenueMember 2023-07-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:SelfPayRevenueMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833sgry:OtherPatientServiceRevenueSourcesMember 2024-07-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:OtherPatientServiceRevenueSourcesMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833sgry:OtherPatientServiceRevenueSourcesMember 2023-07-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:OtherPatientServiceRevenueSourcesMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833sgry:HealthcareOrganizationPatientServiceMember 2024-07-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001638833sgry:HealthcareOrganizationPatientServiceMember 2023-07-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001638833sgry:OtherServicesMember 2024-07-01 2024-09-30 0001638833sgry:OtherServicesMember 2023-07-01 2023-09-30 0001638833sgry:PrivateInsuranceMember 2024-01-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:PrivateInsuranceMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833sgry:PrivateInsuranceMember 2023-01-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:PrivateInsuranceMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833sgry:GovernmentRevenueMember 2024-01-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:GovernmentRevenueMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833sgry:GovernmentRevenueMember 2023-01-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:GovernmentRevenueMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833sgry:SelfPayRevenueMember 2024-01-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:SelfPayRevenueMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833sgry:SelfPayRevenueMember 2023-01-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:SelfPayRevenueMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833sgry:OtherPatientServiceRevenueSourcesMember 2024-01-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:OtherPatientServiceRevenueSourcesMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833sgry:OtherPatientServiceRevenueSourcesMember 2023-01-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:OtherPatientServiceRevenueSourcesMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833sgry:HealthcareOrganizationPatientServiceMember 2024-01-01 2024-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001638833sgry:HealthcareOrganizationPatientServiceMember 2023-01-01 2023-09-30 0001638833us-gaap:CustomerConcentrationRiskMembersgry:HealthcareOrganizationPatientServiceMemberus-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001638833sgry:OtherServicesMember 2024-01-01 2024-09-30 0001638833sgry:OtherServicesMember 2023-01-01 2023-09-30 0001638833sgry:A2017TermLoanMaturing2024Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMember 2024-09-30 0001638833sgry:A2017TermLoanMaturing2024Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMember 2023-12-31 0001638833us-gaap:FairValueInputsLevel2Membersgry:A2017TermLoanMaturing2024Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember 2024-09-30 0001638833us-gaap:FairValueInputsLevel2Membersgry:A2017TermLoanMaturing2024Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember 2023-12-31 0001638833sgry:SeniorUnsecuredNotesDue2025Memberus-gaap:SeniorNotesMember 2023-12-31 0001638833sgry:SeniorUnsecuredNotesDue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-09-30 0001638833sgry:SeniorUnsecuredNotesDue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2023-12-31 0001638833us-gaap:FairValueInputsLevel2Membersgry:SeniorUnsecuredNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-09-30 0001638833us-gaap:FairValueInputsLevel2Membersgry:SeniorUnsecuredNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2023-12-31 0001638833sgry:SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember 2023-12-31 0001638833sgry:SeniorUnsecuredNotesDue2027Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-09-30 0001638833sgry:SeniorUnsecuredNotesDue2027Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2023-12-31 0001638833us-gaap:FairValueInputsLevel2Membersgry:SeniorUnsecuredNotesDue2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-09-30 0001638833us-gaap:FairValueInputsLevel2Membersgry:SeniorUnsecuredNotesDue2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2023-12-31 0001638833sgry:SeniorUnsecuredNotesDue2032Memberus-gaap:SeniorNotesMember 2024-09-30 0001638833sgry:SeniorUnsecuredNotesDue2032Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-09-30 0001638833sgry:SeniorUnsecuredNotesDue2032Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2023-12-31 0001638833us-gaap:FairValueInputsLevel2Membersgry:SeniorUnsecuredNotesDue2032Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-09-30 0001638833us-gaap:FairValueInputsLevel2Membersgry:SeniorUnsecuredNotesDue2032Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2023-12-31 0001638833us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-09-30 0001638833us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-12-31 0001638833sgry:SurgicalFacilitiesAndAnesthesiaPracticeMember 2024-01-01 2024-09-30 0001638833sgry:SurgicalFacilitiesAndAnesthesiaPracticeMember 2024-09-30 0001638833sgry:SurgicalFacilitiesAndPhysicianPracticesMember 2023-01-01 2023-09-30 0001638833sgry:SurgicalFacilitiesAndPhysicianPracticesMember 2023-09-30 0001638833sgry:SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilityMember 2023-01-01 2023-09-

300001638833sgry:SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilityMember2023-09-300001638833us-gaap:EquityMethodInvestmentsMember2023-01-012023-09-300001638833sgry:SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilitiesMember2023-01-012023-09-300001638833sgry:SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilitiesMembersgry:ManagementRightsAgreementMember2023-09-300001638833sgry:SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilitiesMembersgry:ManagementRightsAgreementMemberus-gaap:EquityMethodInvestmentsMember2023-01-012023-09-300001638833us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersgry:SurgicalFacilityEquityMethodInvestmentMember2024-01-012024-09-300001638833us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersgry:SurgicalFacilityWithARetainedInterestMember2024-01-012024-09-300001638833us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersgry:SurgicalFacilityMember2024-01-012024-09-300001638833us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersgry:A2023Disposalsmember2023-01-012023-09-300001638833us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersgry:SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilitiesMember2023-01-012023-09-300001638833sgry:A2017TermLoanMaturing2024Memberus-gaap:SecuredDebtMember2024-09-300001638833sgry:A2017TermLoanMaturing2024Memberus-gaap:SecuredDebtMember2023-12-310001638833sgry:A2017SeniorSecuredCreditFacilityMemberus-gaap:SecuredDebtMember2024-09-300001638833sgry:A2017SeniorSecuredCreditFacilityMemberus-gaap:SecuredDebtMember2023-12-310001638833sgry:SeniorUnsecuredNotesDue2025Memberus-gaap:SeniorNotesMember2024-09-300001638833sgry:SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2024-09-300001638833sgry:SeniorUnsecuredNotesDue2032Memberus-gaap:SeniorNotesMember2023-12-310001638833sgry:NotesPayableAndSecuredLoansMember2024-09-300001638833sgry:NotesPayableAndSecuredLoansMember2023-12-310001638833sgry:A2017SeniorSecuredCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2024-09-300001638833sgry:CreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2024-09-300001638833sgry:CreditFacilityMemberus-gaap:LetterOfCreditMemberus-gaap:SecuredDebtMember2024-09-300001638833sgry:SeniorUnsecuredNotesDue2032Memberus-gaap:SeniorNotesMember2024-04-100001638833sgry:SeniorUnsecuredNotesDue2025Memberus-gaap:SeniorNotesMember2024-04-100001638833sgry:SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2024-04-100001638833sgry:SeniorUnsecuredNotesDue2032Memberus-gaap:SeniorNotesMember2024-01-012024-09-300001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMember2024-06-200001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMembersgry:TermRateBasedSecuredOvernightFinancingRateSOFRMember2024-06-202024-06-200001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMemberus-gaap:FederalFundsEffectiveSwapRateMember2024-06-202024-06-200001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-06-202024-06-200001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMemberus-gaap:BaseRateMember2024-06-202024-06-200001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMember2024-06-202024-06-200001638833sgry:A2024RefinancingTermLoansMemberus-gaap:SecuredDebtMember2024-01-012024-09-300001638833sgry:PayFixedSwapOneMember2024-09-300001638833sgry:PayFixedSwapOneMember2023-12-310001638833sgry:PayFixedSwapTwoMember2024-09-300001638833sgry:PayFixedSwapTwoMember2023-12-310001638833sgry:PayFixedSwapThreeMember2024-09-300001638833sgry:PayFixedSwapThreeMember2023-12-310001638833sgry:InterestRateCapOneMember2024-09-300001638833sgry:InterestRateCapOneMember2023-12-310001638833sgry:InterestRateCapTwoMember2024-09-300001638833sgry:InterestRateCapTwoMember2023-12-310001638833sgry:DeferredPremiumCap1Member2024-09-300001638833sgry:DeferredPremiumCap1Member2023-12-310001638833sgry:DeferredPremiumCap2Member2024-09-300001638833sgry:DeferredPremiumCap2Member2023-12-310001638833sgry:DeferredPremiumCap3Member2024-09-300001638833sgry:DeferredPremiumCap3Member2023-12-310001638833sgry:DeferredPremiumCap4Member2024-09-300001638833sgry:DeferredPremiumCap4Member2023-12-310001638833sgry:DeferredPremiumCap5Member2024-09-300001638833sgry:DeferredPremiumCap5Member2023-12-310001638833us-gaap:InterestRateSwapMember2024-09-300001638833us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001638833us-gaap:InterestRateSwapMembersrt:MinimumMember2024-09-300001638833us-gaap:InterestRateCapMember2024-09-300001638833us-gaap:InterestRateCapMemberus-gaap:NondesignatedMember2023-01-012023-09-300001638833sgry:DeferredPremiumCapMember2024-04-090001638833sgry:DeferredPremiumCapMember2024-09-300001638833us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001638833us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001638833us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001638833us-gaap:NondesignatedMember2024-07-012024-09-300001638833us-gaap:NondesignatedMember2023-07-012023-09-300001638833us-gaap:NondesignatedMember2024-01-012024-09-300001638833us-gaap:NondesignatedMember2023-01-012023-09-300001638833us-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001638833us-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001638833us-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001638833us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001638833us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001638833us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001638833us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001638833us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001638833us-gaap:RestrictedStockMember2024-07-012024-09-300001638833us-gaap:RestrictedStockMember2023-07-012023-09-300001638833us-gaap:RestrictedStockMember2024-01-012024-09-300001638833us-gaap:RestrictedStockMember2023-01-012023-09-300001638833us-gaap:OperatingSegmentsMembersgry:SurgicalFacilityServicesMember2024-07-012024-09-300001638833us-gaap:OperatingSegmentsMembersgry:SurgicalFacilityServicesMember2023-07-012023-09-300001638833us-gaap:OperatingSegmentsMembersgry:SurgicalFacilityServicesMember2024-01-012024-09-300001638833us-gaap:OperatingSegmentsMembersgry:SurgicalFacilityServicesMember2023-01-012023-09-300001638833us-gaap:OperatingSegmentsMembersgry:AncillaryServicesMember2024-07-012024-09-300001638833us-gaap:OperatingSegmentsMembersgry:AncillaryServicesMember2023-07-012023-09-300001638833us-gaap:OperatingSegmentsMembersgry:AncillaryServicesMember2024-01-012024-09-300001638833us-gaap:OperatingSegmentsMembersgry:AncillaryServicesMember2023-01-012023-09-300001638833us-gaap:CorporateNonSegmentMember2024-07-012024-09-300001638833us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001638833us-gaap:CorporateNonSegmentMember2024-01-012024-09-300001638833us-gaap:CorporateNonSegmentMember2023-01-012023-09-300001638833us-gaap:OperatingSegmentsMembersgry:SurgicalFacilityServicesMember2024-09-300001638833us-gaap:OperatingSegmentsMembersgry:SurgicalFacilityServicesMember2023-12-310001638833us-gaap:OperatingSegmentsMembersgry:AncillaryServicesMember2024-09-300001638833us-gaap:OperatingSegmentsMembersgry:AncillaryServicesMember2023-12-310001638833us-gaap:CorporateNonSegmentMember2024-09-300001638833us-gaap:CorporateNonSegmentMember2023-12-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,Â D.C. 20549_____FormÂ 10-Q_____(Mark One)â˜´ Â Â Â Â QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended SeptemberÂ 30, 2024 orâ˜Â Â Â Â TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934Commission file number:Â 001-37576Surgery Partners, Inc.(Exact name of registrant as specified in its charter)DelawareÂ 47-3620923(State or other jurisdiction ofincorporation or organization)Â (I.R.S. EmployerIdentification No.)340 Seven Springs Way, SuiteÂ 600Brentwood, TennesseeÂ 37027(Address of Principal Executive Offices)(Zip Code)(615) 234-5900(Registrantâ€™s telephone number, including area code)_____Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.01 per shareSGRYThe Nasdaq Global Select MarketIndicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days.Â Â YesÂ Â â˜´Â Â NoÂ Â Â â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â YesÂ Â Â â˜´ NoÂ Â Â â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.Â Large accelerated filerÂ Â â˜´Â Accelerated filerÂ Â â˜Non-accelerated filerÂ Â â˜Â Smaller reporting companyÂ Â â˜Emerging growth companyÂ Â â˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act).Â Â Â YesÂ Â â˜Â Â NoÂ Â Â â˜´As of NovemberÂ 5, 2024, there were 127,113,514 shares of the registrantâ€™s common stock outstanding.SURGERY PARTNERS, INC. FORM 10-QTABLE OF CONTENTSPagePART I - FINANCIAL INFORMATIONItem 1.Financial Statements1Condensed Consolidated Balance Sheets (Unaudited)1Condensed Consolidated Statements of Operations (Unaudited)2Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)3Condensed Consolidated Statements of Stockholders' Equity (Unaudited)4Condensed Consolidated Statements of Cash Flows (Unaudited)6Notes to Condensed Consolidated Financial Statements (Unaudited)7Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28PART II - OTHER INFORMATIONItem 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds29Item 3.Defaults Upon Senior Securities29Item 4.Mine Safety Disclosures29Item 5.Other Information29Item 6.Exhibits29Signatures30Table of ContentsPART I - FINANCIAL INFORMATIONItem 1. Financial StatementsSURGERY PARTNERS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS(Dollars in millions, except per share amounts)(Unaudited)September 30,2024December 31,2023ASSETSCurrent assets:Cash and cash equivalents$221.8Â $195.9Â Accounts receivable542.9Â 496.4Â Inventories82.0Â 75.2Â Prepaid expenses45.2Â 31.0Â Other current assets143.9Â 96.5Â Total current assets1,035.8Â 895.0Â Property and equipment, net of accumulated depreciation of $558.8 and $454.4, respectively1,004.5Â 968.7Â Goodwill and other intangible assets, net4,861.5Â 4,380.8Â Investments in and advances to affiliates214.8Â 184.1Â Right-of-use operating lease assets297.5Â 255.3Â Long-term deferred tax assets79.2Â 89.5Â Other long-term assets41.1Â 103.3Â Total assets$7,534.4Â $6,876.7Â LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$170.8Â $171.8Â Accrued payroll and benefits64.9Â 73.8Â Other current liabilities242.2Â 204.1Â Current maturities of long-term debt97.3Â 73.3Â Total current liabilities575.2Â 523.0Â Long-term debt, less current maturities3,094.2Â 2,701.8Â Right-of-use operating lease liabilities286.4Â 248.9Â Other long-term liabilities30.3Â 41.1Â Non-controlling interestsâ€”redeemable436.4Â 327.4Â Stockholders' equity:Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - noneâ€”Â â€”Â Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 127,127,901 and 126,593,727, respectively1.3Â 1.3Â Additional paid-in capital2,513.5Â 2,497.6Â Accumulated other comprehensive income10.5Â 57.5Â Retained deficit(628.8)(569.2)Total Surgery Partners, Inc. stockholders' equity1,896.5Â 1,987.2Â Non-controlling interestsâ€”non-redeemable1,215.4Â 1,047.3Â Total stockholders' equity3,111.9Â 3,034.5Â Total liabilities and stockholders' equity$7,534.4Â $6,876.7Â See notes to unaudited condensed consolidated financial statements.1Table of ContentsSURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited, dollars in millions, except per share amounts; shares in thousands)Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Revenues$770.4Â $674.1Â $2,249.9Â $2,007.9Â Operating expenses:Salaries and benefits228.4Â 195.0Â 666.8Â 592.4Â Supplies201.4Â 179.2Â 589.9Â 549.8Â Professional and medical fees91.0Â 72.4Â 266.0Â 219.9Â Lease expense23.9Â 21.1Â 67.5Â 64.3Â Other operating expenses48.2Â 40.6Â 147.7Â 127.6Â Cost of revenues592.9Â 508.3Â 1,737.9Â 1,554.0Â General and administrative expenses29.2Â 36.8Â 102.7Â 100.0Â Depreciation and amortization50.2Â 28.9Â 118.7Â 87.0Â Transaction and integration costs29.4Â 12.8Â 66.1Â 37.3Â Net loss on disposals, consolidations and deconsolidations14.7Â 5.8Â 21.5Â 7.5Â Equity in earnings of unconsolidated affiliates(5.2)(3.5)(12.3)(9.4)Litigation settlements0.5Â 3.6Â (0.8)8.1Â Loss on debt extinguishmentâ€”Â â€”Â 5.1Â â€”Â Other income, net(2.2)(1.2)(10.7)(3.2)709.5Â 591.5Â 2,028.2Â 1,781.3Â Operating income60.9Â 82.6Â 221.7Â 226.6Â Interest expense, net(50.0)(49.8)(148.8)(144.3)Income before income taxes10.9Â 32.8Â 72.9Â 82.3Â Income tax (expense) benefit(4.5)(3.1)(13.8)6.3Â Net income6.4Â 29.7Â 59.1Â 88.6Â Less: Net income attributable to non-controlling interests(38.1)(34.6)(118.7)(99.5)Net loss attributable to Surgery Partners, Inc.(31.7)(4.9)(59.6)(10.9)Net loss per share attributable to common stockholders:Basic(0.25)(0.04)(0.47)(0.09)Diluted (1)(0.25)(0.04)(0.47)(0.09)Weighted average common shares outstanding: Basic126,172Â 125,747Â 126,093Â 125,559Â Diluted (1)126,172Â 125,747Â 126,093Â 125,559Â (1)The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.See notes to unaudited condensed consolidated financial statements.2Table of ContentsSURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(Unaudited, dollars in millions)Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Net income$6.4Â $29.7Â $59.1Â $88.6Â Other comprehensive (loss) income, net of tax:Derivative activity, net of tax of $0(26.6)(1.8)(47.0)0.8Â Comprehensive (loss) income(20.2)27.9Â 12.1Â 89.4Â Less: Comprehensive income attributable to non-controlling interests(38.1)(34.6)(118.7)(99.5)Comprehensive loss attributable to Surgery Partners, Inc.(58.3)(6.7)(106.6)(10.1)See notes to unaudited condensed consolidated financial statements.3Table of ContentsSURGERY PARTNERS, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited, dollars in millions, shares in thousands)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained DeficitNon-Controlling Interestsâ€” Non-RedeemableTotalSharesAmountBalance as of December 31, 2023126,594$1.3Â $2,497.6Â $57.5Â (569.2)1,047.3Â $3,034.5Â Net (loss) incomeâ€”â€”Â â€”Â â€”Â (12.4)29.3Â 16.9Â Equity-based compensation508â€”Â 4.9Â â€”Â â€”Â â€”Â 4.9Â Other comprehensive lossâ€”â€”Â â€”Â (5.5)â€”Â (5.5)Acquisition and disposal of shares of non-controlling interests, netâ€”â€”Â (6.9)â€”Â â€”Â 23.7Â 16.8Â Distributions to non-controlling interestsâ€”non-redeemable holdersâ€”â€”Â â€”Â â€”Â (29.7)(29.7)Balance as of March 31, 2024127,102$1.3Â $2,495.6Â $52.0Â (581.6)1,070.6Â $3,037.9Â Net (loss) incomeâ€”â€”Â â€”Â (15.5)35.5Â 20.0Â Equity-based compensation22â€”Â 15.1Â â€”Â â€”Â 15.1Â Other comprehensive lossâ€”â€”Â â€”Â (14.9)â€”Â (14.9)Acquisition and disposal of shares of non-controlling interests, netâ€”â€”Â 0.4Â â€”Â â€”Â 147.4Â 147.8Â Distributions to non-controlling interestsâ€”non-redeemable holdersâ€”â€”Â â€”Â â€”Â (29.6)(29.6)Balance as of June 30, 2024127,124$1.3Â $2,511.1Â $37.1Â (597.1)1,223.9Â $3,176.3Â Net (loss) incomeâ€”â€”Â â€”Â (31.7)34.7Â 3.0Â Equity-based compensation4â€”Â 7.0Â â€”Â â€”Â 7.0Â Other comprehensive lossâ€”â€”Â â€”Â (26.6)â€”Â (26.6)Acquisition and disposal of shares of non-controlling interests, netâ€”â€”Â (4.6)â€”Â â€”Â (11.7)(16.3)Distributions to non-controlling interestsâ€”non-redeemable holdersâ€”â€”Â â€”Â â€”Â â€”Â (31.5)(31.5)Balance as of September 30, 2024127,128$1.3Â $2,513.5Â $10.5Â (628.8)1,215.4Â $3,111.9Â See notes to unaudited condensed consolidated financial statements.4Table of ContentsSURGERY PARTNERS, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited, dollars in millions, shares in thousands)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained DeficitNon-Controlling Interestsâ€” Non-RedeemableTotalSharesAmountBalance as of December 31, 2022125,961$1.3Â $2,478.0Â $76.2Â (557.3)942.7Â $2,940.9Â Net (loss) incomeâ€”â€”Â â€”Â â€”Â (25.0)18.3Â (6.7)Equity-based compensation519â€”Â 3.7Â â€”Â â€”Â â€”Â 3.7Â Other comprehensive lossâ€”â€”Â â€”Â (11.3)â€”Â â€”Â (11.3)Acquisition and disposal of shares of non-controlling interests, netâ€”â€”Â (3.6)â€”Â â€”Â 49.7Â 46.1Â Distributions to non-controlling interestsâ€”non-redeemable holdersâ€”â€”Â â€”Â â€”Â (30.2)(30.2)Balance as of March 31, 2023126,480$1.3Â $2,478.1Â $64.9Â (582.3)980.5Â $2,942.5Â Net incomeâ€”â€”Â â€”Â â€”Â 19.0Â 27.6Â 46.6Â Equity-based compensation13â€”Â 4.5Â â€”Â â€”Â â€”Â 4.5Â Other comprehensive incomeâ€”â€”Â â€”Â 13.9Â â€”Â â€”Â 13.9Â Acquisition and disposal of shares of non-controlling interests, netâ€”â€”Â 18.8Â â€”Â â€”Â (19.7)(0.9)Distributions to non-controlling interestsâ€”non-redeemable holdersâ€”â€”Â â€”Â â€”Â â€”Â (23.8)(23.8)Balance as of June 30, 2023126,493$1.3Â $2,501.4Â $78.8Â (563.3)964.6Â $2,982.8Â Net (loss) incomeâ€”â€”Â â€”Â â€”Â (4.9)28.0Â 23.1Â Equity-based compensation(4)â€”Â 4.5Â â€”Â â€”Â â€”Â 4.5Â Other comprehensive lossâ€”â€”Â â€”Â (1.8)â€”Â â€”Â (1.8)Acquisition and disposal of shares of non-controlling interests, netâ€”â€”Â (11.4)â€”Â â€”Â 13.1Â 1.7Â Distributions to non-controlling interestsâ€”non-redeemable holdersâ€”â€”Â â€”Â â€”Â (23.8)(23.8)Balance as of September 30, 2023126,489$1.3Â $2,494.5Â $77.0Â (568.2)981.9Â $2,986.5Â See notes to unaudited condensed consolidated financial statements.4Table of ContentsSURGERY

PARTNERS, INC. [CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS](Unaudited, dollars in millions)Nine Months Ended September 30,20242023Cash flows from operating activities:Net income$59.1Â $88.6Â Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization118.7Â 87.0Â Non-cash lease expense29.2Â 26.4Â Non-cash interest expense, net4.8Â 19.8Â Equity-based compensation expense27.1Â 13.2Â Net loss on disposals, consolidations and deconsolidations21.5Â 7.5Â Loss on debt extinguishment5.1Â â€”Â Deferred income taxes10.3Â (10.8)Equity in earnings of unconsolidated affiliates, net of distributions received0.3Â (2.7)Changes in operating assets and liabilities, net of acquisitions and divestitures:Accounts receivable(31.2)(18.2)Medicare accelerated payments and deferred governmental grantsâ€”Â (1.2)Other operating assets and liabilities(56.2)21.6Â Net cash provided by operating activities188.7Â 231.2Â Cash flows from investing activities:Purchases of property and equipment(68.1)(69.0)Payments for acquisitions, net of cash acquired(291.2)(48.8)Proceeds from disposals of facilities and other assets1.5Â 25.8Â Purchases of equity investments(1.7)(50.2)Proceeds from sales of equity investments4.0Â 1.0Â Other investing activities(21.3)(26.3)Net cash used in investing activities(376.8)(167.5)Cash flows from financing activities:Principal payments on long-term debt(1,108.8)(107.1)Borrowings of long-term debt1,463.8Â 119.4Â Payments of debt issuance costs(15.1)(1.5)Distributions to non-controlling interest holders(122.4)(111.0)Proceeds related to ownership transactions with non-controlling interest holders5.6Â 0.7Â Other financing activities(9.1)(11.1)Net cash provided by (used in) financing activities214.0Â (110.6)Net increase (decrease) in cash and cash equivalents25.9Â (46.9)Cash and cash equivalents at beginning of period195.9Â 282.9Â Cash and cash equivalents at end of period$221.8Â $236.0Â See notes to unaudited condensed consolidated financial statements.5Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)1. Organization and Summary of Accounting PoliciesOrganizationSurgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services.Â The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including orthopedics and pain management, gastroenterology, ophthalmology, and general surgery.Â The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."As of SeptemberÂ 30, 2024, the Company owned or operated a portfolio of 166 surgical facilities, comprised of 147 ASCs and 19 surgical hospitals in 33 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.Â The Company owned a majority interest in 89 of these surgical facilities and consolidated 123 surgical facilities for financial reporting purposes.Basis of PresentationThe accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Companyâ€™s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Companyâ€™s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the "2023 Annual Report on Form 10-K"). Certain prior year amounts have been reclassified to conform with the current year presentation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation. Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.RevenuesThe Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.7Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)The following table presents a summary of revenues by service type as a percentage of total revenues:Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Patient service revenues:Surgical Facility Services 93.3Â %95.8Â %94.1Â %95.9Â %Ancillary Services4.4Â %2.4Â %4.0Â %2.5Â %Total patient service revenues97.7Â %98.2Â %98.1Â %98.4Â %Other service revenues2.3Â %1.8Â %1.9Â %1.6Â %Total revenues100.0Â %100.0Â %100.0Â %100.0Â %Patient service revenues.Â This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.Â The fee does not normally include professional fees charged by the patientâ€™s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (â€œCMSâ€) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses.Other service revenues. Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed. 8Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):Three Months Ended September 30,20242023Amount%Amount%Patient service revenues:Private insurance$393.2Â 52.2Â %$347.1Â 52.4Â %Government318.3Â 42.3Â %271.6Â 41.0Â %Self-pay19.7Â 2.6Â %16.9Â 2.6Â %Other (1)22.0Â 2.9Â %26.7Â 4.0Â %Total patient service revenues753.2Â 100.0Â %662.3Â 100.0Â %Other service revenues17.2Â 11.8Â Total revenues$770.4Â $674.1Â Nine Months Ended September 30,20242023Amount%Amount%Patient service revenues:Private insurance$1,152.2Â 52.2Â %$1,024.3Â 51.8Â %Government932.0Â 42.2Â %837.6Â 42.4Â %Self-pay60.2Â 2.7Â %49.6Â 2.5Â %Other (1)62.2Â 2.9Â %65.2Â 3.3Â %Total patient service revenues2,206.6Â 100.0Â %1,976.7Â 100.0Â %Other service revenues43.3Â 31.2Â Total revenues$2,249.9Â $2,007.9Â (1)Other is comprised of automobile liability, letters of protection and other payor types.Accounts ReceivableAccounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitalsâ€™ cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patientâ€™s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.Income TaxesThe Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected 9Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.The Company's effective tax rate was 18.9% for the nine months ended SeptemberÂ 30, 2024 compared to (7.7)% for the nine months ended SeptemberÂ 30, 2023. For the nine months ended SeptemberÂ 30, 2024, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Companyâ€™s valuation allowance attributable to interest expense limitations, state tax expense, and a discrete tax expense of $1.5Â million related to the valuation allowance impact of the Companyâ€™s impairment to an equity method investment. For the nine months ended SeptemberÂ 30, 2023, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Companyâ€™s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (i) $1.6Â million related to the vesting of restricted stock awards and (ii) $15.8Â million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.GoodwillGoodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions, disposals and deconsolidations for the nine months ended SeptemberÂ 30, 2024 is included in Note 2. "Acquisitions, Disposals and Deconsolidations."A summary of activity related to goodwill for the nine months ended SeptemberÂ 30, 2024 is as follows (in millions):Balance as of December 31, 2023$4,326.0Â Acquisitions, including post acquisition adjustments495.4Â Disposals(6.0)Balance as of September 30, 2024$4,815.4Â A detailed evaluation of potential impairment indicators was performed as of SeptemberÂ 30, 2024, which specifically considered recent changes in interest rates, inflation risk and market volatility. On the basis of available evidence as of SeptemberÂ 30, 2024, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Companyâ€™s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.Derivative Instruments and Hedging ActivitiesThe Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.10Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)Non-Controlling Interestsâ€”RedeemableEach partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.Â In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partnersâ€™ or physician minority membersâ€™, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of SeptemberÂ 30, 2024.Â The non-controlling interestsâ€”redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.A summary of activity related to redeemable non-controlling interests is as follows (in millions):Nine Months Ended September 30,20242023Balance at beginning of period$327.4Â $342.0Â Net income attributable to non-controlling

interestsâ€”redeemable19.2Â 25.6Â Acquisition and disposal of shares of non-controlling interests, netâ€”redeemable121.4Â (2.2)Distributions to non-controlling interest â€”redeemable holders(31.6)(33.2)Balance at end of period$436.4Â $332.2Â Fair Value of Financial InstrumentsThe fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:â€¢Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.â€¢Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.â€¢Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate their fair values under Level 3 calculations.A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):Carrying AmountFair ValueSeptember 30,2024December 31,2023September 30,2024December 31,2023Senior secured term loan$1,391.5Â $1,398.4Â $1,393.2Â $1,401.9Â 6.750% senior unsecured notes due 2025â€”Â $185.0Â $â€”Â $183.2Â 10.000% senior unsecured notes due 2027$â€”Â $320.0Â $â€”Â $321.2Â 7.250% senior unsecured notes due 2032$800.0Â $â€”Â $835.0Â $â€”Â The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.Variable Interest EntitiesThe condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "Consolidation." The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of SeptemberÂ 30, 2024, the Company's consolidated VIEs consisted of nine surgical facilities and 26 physician practices.The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, were $86.2 million and $65.3 million, respectively, and the total liabilities of the consolidated VIEs were $57.9 million and $41.2 million, respectively.11Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)Recent Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which requires enhanced disclosures of significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments in this ASU must be applied retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which establishes new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 and interim periods beginning after December 15, 2025. The amendments in this ASU may be applied prospectively or retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.2. Acquisitions, Disposals and DeconsolidationsAcquisitionsDuring the nine months ended SeptemberÂ 30, 2024:â€¢The Company acquired a controlling interest in six surgical facilities and several physician practices for aggregate cash consideration of $291.2Â million, net of cash acquired, and non-cash consideration of $1.1Â million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $293.2Â million, goodwill of $506.7Â million and investments and advances to affiliates of $44.6Â million related to an acquired surgical facility accounted for as an equity method investment.During the nine months ended SeptemberÂ 30, 2023:â€¢The Company acquired a controlling interest in two surgical facilities and one physician practice for aggregate cash consideration of $23.1Â million, net of cash acquired, and non-cash consideration of $1.3Â million, which consisted of non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $20.4Â million and goodwill of $39.7Â million.â€¢The Company acquired a controlling interest in two surgical facilities and one in-development de novo surgical facility, which were previously accounted for as equity method investments, for aggregate cash consideration of $26.9Â million, net of cash acquired. The Company also amended the operating agreement of a previously non-controlled surgical facility resulting in the Company obtaining a controlling interest in the facility. These transactions resulted in the consolidation of the previously non-consolidated entities. The previously held non-controlling interests were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $27.3Â million. As a result of increasing its ownership interest, the Company recognized a net loss of $7.1Â million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the consolidation of these facilities, the Company preliminarily recognized non-controlling interests of $55.1Â million and goodwill of $106.3Â million.â€¢The Company acquired non-controlling interests in five surgical facilities and two in-development de novo surgical facilities for aggregate cash consideration of $50.2Â million. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the condensed consolidated balance sheets. The Company also paid cash consideration of $21.0Â million to acquire management rights from the prior management service provider related to four of the aforementioned surgical facilities. Management rights agreements are accounted for and recorded as a component of intangibles assets, net in the accompanying condensed consolidated balance sheets. The cash paid to acquire the management rights is presented as a component of other investing activities on the condensed consolidated statements of cash flows.Disposals and DeconsolidationsDuring the nine months ended SeptemberÂ 30, 2024:â€¢The Company disposed of its non-controlling interests in one surgical facility, which was previously accounted for as an equity method investment, for cash proceeds of $2.0Â million. In connection with this transaction, the Company recognized a pre-tax loss of $3.7Â million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2024. 12Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€¢The Company sold a portion of its interests in one surgical facility for net cash proceeds of $2.5Â million. As a result of the transaction, the Company no longer controlled the previously controlled surgical facility but retained a non-controlling interest, resulting in the deconsolidation of the previously consolidated entity. This transaction resulted in a pretax net gain on deconsolidation of $2.7Â million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2024. The net gain was determined based on the difference between the net cash proceeds plus the fair value of the Companyâ€™s retained interests in the entity and the carrying values of both the tangible and intangible assets of the entity immediately prior to the transaction.â€¢The Company sold its interests in one surgical facility for a nominal amount of cash proceeds. In connection with the sale, the Company recognized a pre-tax loss of $3.4 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2024. â€¢The Company recognized a pre-tax loss of $10.0Â million related to an equity investment previously held at cost, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2024. During the nine months ended SeptemberÂ 30, 2023:â€¢The Company sold its interests in six surgical facilities for aggregate net cash proceeds of $30.4Â million, a portion of which was held in escrow pursuant to the purchase agreements for such transactions. In connection with these transactions, the Company recognized a pre-tax gain of $26.9Â million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2023.â€¢The Company disposed of its non-controlling interests in a surgical facility and an in-development de novo surgical facility, which were previously accounted for as equity method investments, for cash proceeds of $1.5Â million. In connection with these transactions, the Company recognized a pre-tax loss of $13.7Â million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2023.3. Long-Term Debt A summary of long-term debt follows (in millions):September 30,2024December 31,2023Senior secured term loan (1)$1,391.5Â $1,398.4Â Senior secured revolving credit facility98.0Â â€”Â 6.750% senior unsecured notes due 2025â€”Â 185.0Â 10.000% senior unsecured notes due 2027â€”Â 320.0Â 7.250% senior unsecured notes due 2032800.0Â â€”Â Notes payable and other secured loans212.5Â 205.2Â Finance lease obligations723.6Â 693.6Â Less: unamortized debt issuance costs and discounts(34.1)(27.1)Total debt3,191.5Â 2,775.1Â Less: current maturities97.3Â 73.3Â Total long-term debt$3,094.2Â $2,701.8Â (1)Includes unamortized fair value discount of $1.5 million and $1.6 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively.Revolving Credit FacilityAs of SeptemberÂ 30, 2024, the Company's availability on its $703.8 million senior secured revolving credit facility (the "Revolver") was $595.8 million (including letters of credit of $10.0 million). The increase in outstanding borrowings on the Revolver compared to DecemberÂ 31, 2023 was primarily due to the timing of acquisitions completed during 2024.13Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)7.250% Senior Unsecured Notes Due 2032On April 10, 2024, the Company completed the issuance and sale of $800.0Â million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes were issued pursuant to an Indenture dated April 10, 2024 by and among Surgery Center Holdings, Inc., certain subsidiaries of Surgery Center Holdings, Inc., as guarantors, and Wilmington Trust, National Association, as trustee. The 2032 Notes bear interest at an annual rate of 7.250% per year, payable semi-annually on April 15 and October 15 of each year, beginning on OctoberÂ 15, 2024. Proceeds from the sale of the 2032 Notes were used (i) to redeem all of the outstanding 6.750% senior unsecured notes due 2025 (the "2025 Notes") and the 10.000% senior unsecured notes due 2027 (the "2027 Notes," together with the 2025 Notes, the "Existing Notes"), (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes and (iv) for general corporate purposes, including to fund future acquisitions.In connection with this financing transaction, the Company recorded debt issuance costs and discount of $12.5Â million, and a debt extinguishment loss of $2.8Â million, which is included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2024. First Amendment to Credit AgreementOn June 20, 2024, the Company entered into a first amendment (the "Amendment") to its credit agreement, dated as of December 19, 2023, by and among Surgery Center Holdings, Inc., the Borrower, Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time (the "Credit Agreement") to provide for a new tranche of term loans under the Credit Agreement in an aggregate principal amount of $1,400Â million (the â€œ2024 Refinancing Term Loansâ€), which 2024 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), all as further set forth in the Amendment. The 2024 Refinancing Term Loans mature on December 19, 2030. The 2024 Refinancing Term Loans bear interest at a rate per annum equal to (x) the forward-looking term rate based on Secured Overnight Financing Rate (â€œTerm SOFRâ€) plus 2.75% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate plus 0.5% per annum above the federal funds effective rate and (ii) Term SOFR plus 1.00% per annum (which shall not be less than 1.00%)) plus 1.75% per annum. The 2024 Refinancing Term Loans amortize in equal quarterly installments of 0.25% of the aggregate original principal amount of the 2024 Refinancing Term Loans. Voluntary prepayments of the 2024 Refinancing Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except a 1.00% call premium in the case of certain repricing events occurring prior to the sixth month anniversary of the effective date of the Amendment).In connection with the Amendment, the Company recorded debt issuance costs and discount of $2.4Â million, and a debt extinguishment loss of $2.3Â million, which is included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations for the nine months ended SeptemberÂ 30, 2024. The loss on debt extinguishment includes the partial write-off of unamortized debt issuance costs and discounts.4. LeasesThe Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. 14Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions):Classification in Condensed Consolidated Balance SheetsSeptember 30, 2024December 31, 2023Assets:Operating lease assetsRight-of-use operating lease assets$297.5Â $255.3Â Finance lease assetsProperty and equipment, net of accumulated depreciation588.6Â 587.0Â Total leased assets$886.1Â $842.3Â Liabilities:Operating lease liabilities:CurrentOther current liabilities$41.4Â $37.6Â Long-termRight-of-use operating lease liabilities286.4Â 248.9Â Total operating lease liabilities327.8Â 286.5Â Finance lease liabilities:CurrentCurrent maturities of long-term debt29.5Â 25.4Â Long-termLong-term debt, less current maturities694.1Â 668.2Â Total finance lease liabilities723.6Â 693.6Â Total lease liabilities$1,051.4Â $980.1Â The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions):Nine Months Ended September 30,20242023Operating lease costs$50.1Â $48.7Â Finance lease costs:Amortization of leased assets47.5Â 29.0Â Interest on lease liabilities40.6Â 35.9Â Total finance lease costs88.1Â 64.9Â Variable and short-term lease costs18.1Â 16.3Â Total lease costs$156.3Â $129.9Â The following table presents supplemental cash flow information (in millions):Nine Months Ended September 30,20242023Cash paid for amounts included in the measurement of lease liabilities:Operating cash outflows from operating leases$48.0Â $47.2Â Operating cash outflows from finance leases$38.6Â $34.1Â Financing cash outflows from finance leases$24.4Â $19.3Â Right-of-use assets obtained in exchange for lease obligations:Operating leases$79.3Â $39.9Â Finance leases$40.8Â $108.7Â 5. Derivatives and Hedging Activities The Companyâ€™s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its 15Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)interest rate risk management strategy. During 2024 and 2023, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.The key terms of interest rate swaps and interest rate caps outstanding are presented below:September 30, 2024December 31, 2023DescriptionEffective DateNotional Amount (in millions)StatusNotional Amount (in millions)StatusMaturity DatePay-fixed swapMay 7, 2021$435.0Â Active$435.0Â ActiveMarch 31, 2025Pay-fixed swapMay 7, 2021330.0Â Active330.0Â ActiveMarch 31, 2025Pay-fixed swapMay 7, 2021435.0Â Active435.0Â ActiveMarch 31, 2025Interest rate capSeptember 30, 2021145.6Â Active151.4Â ActiveMarch 31, 2025Interest rate capSeptember 30, 20218.3Â Active8.7Â ActiveMarch 31, 2025Deferred premium capMarch 31, 2025396.0Â Activeâ€”Â N/ADecember 31, 2028Deferred premium capMarch 31, 2025198.0Â Activeâ€”Â N/ADecember 31, 2028Deferred premium capMarch 31, 2025396.0Â Activeâ€”Â N/ADecember 31, 2028Deferred premium capMarch 31, 2025198.0Â Activeâ€”Â N/ADecember 31, 2028Deferred premium capMarch 31, 2025198.0Â Activeâ€”Â N/ADecember 31, 2028$2,739.9Â $1,360.1Â As of SeptemberÂ 30, 2024, the Company had three interest rate swaps with a total net notional amount of $1.2Â billion. The interest rate swaps are pay-fixed, receive 1-Month Secured Overnight Financing Rate ("SOFR") (subject to a minimum of 0.75%) designated in cash flow hedging relationships and have a termination date of March 31, 2025. As of SeptemberÂ 30, 2024, the Company had two interest rate caps designated in cash flow hedging relationships with a total notional amount of $153.9 million. The interest rate caps each have a termination date of March 31, 2025. During the nine months ended SeptemberÂ 30, 2023, the Company partially terminated a previously undesignated portion of one of its interest rate caps. In connection with the termination, the Company received $8.6Â million, which is included as a component of operating activities in the condensed consolidated statements of cash flows for the nine months ended SeptemberÂ 30, 2023.On April 9, 2024, the Company entered into five deferred premium interest rate cap agreements, each with an effective date of MarchÂ 31, 2025. The interest rate caps are designated in cash flow hedging relationships with a total notional amount of $1.4Â billion. The deferred premium interest rate caps each have a termination date of December 31, 2028. These financial instruments are designed to limit the Company's interest rate exposure on its term loan concurrent with the expected maturity of positions held as of SeptemberÂ 30, 2024. As of SeptemberÂ 30, 2024, the Company's deferred premium interest rate caps had a total notional amount of $1.4Â billion. The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash

flow hedge. Within the Companyâ€™s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Within the Companyâ€™s condensed consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the condensed consolidated statements of cash flows.The Company's interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps is determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Companyâ€™s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Companyâ€™s variable-rate debt. Over the next 12 months, the Company estimates that an additional $19.0 million will be reclassified as a decrease to interest expense.16Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):September 30, 2024December 31, 2023AssetsLiabilitiesAssetsLiabilitiesDerivatives in cash flow hedging relationshipsInterest rate caps (1)$2.2Â $â€”Â $6.0Â $â€”Â Interest rate swaps (1)19.5Â â€”Â 51.4Â â€”Â Interest rate caps (2)â€”Â 11.4Â â€”Â â€”Â Interest rate swaps (2)(3)â€”Â 7.0Â â€”Â 17.8Â Total$21.7Â $18.4Â $57.4Â $17.8Â (1)Amounts were included in other current assets and other long-term assets on the condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. (2)Amounts were included in other current liabilities and other long-term liabilities on the condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. (3)Amounts related to the financing component of the pay-fixed interest rate swaps.The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statements of operations (in millions):Three Months Ended September 30,Nine Months Ended September 30,Location2024202320242023Derivatives not designated as hedging instrumentsLoss recognized in incomeOther income, net$â€”Â $â€”Â $â€”Â $0.6Â Derivatives in cash flow hedging relationshipsGain (loss) recognized in OCI (effective portion)(11.8)7.4Â (2.7)24.1Â Gain reclassified from accumulated OCI into income (effective portion) (1)Interest expense, net(14.8)(9.2)(44.3)(23.3)(1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million and $16.0 million for the three and nine months ended SeptemberÂ 30, 2023, respectively. There were no corresponding amounts for the three and nine months ended SeptemberÂ 30, 2024. 17Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)6. Earnings Per ShareBasic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands): Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Numerator:Net loss attributable to Surgery Partners, Inc.(31.7)(4.9)(59.6)(10.9)Denominator:Weighted average common shares outstanding: Basic126,172Â 125,747Â 126,093Â 125,559Â Diluted (1)126,172Â 125,747Â 126,093Â 125,559Â Net loss per share attributable to common stockholders:Basic(0.25)(0.04)(0.47)(0.09)Diluted (1)(0.25)(0.04)(0.47)(0.09)Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:Stock options1,187Â 1,421Â 1,164Â 1,412Â Restricted shares281Â 208Â 264Â 202Â (1)The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.7. Other Current LiabilitiesA summary of other current liabilities was as follows (in millions):September 30,2024December 31, 2023Right-of-use operating lease liabilities$41.4Â $37.6Â Cost report liabilities20.7Â 23.9Â Amounts due to patients and payors29.4Â 23.9Â Interest payable29.9Â 17.8Â Interest rate swaps7.0Â â€”Â Accrued expenses and other113.8Â 100.9Â Total$242.2Â $204.1Â 8. Commitments and ContingenciesProfessional, General and Workers' Compensation, and Cyber Liability RisksThe Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation and cyber liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were $18.1 million and $18.2 million, respectively. Expected insurance recoveries of $10.2 million as of both SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. 18Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)9. Segment ReportingThe Company currently operates inÂ twoÂ major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment includes the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of amounts attributable to the Company's corporate general and administrative functions.The following tables present financial information for each reportable segment (in millions):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Revenues:Surgical Facility Services$735.4Â $657.3Â $2,158.5Â $1,956.5Â Ancillary Services35.0Â 16.8Â 91.4Â 51.4Â Total$770.4Â $674.1Â $2,249.9Â $2,007.9Â Adjusted EBITDA:Surgical Facility Services$149.6Â $138.6Â $419.3Â $384.1Â Ancillary Services0.7Â (1.2)(0.6)(2.7)All other(21.7)(31.9)(74.3)(85.6)Total$128.6Â $105.5Â $344.4Â $295.8Â Reconciliation of Adjusted EBITDA:Income before income taxes$10.9Â $32.8Â $72.9Â $82.3Â Net income attributable to non-controlling interests(38.1)(34.6)(118.7)(99.5)Interest expense, net50.0Â 49.8Â 148.8Â 144.3Â Depreciation and amortization50.2Â 28.9Â 118.7Â 87.0Â Equity-based compensation expense7.1Â 4.4Â 27.1Â 13.2Â Transaction, integration and acquisition costs (1)31.5Â 13.0Â 71.2Â 38.8Â Net loss on disposals, consolidations and deconsolidations14.7Â 5.8Â 21.5Â 7.5Â Litigation settlements and regulatory change impact (2)1.6Â 4.2Â 1.5Â 13.9Â Loss on debt extinguishmentâ€”Â â€”Â 5.1Â â€”Â Undesignated derivative activityâ€”Â â€”Â â€”Â 0.6Â Other (3)0.7Â 1.2Â (3.7)7.7Â Adjusted EBITDA$128.6Â $105.5Â $344.4Â $295.8Â (1)This amount includes transaction and integration costs of $29.4 million and $12.8 million for the three months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $2.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively.This amount includes transaction and integration costs of $66.1 million and $37.3 million for the nine months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $5.1 million and $1.5 million for the nine months ended September 30, 2024 and 2023, respectively.(2)This amount includes a litigation settlement loss of $0.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $1.1 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount includes a litigation settlements gain of $0.8 million and a loss of $8.1 million for the nine months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $2.3 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, the nine months ended SeptemberÂ 30, 2023 includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.(3)For the three months ended SeptemberÂ 30, 2024, this amount includes hurricane-related impacts. For the three months ended SeptemberÂ 30, 2023, this amount includes estimates for the net impact of a cyber event. For the nine months ended SeptemberÂ 30, 2024, this amount includes hurricane-related impacts in the third quarter of 2024, net of insurance proceeds related to cyber event losses predominantly incurred in 2023. For the nine months ended SeptemberÂ 30, 2023, this amount includes estimates for the net impact of the same cyber event and losses from a divested business. 19Table of ContentsSURGERY PARTNERS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)September 30,2024December 31, 2023Assets:Surgical Facility Services$6,935.7Â $6,347.4Â Ancillary Services85.1Â 36.3Â All other513.6Â 493.0Â Total assets$7,534.4Â $6,876.7Â Nine Months Ended September 30,20242023Cash purchases of property and equipment:Surgical Facility Services$62.5Â $68.4Â Ancillary Services1.9Â 0.6Â All other3.7Â â€”Â Total cash purchases of property and equipment$68.1Â $69.0Â 10. Subsequent EventsOn November 8, 2024, the Company purchased a controlling interest in two ASCs for $87.0Â million. As of the date of this filing, the Company has not completed its preliminary estimation of the fair values assigned to the assets acquired and liabilities assumed.20Table of ContentsItem 2. Management's Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and our 2023 Annual Report on Form 10-K. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries, and the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.Cautionary Note Regarding Forward-Looking StatementsThis report contains forward-looking statements, which are based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report are forward-looking statements. These statements include, but are not limited to, statements regarding our future financial position, business strategy, budgets, effective tax rate, projected costs and plans and objectives of management for future operations. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements. By their nature, forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ from the expectations expressed in the statements. Many of these factors are beyond our ability to control or predict. These factors include, without limitation, reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions; changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties set forth under the heading "Risk Factors" in our 2023 Annual Report on FormÂ 10-K and discussed from time to time in our reports filed with the SEC.Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this report.These forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise. Executive Overview As of SeptemberÂ 30, 2024, we owned or operated, primarily in partnership with physicians, a portfolio of 166 surgical facilities comprised of 147 ASCs and 19 surgical hospitals across 33 states.Â We owned a majority interest in 89 of the surgical facilities and consolidated 123 of these facilities for financial reporting purposes.Total revenues for the third quarter of 2024 increased 14.3% toÂ $770.4 millionÂ fromÂ $674.1 millionÂ for the third quarter of 2023. The increase in revenues was attributable to same-facility revenue growth and the net impact from acquisitions and divestitures completed during the twelve months ended SeptemberÂ 30, 2024. Days adjusted same-facility revenues for the third quarter of 2024 increased 4.2% from the third quarter of 2023, with an 0.5% increase in revenue per case and a 3.7% increase in same-facility cases. Additionally, for the third quarter of 2024, Adjusted EBITDA increased 21.9% to $128.6 millionÂ compared to $105.5 millionÂ for the same period in 2023. The increase in Adjusted EBITDA was primarily attributable to revenue growth, continued cost management initiatives and acquisitions completed since the prior year period. For the third quarter of 2024, net loss attributable to Surgery Partners, Inc. was $31.7 million compared to $4.9 million for the same period in 2023. A reconciliation of non-GAAP financial measures appears below under the heading "Certain Non-GAAP Measures."We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and other portfolio management initiatives. During the third quarter of 2024, we acquired a controlling interest in several physician practices for aggregate cash consideration of $26.6Â million, net of cash acquired.WeÂ had cash and cash equivalents ofÂ $221.8 millionÂ andÂ $595.8 million of borrowing capacity under the Revolver as of SeptemberÂ 30, 2024. 21Table of ContentsRevenuesOur revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facility Services and Ancillary Services segments. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services. The following table summarizes revenues by service type as a percentage of total revenues: Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Patient service revenues:Surgical Facility Services93.3Â %95.8Â %94.1Â %95.9Â %Ancillary Services4.4Â %2.4Â %4.0Â %2.5Â %Total patient service revenues97.7Â %98.2Â %98.1Â %98.4Â %Other service revenues2.3Â %1.8Â %1.9Â %1.6Â %Total revenues100.0Â %100.0Â %100.0Â %100.0Â %Payor MixThe following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes: Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Private insurance payors52.2Â %52.4Â %52.2Â %51.8Â %Government payors42.3Â %41.0Â %42.2Â %42.4Â %Self-pay payors2.6Â %2.6Â %2.7Â %2.5Â %Other payors (1)2.9Â %4.0Â %2.9Â %3.3Â %Total100.0Â %100.0Â %100.0Â %100.0Â %(1)Other is comprised of automobile liability, letters of protection and other payor types. Surgical Case MixWe primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume. The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes for the periods indicated:Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Orthopedics and pain management40.4Â %35.7Â %40.1Â %35.4Â %Ophthalmology23.4Â %24.8Â %23.4Â %24.5Â %Gastrointestinal22.8Â %23.6Â %22.5Â %24.0Â %General surgery2.2Â %2.5Â %2.3Â %2.7Â %Other11.2Â %13.4Â %11.7Â %13.4Â %Total100.0Â %100.0Â %100.0Â %100.0Â %22Table of ContentsCritical Accounting Policies A summary of significant accounting policies is disclosed in our 2023 Annual Report on Form 10-K under the caption â€œCritical Accounting Policiesâ€ in the Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies or the application of those policies since DecemberÂ 31, 2023.Results of OperationsComparison of Operating Results for the Three Months Ended September 30, 2024 to the Three Months Ended September 30, 2023The following tables summarize

certain results from the statements of operations for the periods indicated (in millions):Three Months Ended September 30,20242023Revenues$770.4Â $674.1Â Operating expenses:Cost of revenues592.9Â 508.3Â General and administrative expenses29.2Â 36.8Â Depreciation and amortization50.2Â 28.9Â Transaction and integration costs29.4Â 12.8Â Net loss on disposals, consolidations and deconsolidations14.7Â 5.8Â Equity in earnings of unconsolidated affiliates(5.2)(3.5)Litigation settlements0.5Â 3.6Â Other income, net(2.2)(1.2)709.5Â 591.5Â Operating income60.9Â 82.6Â Interest expense, net(50.0)(49.8)Income before income taxes 10.9Â 32.8Â Income tax expense(4.5)(3.1)Net income6.4Â 29.7Â Less: Net income attributable to non-controlling interests(38.1)(34.6)Net loss attributable to Surgery Partners, Inc.(31.7)(4.9)Revenues. The following table sets forth patient service revenues (in millions):Three Months Ended September 30,20242023Patient service revenues$753.2Â $662.3Â Other service revenues17.2Â 11.8Â Total revenues$770.4Â $674.1Â Patient service revenues increased 13.7% to $753.2 million for the three months ended SeptemberÂ 30, 2024 compared to $662.3 million for the three months ended SeptemberÂ 30, 2023. The increase was primarily driven by a 4.2% increase in days adjusted same-facility revenues and the net impact from acquisitions and divestitures completed during the twelve months ended SeptemberÂ 30, 2024. The increase in days adjusted same-facility revenues was attributable to a 3.7% increase in same-facility case volumes and a 0.5% increase in same-facility revenue per case. Cost of Revenues. Cost of revenues was $592.9 million for the three months ended SeptemberÂ 30, 2024 compared to $508.3 million for the three months ended SeptemberÂ 30, 2023. The increase was primarily driven by an increase in case volume and the performance of high acuity procedures as well as acquisitions completed during the twelve months ended SeptemberÂ 30, 2024. As a percentage of revenues, cost of revenues was 77.0% and 75.4% for the three months ended SeptemberÂ 30, 2024 and 2023, respectively.General and Administrative Expenses. General and administrative expenses were $29.2 million and $36.8 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. As a percentage of revenues, general and administrative expenses were 3.8% and 5.5% for the three months ended SeptemberÂ 30, 2024 and 2023, respectively.23Table of ContentsDepreciation and Amortization. Depreciation and amortization expenses were $50.2 million and $28.9 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. As a percentage of revenues, depreciation and amortization expenses were 6.5% and 4.3% for the three months ended SeptemberÂ 30, 2024 and 2023, respectively.Transaction and Integration Costs. The Company incurred $29.4 million of transaction and integration costs for the three months ended SeptemberÂ 30, 2024 compared to $12.8 million for the three months ended SeptemberÂ 30, 2023. The costs for both periods primarily related to ongoing development initiatives and the integration of acquisitions.Net Loss on Disposals, Consolidations and Deconsolidations. The net loss on disposals, consolidations and deconsolidations for the three months ended SeptemberÂ 30, 2024 and 2023 includes activity discussed in Note 2. "Acquisitions, Disposals and Deconsolidations" of the accompanying notes to the condensed consolidated financial statements. The remaining net loss in both periods was primarily attributable to sales and disposals of other assets.Interest Expense, Net. Interest expense, net was $50.0 million for the three months ended SeptemberÂ 30, 2024 compared to $49.8 million for the three months ended SeptemberÂ 30, 2023. As a percentage of revenues, interest expense, net was 6.5% and 7.4% for the three months ended SeptemberÂ 30, 2024 and 2023, respectively.Income Tax Expense. Income tax expense was $4.5 million and $3.1 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. The effective tax rate was 41.3% and 9.5% for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. See Note 1. "Organization and Summary of Accounting Policies" under the heading Income Taxes for additional information related to the Company's effective tax rates for the three months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023, including why these rates differed from the U.S. federal statutory rate of 21%.Net Income Attributable to Non-Controlling Interests. As a percentage of revenues, net income attributable to non-controlling interests was 4.9% and 5.1% for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. Comparison of Operating Results for the Nine Months Ended September 30, 2024 to the Nine Months Ended September 30, 2023The following tables summarize certain results from the statements of operations for the periods indicated (dollars in millions):Nine Months Ended September 30,20242023Revenues$2,249.9Â $2,007.9Â Operating expenses:Cost of revenues1,737.9Â 1,554.0Â General and administrative expenses102.7Â 100.0Â Depreciation and amortization118.7Â 87.0Â Transaction and integration costs66.1Â 37.3Â Net loss on disposals, consolidations and deconsolidations21.5Â 7.5Â Equity in earnings of unconsolidated affiliates(12.3)(9.4)Litigation settlements(0.8)8.1Â Loss on debt extinguishment5.1Â â€”Â Other income, net(10.7)(3.2)2,028.2Â 1,781.3Â Operating income221.7Â 226.6Â Interest expense, net(148.8)(144.3)Income before income taxes 72.9Â 82.3Â Income tax (expense) benefit(13.8)6.3Â Net income59.1Â 88.6Â Less: Net income attributable to non-controlling interests(118.7)(99.5)Net loss attributable to Surgery Partners, Inc.(59.6)(10.9)24Table of ContentsRevenues. The following table sets forth patient service revenues (in millions):Nine Months Ended September 30,20242023Patient service revenues$2,206.6Â $1,976.7Â Other service revenues43.3Â 31.2Â Total revenues$2,249.9Â $2,007.9Â Patient service revenues increased 11.6% to $2.2 billion for the nine months ended SeptemberÂ 30, 2024 compared to $2.0 billion for the nine months ended SeptemberÂ 30, 2023. The increase was primarily driven by an 8.7% increase in days adjusted same-facility revenues and the net impact from acquisitions and divestitures completed in 2024. The increase in days adjusted same-facility revenues was attributable to a 3.4% increase in same-facility case volumes and a 5.2% increase in same-facility revenue per case. Cost of Revenues. Cost of revenues was $1.7 billion for the nine months ended SeptemberÂ 30, 2024 compared to $1.6 billion for the nine months ended SeptemberÂ 30, 2023. The increase was primarily driven by an increase in case volume and the performance of high acuity procedures as well as acquisitions completed in 2024. As a percentage of revenues, cost of revenues was 77.2% and 77.4% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.General and Administrative Expenses. General and administrative expenses were $102.7 million and $100.0 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. As a percentage of revenues, general and administrative expenses were 4.6% and 5.0% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.Depreciation and Amortization. Depreciation and amortization expenses were $118.7 million and $87.0 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. As a percentage of revenues, depreciation and amortization expenses were 5.3% and 4.3% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.Transaction and Integration Costs. The Company incurred $66.1 million of transaction and integration costs for the nine months ended SeptemberÂ 30, 2024 compared to $37.3 million for the nine months ended SeptemberÂ 30, 2023. The costs for both periods primarily related to ongoing development initiatives and the integration of acquisitions.Net Loss on Disposals, Consolidations and Deconsolidations. The net loss on disposals, consolidations and deconsolidations for the nine months ended SeptemberÂ 30, 2024 and 2023 includes activity discussed in Note 2. "Acquisitions, Disposals and Deconsolidations" of the accompanying notes to the condensed consolidated financial statements. The remaining net loss in both periods was primarily attributable to sales and disposals of other assets.Interest Expense, Net. Interest expense, net was $148.8 million for the nine months ended SeptemberÂ 30, 2024 compared to $144.3 million for the nine months ended SeptemberÂ 30, 2023. As a percentage of revenues, interest expense, net was 6.6% and 7.2% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.Income Tax (Expense) Benefit. Income tax expense was $13.8 million for the nine months ended SeptemberÂ 30, 2024 compared to income tax benefit of $6.3 million for the nine months ended SeptemberÂ 30, 2023. The effective tax rate was 18.9% and (7.7)% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. See Note 1. "Organization and Summary of Accounting Policies" under the heading Income Taxes for additional information related to the Company's effective tax rates for the nine months ended SeptemberÂ 30, 2024 and 2023, including why these rates differed from the U.S. federal statutory rate of 21%.Net Income Attributable to Non-Controlling Interests. As a percentage of revenues, net income attributable to non-controlling interests was 5.3% and 5.0% for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.Liquidity and Capital ResourcesCash and cash equivalents were $221.8 million at SeptemberÂ 30, 2024 compared to $195.9 million at DecemberÂ 31, 2023.The primary source of our operating cash flows is the collection of accounts receivable from private insurance companies, federal and state agencies (under the Medicare and Medicaid programs) and individuals. Our cash flows provided by operating activities was $188.7 million for the nine months ended SeptemberÂ 30, 2024 compared to $231.2 million for the nine months ended SeptemberÂ 30, 2023. The $42.5 million decrease was primarily driven by increased transaction-related costs, the timing of routine transactions involving working capital and the impact of Hurricane Helene on collections.Net cash used in investing activities for the nine months ended SeptemberÂ 30, 2024 was $376.8 million compared to $167.5 million for the nine months ended SeptemberÂ 30, 2023. The $209.3 million increase was primarily driven by an aggregate net increase of $193.9 million in payments for acquisitions (net of cash acquired) and purchases of equity method investments and a $24.3 million decrease in proceeds from sales of facilities.25Table of ContentsNet cash provided by financing activities for the nine months ended SeptemberÂ 30, 2024 was $214.0 million compared to net cash used of $110.6 million for the nine months ended SeptemberÂ 30, 2023. The increase of $324.6 million was primarily driven by net proceeds received from the issuance and sale of $800.0 million in senior unsecured notes, partially offset by the redemption of all the Existing Notes (as discussed in the following section). The remaining increase was due to net borrowings on the Revolver used to fund acquisitions completed during the nine months ended SeptemberÂ 30, 2024.Debt On April 10, 2024, we completed the issuance and sale of $800.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes bear interest at an annual rate of 7.250% per year, payable semi-annually on April 15 and October 15 of each year, beginning on OctoberÂ 15, 2024. Proceeds from sale of the 2032 Notes were used (i) to redeem all of the outstanding 2025 Notes and 2027 Notes, (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes, and (iv) for general corporate purposes, including to fund future acquisitions.On June 20, 2024, the Company entered into the Amendment to the Credit Agreement, to provide for the 2024 Refinancing Term Loans in an aggregate principal amount of $1.4Â billion. The 2024 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), all as further set forth in the Amendment. The 2024 Refinancing Term Loans mature on December 19, 2030. The 2024 Refinancing Term Loans shall bear interest at a rate per annum equal to (x) the forward-looking term rate based on Term SOFR plus 2.75% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate plus 0.5% per annum above the federal funds effective rate and (ii) Term SOFR plus 1.00% per annum (which shall not be less than 1.00%) plus 1.75% per annum. The 2024 Refinancing Term Loans amortize in equal quarterly installments of 0.25% of the aggregate original principal amount of the 2024 Refinancing Term Loans. Voluntary prepayments of the 2024 Refinancing Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except a 1.00% call premium in the case of certain repricing events occurring prior to the sixth month anniversary of the effective date of the Amendment).Capital Resources Net working capital was approximately $460.6 million at SeptemberÂ 30, 2024 compared to $372.0 million at DecemberÂ 31, 2023.In addition to cash flows from operations and available cash, other sources of capital include amounts available on our Revolver as well as anticipated continued access to the capital markets.Material Cash RequirementsThere have been no material changes outside of the ordinary course of business to our upcoming cash obligations during the nine months ended SeptemberÂ 30, 2024 from those disclosed under â€œMaterial Cash Requirementsâ€ in Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 Annual Report on Form 10-K.SummaryBroad economic factors, including recent changes in interest rates, inflation and supply chain risks and market volatility, could negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital.If general economic conditions, including recent changes in interest rates, inflation risk and market volatility, continue to deteriorate or remain uncertain for an extended period of time, our ability to access capital could be harmed, which could negatively affect our liquidity and ability to repay our outstanding debt.Based on our current level of operations, we believe cash flows from operations, available cash, available capacity on our Revolver and continued anticipated access to capital markets, will be adequate to meet our short-term (i.e., 12 months) and long-term (beyond 12 months) liquidity needs.Certain Non-GAAP MeasuresAdjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from this non-GAAP metric are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by our management to assess operating performance, make business decisions and allocate resources.26Table of ContentsThe following table reconciles Adjusted EBITDA to income before income taxes, the most directly comparable GAAP financial measure (in millions and unaudited):Three Months Ended September 30,Nine Months Ended September 30,202420232024Condensed Consolidated Statements of Operations Data:Income before income taxes$10.9Â $32.8Â $72.9Â $82.3Â Plus (minus):Net income attributable to non-controlling interests(38.1)(34.6)(118.7)(99.5)Depreciation and amortization50.2Â 28.9Â 118.7Â 87.0Â Interest expense, net50.0Â 49.8Â 148.8Â 144.3Â Equity-based compensation expense7.1Â 4.4Â 27.1Â 13.2Â Transaction, integration and acquisition costs (1)31.5Â 13.0Â 71.2Â 38.8Â Net loss on disposals, consolidations and deconsolidations14.7Â 5.8Â 21.5Â 7.5Â Litigation settlements and regulatory change impact (2)1.6Â 4.2Â 1.5Â 13.9Â Loss on debt extinguishmentâ€”Â â€”Â 5.1Â â€”Â Undesignated derivative activityâ€”Â â€”Â 0.6Â Other (3)0.7Â 1.2Â (3.7)7.7Â Adjusted EBITDA128.6Â 105.5Â 344.4Â 295.8Â (1)This amount includes transaction and integration costs of $29.4 million and $12.8 million for the three months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $2.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively.This amount includes transaction and integration costs of $66.1 million and $37.3 million for the nine months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $5.1 million and $1.5 million for the nine months ended September 30, 2024 and 2023, respectively.(2)This amount includes a litigation settlement loss of $0.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $1.1 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount includes a litigation settlements gain of $0.8 million and a loss of $8.1 million for the nine months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $2.3 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, the nine months ended SeptemberÂ 30, 2023 includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.(3)For the three months ended SeptemberÂ 30, 2024, this amount includes hurricane-related impacts. For the three months ended SeptemberÂ 30, 2023, this amount includes estimates for the net impact of a cyber event. For the nine months ended SeptemberÂ 30, 2024, this amount includes hurricane-related impacts in the third quarter of 2024, net of insurance proceeds related to cyber event losses predominantly incurred in 2023. For the nine months ended SeptemberÂ 30, 2023, this amount includes estimates for the net impact of the aforementioned cyber event and losses from a divested business. We use Credit Agreement EBITDA as a measure of liquidity and to determine our compliance under certain covenants pursuant to our Credit Agreement, as amended. Credit Agreement EBITDA is determined on a trailing twelve-month basis. We have included it because we believe that it provides investors with additional information about our ability to incur and service debt and make capital expenditures. Credit Agreement EBITDA is not a measurement of liquidity under GAAP and should not be considered in isolation or as a substitute for any other measure calculated in accordance with GAAP. The items excluded from Credit Agreement EBITDA are significant components in understanding and evaluating our liquidity. Our calculation of Credit Agreement EBITDA may not be comparable to similarly titled measures reported by other companies.When we use the term "Credit Agreement EBITDA," we are referring to Adjusted EBITDA, as defined above, further adjusted for acquisitions and synergies. These adjustments do not relate to our historical financial performance and instead relate to estimates compiled by management and calculated in conformance with the definition of "Consolidated EBITDA" used in the credit agreements governing our credit facilities.27Table of ContentsThe following table reconciles Credit Agreement EBITDA to cash flows from operating activities, the most directly comparable GAAP financial measure (in millions and unaudited):Twelve Months Ended September 30, 2024Cash flows from operating activities$251.3Â Plus (minus):Non-cash interest expense, net(10.0)Non-cash lease expense(38.0)Deferred income taxes(19.4)Equity in earnings of unconsolidated affiliates, net of distributions received(0.8)Changes in operating assets and liabilities, net of acquisitions and divestitures153.1Â Income tax expense19.8Â Net income attributable to non-controlling interests(166.4)Interest expense, net197.5Â Transaction, integration and acquisition costs97.3Â Litigation settlements and other litigation costs5.1Â Other (1)(2.8)Acquisitions and synergies (2)64.9Â Credit Agreement EBITDA$551.6Â (1)This amount includes estimates for the impact of hurricanes, a cyber event and losses from divested business that occurred in 2023.(2)Represents impact of acquisitions as if each acquisition had occurred on October 1, 2023. Further this includes revenue and cost synergies from other business initiatives and de novo facilities and an adjustment for the effects of adopting the new lease accounting standard, as defined in the credit agreement governing the Credit Agreement, as amended.Item 3. Quantitative and Qualitative Disclosures about Market RiskWe are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.Â We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage

our exposures to changes in interest rates.Â Additionally, we periodically enter into interest rate swap and cap agreements to manage our exposure to interest rate fluctuations. Our interest rate swap and cap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the swap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions. The interest payments under these agreements are settled on a net basis. These derivatives have been recognized in the financial statements at their respective fair values. Changes in the fair value of these derivatives, which are designated as cash flow hedges, are included in other comprehensive income.Our variable rate debt instruments are primarily indexed to the prime rate or SOFR.Â Without derivatives, interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements. Based on our indebtedness and the effectiveness of our interest rate swap and cap agreements at SeptemberÂ 30, 2024, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2024.For more information regarding our interest rate swap and cap agreements, please refer to Note 5. "Derivatives and Hedging Activities" of the accompanying notes to the condensed consolidated financial statements for additional information.Item 4. Controls and ProceduresEvaluation of Disclosure Controls and ProceduresÂ An evaluation was performed under the supervision and with the participation of our management, including the chief executive officer and the chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended) as of SeptemberÂ 30, 2024. Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective.Changes in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting during the quarter ended SeptemberÂ 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.28Table of ContentsPART II - OTHER INFORMATIONItem 1. Legal ProceedingsWe are, from time to time, subject to claims and suits, or threats of claims or suits, relating to our business, including claims for damages for personal injuries, breach of management contracts and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages, which may not be covered by insurance or may otherwise have a material adverse effect on our business or results of operations. In the opinion of management, we are not currently a party to any proceedings that would have a material adverse effect on our business, financial condition, or results of operations. Item 1A. Risk FactorsThere have been no material changes with respect to the risk factors discussed in our 2023 Annual Report on Form 10-K.Item 2. Unregistered Sales of Equity Securities and Use of ProceedsNone.Item 3. Defaults Upon Senior SecuritiesNone.Item 4. Mine Safety DisclosuresNot applicable.Item 5. Other InformationInsider Trading ArrangementsFrom time to time, certain of our executive officers and directors have, and we expect they will in the future, enter into, amend and terminate written trading arrangements pursuant to Rule 10b5-1 of the Securities and Exchange Act of 1934 or otherwise. During the three months ended SeptemberÂ 30, 2024, none of the Companyâ€™s directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).Item 6. ExhibitsNo.Description10.1Retirement Agreement, dated August 5, 2024, by and between Surgery Partners, Inc. and Bradley R. Owens (incorporated herein by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on August 6, 2024).10.2SP Management Services, Inc. Nonqualified Deferred Compensation Plan (incorporated herein by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on August 6, 2024).31.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002.101.INSInline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.101.SCHInline XBRL Taxonomy Extension Schema Document101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document101.LABInline XBRL Taxonomy Extension Label Linkbase Document101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document104The cover page from the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ended SeptemberÂ 30, 2024, formatted in Inline XBRL (included in Exhibit 101).29Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.SURGERY PARTNERS,Â INC.Date:November 12, 2024By:/s/ David T. DohertyDavid T. DohertyExecutive Vice President and Chief Financial Officer(Principal Financial and Accounting Officer)30 EX-31.1 2 a2024q3exhibit311.htm EX-31.1 DocumentExhibit 31.1CERTIFICATIONSI, J. Eric Evans, certify that: 1. Â Â Â Â I have reviewed this quarterly report on Form 10-Q of Surgery Partners, Inc.;2. Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. Â Â Â Â The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Â Â Â Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Â Â Â Â Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5. Â Â Â Â The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a) Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b) Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.By:/s/ J. Eric EvansJ. Eric EvansChief Executive OfficerDate: NovemberÂ 12, 2024 EX-31.2 3 a2024q3exhibit312.htm EX-31.2 DocumentExhibit 31.2CERTIFICATIONSI, David T. Doherty, certify that: 1. Â Â Â Â I have reviewed this quarterly report on Form 10-Q of Surgery Partners, Inc.;2. Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. Â Â Â Â The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Â Â Â Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Â Â Â Â Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5. Â Â Â Â The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a) Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b) Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.By:/s/ David T. DohertyDavid T. DohertyExecutive Vice President and Chief Financial OfficerDate: NovemberÂ 12, 2024 EX-32.1 4 a2024q3exhibit321.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the quarterly report of Surgery Partners, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), each of the undersigned certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1)Â Â Â Â The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)Â Â Â Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. By:/s/ J. Eric EvansJ. Eric EvansChief Executive OfficerDate: NovemberÂ 12, 2024By:/s/ David T. DohertyDavid T. DohertyExecutive Vice President and Chief Financial OfficerDate: NovemberÂ 12, 2024 EX-101.SCH 5 sgry-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Organization and Summary of Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Acquisitions, Disposals and Deconsolidations link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Derivatives and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Organization and Summary of Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Organization and Summary of Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Derivatives and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Organization and Summary of Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Organization and Summary of Accounting Policies - Revenues by Sources (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Organization and Summary of Accounting Policies - Non-Controlling Interests - Redeemable (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Acquisitions, Disposals and Deconsolidations - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Acquisitions, Disposals and Deconsolidations - Disposals and Deconsolidations (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Schedule of Lease Expense and Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Derivatives and Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Derivatives and Hedging Activities - Schedule of Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Earnings Per Share - Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Segment Reporting - Schedule of Segment Revenue and Operating Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 sgry-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 sgry-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 sgry-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Federal Funds Effective Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Acquisitions, including post acquisition adjustments Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Principal payments on long-term debt Repayments of Long-Term Debt Total cash purchases of property and equipment Segment, Expenditure, Addition to Long-Lived Assets Surgical Facility With A Retained Interest Surgical Facility With A Retained Interest [Member] Surgical Facility With A Retained Interest Total debt Long-Term Debt and Lease Obligation, Including Current Maturities

Schedule of Lease Expense and Cash Flow Information Lease, Cost [Table Text Block] Cover [Abstract] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other current liabilities Total Other Liabilities, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Long-term debt, less current maturities Total long-term debt Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Adjusted EBITDA Earnings Before Interest Taxes Depreciation And Amortization Earnings Before Interest Taxes Depreciation And Amortization Distributions to non-controlling interestsâ€”non-redeemable holders Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Non-controlling interestsâ€”redeemable Balance at beginning of period Balance at end of period Redeemable Noncontrolling Interest, Equity, Carrying Amount Effective income tax rate reconciliation, disposition of business, amount Effective Income Tax Rate Reconciliation, Disposition of Business, Amount Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Derivative activity, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Accounts receivable Increase (Decrease) in Accounts Receivable Litigation settlements and regulatory change impact Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact Derivative [Table] Derivative [Table] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Goodwill and other intangible assets, net Intangible Assets, Net (Including Goodwill) Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Surgical Facilities And In-Development De Novo Surgical Facility Surgical Facilities And In-Development De Novo Surgical Facility [Member] Surgical Facilities And In-Development De Novo Surgical Facility Award Timing Disclosures [Line Items] Other operating assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Loss recognized in income Derivative, Gain (Loss) on Derivative, Net Total lease liabilities Lease, Liability Lease, Liability Other Performance Measure, Amount Other Performance Measure, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (shares) Beginning Balance (shares) Ending Balance (shares) Common Stock, Shares, Outstanding Operating lease costs Operating Lease, Cost Credit Facility Credit Facility [Member] Credit Facility Right-of-use operating lease liabilities Long-term Operating Lease, Liability, Noncurrent Acquisition and disposal of shares of non-controlling interests, netâ€”redeemable Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests Interest on lease liabilities Finance Lease, Interest Expense Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Accumulated Other Comprehensive (Loss) Income AOCI Including Portion Attributable to Noncontrolling Interest [Member] Private insurance Private Insurance [Member] Private Insurance [Member] Operating Segments Operating Segments [Member] Notes payable and other secured loans Notes Payable and Secured Loans [Member] Notes Payable and Secured Loans [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding Schedule of Derivative Instruments [Table Text Block] Net loss per share attributable to common stockholders: Net loss per share attributable to common stockholders: Earnings Per Share Reconciliation [Abstract] Secured Debt Secured Debt [Member] Other operating expenses Other Cost and Expense, Operating Deferred premium cap Deferred Premium Cap 3 [Member] Deferred Premium Cap 3 Term Rate Based Secured Overnight Financing Rate (SOFR) Term Rate Based Secured Overnight Financing Rate (SOFR) [Member] Term Rate Based Secured Overnight Financing Rate (SOFR) Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Number of non-controlling interests in in-development de novo surgical facilities acquired Number Of Non-Controlling Interests Acquired Number Of Non-Controlling Interests Acquired Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Derivative asset, notional amount Derivative Asset, Notional Amount Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Number of surgical facilities owned, majority interest Number Of Surgical Facilities Owned, Majority Interest Number of Surgical Facilities Owned, Majority Interest Compensation Amount Outstanding Recovery Compensation Amount Disposal Group Classification [Axis] Disposal Group Classification [Axis] Number of states in which entity operates Number of States in which Entity Operates Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Payments of debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Deferred premium cap Deferred Premium Cap [Member] Deferred Premium Cap Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt instrument, basis spread on variable rate, floor Debt Instrument, Basis Spread On Variable Rate, Floor Debt Instrument, Basis Spread On Variable Rate, Floor Non-cash lease expense Operating Lease, Expense Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Deferred premium cap Deferred Premium Cap 5 [Member] Deferred Premium Cap 5 Current assets: Assets, Current [Abstract] Goodwill, beginning of period Goodwill, end of period Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Stock options Stock Option Share-Based Payment Arrangement, Option [Member] Number of interest rate swaps held Number of Interest Rate Derivatives Held Goodwill [Roll Forward] Goodwill [Roll Forward] Other financing activities Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss attributable to Surgery Partners, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Award Type Award Type [Axis] Senior secured revolving credit facility 2017 Senior Secured Credit Facility [Member] 2017 Senior Secured Credit Facility [Member] Liabilities Liabilities Non-controlling interestsâ€”non-redeemable Equity, Attributable to Noncontrolling Interest Salaries and benefits Labor and Related Expense Facilities, Surgical Hospitals Facilities, Surgical Hospitals [Member] Facilities, Surgical Hospitals [Member] Transaction, integration and acquisition costs Business Combination, Integration Related Costs, And Merger Costs Business Combination, Integration Related Costs, And Merger Costs Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Current Right-of-use operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Finance lease liabilities: Finance Lease, Liability [Abstract] Revenue by service type as a proportion of total revenues (percent) Concentration Risk, Percentage 10.000% senior unsecured notes due 2027 Senior Unsecured Notes, Due 2027 [Member] Senior Unsecured Notes, Due 2027 [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] 7.250% senior unsecured notes due 2032 Senior Unsecured Notes Due 2032 [Member] Senior Unsecured Notes Due 2032 Gain (loss) recognized in OCI (effective portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (shares) Common Stock, Shares Authorized Finance lease costs: Finance Lease, Cost1 [Abstract] Finance Lease, Cost1 [Abstract] Accumulated depreciation on property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Payments for acquisitions, net of cash acquired Total cash consideration, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Proceeds related to ownership transactions with non-controlling interest holders Proceeds from (Payments to) Noncontrolling Interests Diluted (shares) Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Derivative liability, notional amount Derivative Liability, Notional Amount MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total Surgery Partners, Inc. stockholders' equity Equity, Attributable to Parent Operating lease liabilities: Operating Lease, Liability [Abstract] Hedging Designation [Domain] Hedging Designation [Domain] Deferred income taxes Deferred Income Tax Expense (Benefit) (Gain) loss reclassified from accumulated OCI into income (effective portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of Rollforward of Goodwill Schedule of Goodwill [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Outstanding letters of credit Letters of Credit Outstanding, Amount Surgical Facilities and Physician Practices Surgical Facilities And Physician Practices [Member] Surgical Facilities And Physician Practices Interest rate caps (2) Interest Rate Cap [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Start-up costs Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration] OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Acquisitions, Disposals and Deconsolidations Mergers, Acquisitions and Dispositions Disclosures [Text Block] ASSETS Assets: Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Additional interest expense for Florida LOP regulation change Interest Expense, Impact Of Change In Letter Of Protection Regulation Interest Expense, Impact Of Change In Letter Of Protection Regulation Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Financial Information by Reportable Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Investments in and advances to affiliates Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures 2023 Disposals 2023 Disposals [Member] 2023 Disposals Loss on sale of equity method investment Equity Method Investment, Realized Gain (Loss) on Disposal Surgical Facility Surgical Facility [Member] Surgical Facility Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Liabilities: Liabilities [Abstract] Litigation settlements (Loss) gain on litigation settlement Gain (Loss) from Litigation Settlement Net income attributable to non-controlling interestsâ€”redeemable Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Current Fiscal Year End Date Current Fiscal Year End Date Total lease costs Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Investments and advances to affiliates Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Non-controlling interest, fair value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Equity-based compensation (shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term deferred tax assets Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Accrued expenses and other Accrued Liabilities and Other Liabilities Additional Paid-in Capital Additional Paid-in Capital [Member] Long-term Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Long-Term Debt Long-Term Debt [Text Block] Diluted (in USD per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Revenues Revenue from Contract with Customer [Policy Text Block] Name Measure Name Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Domestic Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Other income, net Other Nonrecurring (Income) Expense Number of operating segments Number of Operating Segments Preferred stock, shares issued (shares) Preferred Stock, Shares Issued Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Equity-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Pre-tax gain (loss) on disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Equity Method Investments Equity Method Investments [Member] Income tax (expense) benefit Income Tax Expense (Benefit) Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Current notional amount Derivative, Notional Amount All other All other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Product Information [Line Items] Product Information [Line Items] Lease expense Operating And Finance Lease, Expense Operating And Finance Lease, Expense Surgical Facilities and In-Development De Novo Surgical Facilities Surgical Facilities and In-Development De Novo Surgical Facilities [Member] Surgical Facilities and In-Development De Novo Surgical Facilities Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Distributions to non-controlling interest â€”redeemable holders Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating income Operating Income (Loss) Variable Rate [Domain] Variable Rate [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Total liabilities and stockholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Net loss on disposals, consolidations and deconsolidations Net loss on disposals, consolidations and deconsolidations Gain (Loss) On Disposition Of Assets And Deconsolidation Gain (Loss) On Disposition of Assets And Deconsolidation Accrued payroll and benefits Employee-related Liabilities, Current Additional paid-in capital Additional Paid in Capital Hedging Designation [Axis] Hedging Designation [Axis] Interest rate swaps Derivative Liability, Current Number of facilities included in VIE Variable Interest Entity, Number Of Facilities Variable Interest Entity, Number of Facilities Derivatives and Hedging

Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Surgical Facility, Equity Method Investment Surgical Facility, Equity Method Investment [Member] Surgical Facility, Equity Method Investment Other service revenues Other Services [Member] Other Services [Member] Interest expense, net Interest expense, net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Components of Right-of-use Assets and Liabilities Related to Leases Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Current maturities of long-term debt Less: current maturities Long-Term Debt and Lease Obligation, Current Non-Controlling Interests - Redeemable [Roll Forward] Redeemable Noncontrolling Interest [Roll Forward] Redeemable Noncontrolling Interest [Roll Forward] Disposed of by Sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Amounts due to patients and payors Broker-Dealer, Payable to Customer Individual: Individual [Axis] Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 127,127,901 and 126,593,727, respectively Common Stock, Value, Outstanding Inventories Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Medicare accelerated payments and deferred governmental grants Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Segment Revenue and Operating Income Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Operating expenses: Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Management Rights Agreement Management Rights Agreement [Member] Management Rights Agreement Derivative Instruments and Hedging Activities Derivatives, Policy [Policy Text Block] Less: unamortized debt issuance costs and discounts Debt issuance costs and discount Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Fair Value Estimate of Fair Value Measurement [Member] Reconciliation of Adjusted EBITDA: Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract] Number of surgical facilities owned, consolidated Number Of Surgical Facilities Owned, Consolidated Number of Surgical Facilities Owned, Consolidated Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Right-of-use operating lease assets Operating lease assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Purchases of equity investments Payments to Acquire Equity Method Investments Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt Long-Term Debt, Gross Exercise Price Award Exercise Price Earnings Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Leases Lessee, Finance Leases [Text Block] Schedule of Variable Interest Entities [Table] Variable Interest Entity [Table] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Finance lease obligations Total finance lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] Organization and Summary of Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Number of interests sold Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed PEO PEO [Member] Variable Rate [Axis] Variable Rate [Axis] Deferred premium cap Deferred Premium Cap 4 [Member] Deferred Premium Cap 4 Name Trading Arrangement, Individual Name Other Other Nonoperating Income (Expense) Gain on termination Proceeds from Terminated Derivative Instrument, Operating Activities Proceeds from Terminated Derivative Instrument, Operating Activities Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Total leased assets Lease, Right-Of-Use Asset Lease, Right-of-Use Asset Disposal Group Name [Axis] Disposal Group Name [Axis] Self-pay Self-Pay Revenue [Member] Self-Pay Revenue [Member] Equity in earnings of unconsolidated affiliates Income (Loss) from Equity Method Investments Other Other Patient Service Revenue Sources [Member] Other Patient Service Revenue Sources [Member] Cost of revenues Operating Costs and Expenses Schedule of Revenues Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Number of surgical facilities owned Number of Surgical Facilities Owned Number of Surgical Facilities Owned Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Loan amortization rate Loan Amortization Rate Loan Amortization Rate Amortization of accumulated OCI related Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Surgical Facility Services Surgical Facility Services [Member] Surgical Facility Services [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Interest rate cap Interest Rate Cap Two [Member] Interest Rate Cap Two 6.750% senior unsecured notes due 2025 Senior Unsecured Notes Due 2025 [Member] Senior Unsecured Notes Due 2025 [Member] Changes in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] SOFR Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Ancillary Services Ancillary Services Ancillary Services [Member] Ancillary Services [Member] Interest payable Interest Payable, Current Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Equity-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Asset Class [Domain] Asset Class [Domain] Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Segment Reporting [Abstract] Non-cash interest expense, net Noncash Interest Income (Expense), Net Noncash Interest Income (Expense), Net Entity Central Index Key Entity Central Index Key Debt instrument, call premium percentage Debt Instrument, Call Premium Percentage Debt Instrument, Call Premium Percentage Facilities, Ambulatory Surgery Centers Facilities, Ambulatory Surgery Centers [Member] Facilities, Ambulatory Surgery Centers [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Government Government Revenue [Member] Government Revenue [Member] Segment Reporting Segment Reporting Disclosure [Text Block] 2024 Refinancing Term Loans 2024 Refinancing Term Loans [Member] 2024 Refinancing Term Loans Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Restricted shares Restricted Stock [Member] Professional and medical fees Professional Fees Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Recognized non-controlling interests Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Title Trading Arrangement, Individual Title Estimated insurance recoveries Estimated Insurance Recoveries Consolidated Entities [Axis] Consolidated Entities [Axis] Statement [Table] Statement [Table] Number of non-controlling interests in surgical facilities acquired Number Of Non-Controlling Interests In Surgical Facilities Acquired Number Of Non-Controlling Interests In Surgical Facilities Acquired Cost report liabilities Cost Report Liabilities, Current Cost Report Liabilities, Current Less: Comprehensive income attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Consolidation Items [Domain] Consolidation Items [Domain] Senior secured term loan Senior secured term loan 2017 Term Loan, Maturing 2024 [Member] 2017 Term Loan, Maturing 2024 [Member] Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Professional, general and workers' compensation insurance reserve Self Insurance Reserve Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Outstanding balance on debt Line of Credit Facility, Remaining Borrowing Capacity Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounts Receivable Receivable [Policy Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Undesignated derivative activity Undesignated Derivative Activity Undesignated Derivative Activity Earnings Per Share [Abstract] Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Retained deficit Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Amount estimated to be reclassified as a reduction to interest expense over next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Net (loss) income Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Schedule of Long-Term Debt Schedule of Debt [Table Text Block] General and administrative expenses General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total operating lease liabilities Operating Lease, Liability Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Proceeds from sales of equity investments Proceeds from Sale of Equity Method Investments Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Pay-fixed swap Pay-fixed Swap One [Member] Pay-fixed Swap One Member Carrying Amount Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Fair Value as of Grant Date Award Grant Date Fair Value Amortization of leased assets Finance Lease, Right-of-Use Asset, Amortization Customer Customer Concentration Risk [Member] Schedule of Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Stockholders' equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Original balance of debt Debt Instrument, Face Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of Consolidation Consolidation, Policy [Policy Text Block] Interest rate swaps Interest Rate Swap [Member] Distributions to non-controlling interest holders Payments of Ordinary Dividends, Noncontrolling Interest Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Operating cash outflows from finance leases Finance Lease, Interest Payment on Liability Transaction and integration costs Business Combination, Integration Related Costs Acquisition and disposal of shares of non-controlling interests, net Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred premium cap Deferred Premium Cap 1 [Member] Deferred Premium Cap 1 Pay-fixed swap Pay-fixed Swap Two [Member] Pay-fixed Swap Two Member Other investing activities Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none Preferred Stock, Value, Issued Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basic (in USD per share) Earnings Per Share, Basic Tax expense (benefits) related to vesting of restricted stock awards Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Operating cash outflows from operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Schedule of Product Information [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Property and equipment, net of accumulated depreciation of $558.8 and $454.4, respectively Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Financing cash outflows from finance leases Finance Lease, Principal Payments Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivatives in cash flow hedging relationships Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Other Current Liabilities Other Liabilities Disclosure [Text Block] Total assets Assets Total assets Assets Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net loss on fair value of non-controlling interest Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Total patient service revenues Healthcare Organization, Patient Service [Member] Healthcare Organization, Patient Service [Member] Termination Date Trading Arrangement Termination Date Noncash consideration Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Pay-fixed swap Pay-fixed Swap Three [Member] Pay-fixed Swap Three Member Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] Total finance lease costs Finance Lease, Cost Finance Lease, Cost Entity Address, City or Town Entity Address, City or Town Borrowings of long-term debt Proceeds from Issuance of Long-Term Debt Leases Lessee, Leases [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Carrying Amounts and Fair Values of Long-Term Debt Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Deferred premium cap Deferred Premium Cap 2 [Member] Deferred Premium Cap 2 Net loss attributable to Surgery Partners, Inc. Net loss attributable to Surgery Partners, Inc. Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Revenues Total revenues Revenue from Contract with Customer, Including Assessed Tax Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Right-of-use assets obtained in exchange for lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Obligations [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Obligations Equity Awards Adjustments, Excluding Value

Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Derivative activity, net of tax of $0 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Consolidated Entities [Domain] Consolidated Entities [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Non-Controlling Interestsâ€" Non-Redeemable Noncontrolling Interest [Member] Income Statement Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Revenue Source Product Concentration Risk [Member] Weighted average common shares outstanding: Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name Unamortized fair value discount Debt Instrument, Unamortized Discount (Premium), Net Document Period End Date Document Period End Date Schedule of Effect of Interest Rate Swaps Schedule of Interest Rate Derivatives [Table Text Block] Current Finance Lease, Liability, Current Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Base Rate Base Rate [Member] Equity in earnings of unconsolidated affiliates, net of distributions received Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Less: Net income attributable to non-controlling interests Net income attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Disposals Goodwill, Written off Related to Sale of Business Unit Supplies Supplies Expense Schedule of Rollforward of Non-Controlling Interests - Redeemable Redeemable Noncontrolling Interest [Table Text Block] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Service Cost [Member] Surgical Facilities and Anesthesia Practice Surgical Facilities And Anesthesia Practice [Member] Surgical Facilities And Anesthesia Practice Other litigation costs Litigation Settlement, Fee Expense Variable and short-term lease costs Variable And Short-Term Lease, Cost Variable And Short-Term Lease, Cost Basic (shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Interest rate cap Interest Rate Cap One [Member] Interest Rate Cap One Proceeds from disposals of facilities and other assets Proceeds from Sale of Productive Assets Total stockholders' equity Beginning Balance Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Variable interest rate of derivative instrument (percent) Derivative, Variable Interest Rate Non-Controlling Interestsâ€"Redeemable Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Revenue Revenue Benchmark [Member] Number of business entities acquired Number of Businesses Acquired Entity Filer Category Entity Filer Category Schedule of Current Liabilities Other Current Liabilities [Table Text Block] Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 sgry-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 sgry-20240930_g1.jpg begin 644 sgry-20240930_g1.jpg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·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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended	
	Sep. 30, 2024	Nov. 05, 2024
Cover [Abstract]		
Document Type	10-Q	
Document Quarterly Report	true	
Document Period End Date	Sep. 30, 2024	
Document Transition Report	false	
Entity File Number	001-37576	
Entity Registrant Name	Surgery Partners, Inc.	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	47-3620923	
Entity Address, Address Line One	340 Seven Springs Way, Suite 600	
Entity Address, City or Town	Brentwood	
Entity Address, State or Province	TN	
Entity Address, Postal Zip Code	37027	
City Area Code	615	
Local Phone Number	234-5900	

Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	SGRY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	127,113,514
Entity Central Index Key	0001638833
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions

	Sep. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	$ 221.8	$ 195.9
Accounts receivable	542.9	496.4
Inventories	82.0	75.2
Prepaid expenses	45.2	31.0
Other current assets	143.9	96.5
Total current assets	1,035.8	895.0
Property and equipment, net of accumulated depreciation of $558.8 and $454.4, respectively	1,004.5	968.7
Goodwill and other intangible assets, net	4,861.5	4,380.8
Investments in and advances to affiliates	214.8	184.1
Right-of-use operating lease assets	297.5	255.3
Long-term deferred tax assets	79.2	89.5
Other long-term assets	41.1	103.3
Total assets	7,534.4	6,876.7
Current liabilities:		
Accounts payable	170.8	171.8
Accrued payroll and benefits	64.9	73.8
Other current liabilities	242.2	204.1
Current maturities of long-term debt	97.3	73.3
Total current liabilities	575.2	523.0
Long-term debt, less current maturities	3,094.2	2,701.8
Right-of-use operating lease liabilities	286.4	248.9
Other long-term liabilities	30.3	41.1
Non-controlling interests—redeemable	436.4	327.4
Stockholders' equity:		
Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none	0.0	0.0
Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 127,127,901 and 126,593,727, respectively	1.3	1.3
Additional paid-in capital	2,513.5	2,497.6
Accumulated other comprehensive income	10.5	57.5
Retained deficit	(628.8)	(569.2)
Total Surgery Partners, Inc. stockholders' equity	1,896.5	1,987.2
Non-controlling interests—non-redeemable	1,215.4	1,047.3
Total stockholders' equity	3,111.9	3,034.5
Total liabilities and stockholders' equity	$ 7,534.4	$ 6,876.7

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions

	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Accumulated depreciation on property and equipment	$ 558.8	$ 454.4
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	20,310,000	20,310,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	300,000,000	300,000,000
Common stock, shares issued (shares)	127,127,901	126,593,727
Common stock, shares outstanding (shares)	127,127,901	126,593,727

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions

	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]				
Revenues	$ 770.4	$ 674.1	$ 2,249.9	$ 2,007.9
Operating expenses:				
Salaries and benefits	228.4	195.0	666.8	592.4
Supplies	201.4	179.2	589.9	549.8
Professional and medical fees	91.0	72.4	266.0	219.9
Lease expense	23.9	21.1	67.5	64.3
Other operating expenses	48.2	40.6	147.7	127.6
Cost of revenues	592.9	508.3	1,737.9	1,554.0
General and administrative expenses	29.2	36.8	102.7	100.0
Depreciation and amortization	50.2	28.9	118.7	87.0
Transaction and integration costs	29.4	12.8	66.1	37.3
Net loss on disposals, consolidations and deconsolidations	14.7	5.8	21.5	7.5
Equity in earnings of unconsolidated affiliates	(5.2)	(3.5)	(12.3)	(9.4)
Litigation settlements	0.5	3.6	(0.8)	8.1
Loss on debt extinguishment	0.0	0.0	5.1	0.0
Other income, net	(2.2)	(1.2)	(10.7)	(3.2)
Total operating expenses	709.5	591.5	2,028.2	1,781.3
Operating income	60.9	82.6	221.7	226.6
Interest expense, net	(50.0)	(49.8)	(148.8)	(144.3)
Income before income taxes	10.9	32.8	72.9	82.3

Income tax (expense) benefit	(4.5)	(3.1)	(13.8)	6.3
Net income	6.4	29.7	59.1	88.6
Less: Net income attributable to non-controlling interests	(38.1)	(34.6)	(118.7)	(99.5)
Net loss attributable to Surgery Partners, Inc.	$ (31.7)	$ (4.9)	$ (59.6)	$ (10.9)
Net loss per share attributable to common stockholders:				
Basic (in USD per share)	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Diluted (in USD per share) [1]	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Weighted average common shares outstanding:				
Basic (shares)	126,172	125,747	126,093	125,559
Diluted (shares) [1]	126,172	125,747	126,093	125,559

[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Statement of Comprehensive Income [Abstract]				
Net income	$ 6.4	$ 29.7	$ 59.1	$ 88.6
Other comprehensive (loss) income, net of tax:				
Derivative activity, net of tax of $0	(26.6)	(1.8)	(47.0)	0.8
Comprehensive (loss) income	(20.2)	27.9	12.1	89.4
Less: Comprehensive income attributable to non-controlling interests	(38.1)	(34.6)	(118.7)	(99.5)
Comprehensive loss attributable to Surgery Partners, Inc.	$ (58.3)	$ (6.7)	$ (106.6)	$ (10.1)

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Statement of Comprehensive Income [Abstract]				
Derivative activity, tax	$ 0.0	$ 0.0	$ 0.0	$ 0.0

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions	**Total**	**Common Stock**	**Additional Paid-in Capital**	**Accumulated Other Comprehensive (Loss) Income**	**Retained Deficit**	**Non-Controlling Interests— Non-Redeemable**
Beginning Balance (shares) at Dec. 31, 2022		125,961,000				
Beginning Balance at Dec. 31, 2022	$ 2,940.9	$ 1.3	$ 2,478.0	$ 76.2	$ (557.3)	$ 942.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Net (loss) income	(6.7)				(25.0)	18.3
Equity-based compensation (shares)		519,000				
Equity-based compensation	3.7		3.7			
Other comprehensive (loss) income	(11.3)			(11.3)		
Acquisition and disposal of shares of non-controlling interests, net	46.1		(3.6)			49.7
Distributions to non-controlling interests—non-redeemable holders	(30.2)					(30.2)
Ending Balance (shares) at Mar. 31, 2023		126,480,000				
Ending Balance at Mar. 31, 2023	2,942.5	$ 1.3	2,478.1	64.9	(582.3)	980.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Net (loss) income	46.6				19.0	27.6
Equity-based compensation (shares)		13,000				
Equity-based compensation	4.5		4.5			
Other comprehensive (loss) income	13.9			13.9		
Acquisition and disposal of shares of non-controlling interests, net	(0.9)		18.8			(19.7)
Distributions to non-controlling interests—non-redeemable holders	(23.8)					(23.8)
Ending Balance (shares) at Jun. 30, 2023		126,493,000				
Ending Balance at Jun. 30, 2023	2,982.8	$ 1.3	2,501.4	78.8	(563.3)	964.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Net (loss) income	23.1				(4.9)	28.0
Equity-based compensation (shares)		(4,000)				
Equity-based compensation	4.5		4.5			
Other comprehensive (loss) income	(1.8)			(1.8)		
Acquisition and disposal of shares of non-controlling interests, net	1.7		(11.4)			13.1
Distributions to non-controlling interests—non-redeemable holders	(23.8)					(23.8)
Ending Balance (shares) at Sep. 30, 2023		126,489,000				
Ending Balance at Sep. 30, 2023	$ 2,986.5	$ 1.3	2,494.5	77.0	(568.2)	981.9
Beginning Balance (shares) at Dec. 31, 2023	126,593,727	126,594,000				
Beginning Balance at Dec. 31, 2023	$ 3,034.5	$ 1.3	2,497.6	57.5	(569.2)	1,047.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Net (loss) income	16.9				(12.4)	29.3
Equity-based compensation (shares)		508,000				
Equity-based compensation	4.9		4.9			
Other comprehensive (loss) income	(5.5)			(5.5)		
Acquisition and disposal of shares of non-controlling interests, net	16.8		(6.9)			23.7
Distributions to non-controlling interests—non-redeemable holders	(29.7)					(29.7)
Ending Balance (shares) at Mar. 31, 2024		127,102,000				
Ending Balance at Mar. 31, 2024	3,037.9	$ 1.3	2,495.6	52.0	(581.6)	1,070.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Net (loss) income	20.0				(15.5)	35.5
Equity-based compensation (shares)		22,000				
Equity-based compensation	15.1		15.1			
Other comprehensive (loss) income	(14.9)			(14.9)		

Acquisition and disposal of shares of non-controlling interests, net	147.8		0.4			147.4
Distributions to non-controlling interests—non-redeemable holders	(29.6)					(29.6)
Ending Balance (shares) at Jun. 30, 2024		127,124,000				
Ending Balance at Jun. 30, 2024	3,176.3	$ 1.3	2,511.1	37.1	(597.1)	1,223.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Net (loss) income	3.0				(31.7)	34.7
Equity-based compensation (shares)		4,000				
Equity-based compensation	7.0		7.0			
Other comprehensive (loss) income	(26.6)			(26.6)		
Acquisition and disposal of shares of non-controlling interests, net	(16.3)		(4.6)			(11.7)
Distributions to non-controlling interests—non-redeemable holders	$ (31.5)					(31.5)
Ending Balance (shares) at Sep. 30, 2024	127,127,901	127,128,000				
Ending Balance at Sep. 30, 2024	$ 3,111.9	$ 1.3	$ 2,513.5	$ 10.5	$ (628.8)	$ 1,215.4

XML 19 R8.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:		
Net income	$ 59.1	$ 88.6
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	118.7	87.0
Non-cash lease expense	29.2	26.4
Non-cash interest expense, net	4.8	19.8
Equity-based compensation expense	27.1	13.2
Net loss on disposals, consolidations and deconsolidations	21.5	7.5
Loss on debt extinguishment	5.1	0.0
Deferred income taxes	10.3	(10.8)
Equity in earnings of unconsolidated affiliates, net of distributions received	0.3	(2.7)
Changes in operating assets and liabilities, net of acquisitions and divestitures:		
Accounts receivable	(31.2)	(18.2)
Medicare accelerated payments and deferred governmental grants	0.0	(1.2)
Other operating assets and liabilities	(56.2)	21.6
Net cash provided by operating activities	188.7	231.2
Cash flows from investing activities:		
Purchases of property and equipment	(68.1)	(69.0)
Payments for acquisitions, net of cash acquired	(291.2)	(48.8)
Proceeds from disposals of facilities and other assets	1.5	25.8
Purchases of equity investments	(1.7)	(50.2)
Proceeds from sales of equity investments	4.0	1.0
Other investing activities	(21.3)	(26.3)
Net cash used in investing activities	(376.8)	(167.5)
Cash flows from financing activities:		
Principal payments on long-term debt	(1,108.8)	(107.1)
Borrowings of long-term debt	1,463.8	119.4
Payments of debt issuance costs	(15.1)	(1.5)
Distributions to non-controlling interest holders	(122.4)	(111.0)
Proceeds related to ownership transactions with non-controlling interest holders	5.6	0.7
Other financing activities	(9.1)	(11.1)
Net cash provided by (used in) financing activities	214.0	(110.6)
Net increase (decrease) in cash and cash equivalents	25.9	(46.9)
Cash and cash equivalents at beginning of period	195.9	282.9
Cash and cash equivalents at end of period	$ 221.8	$ 236.0

XML 20 R9.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Organization and Summary of Accounting Policies	Organization and Summary of Accounting Policies

Organization

Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including orthopedics and pain management, gastroenterology, ophthalmology, and general surgery. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."

As of September 30, 2024, the Company owned or operated a portfolio of 166 surgical facilities, comprised of 147 ASCs and 19 surgical hospitals in 33 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves. The Company owned a majority interest in 89 of these surgical facilities and consolidated 123 surgical facilities for financial reporting purposes.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company's fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report on Form 10-K"). Certain prior year amounts have been reclassified to conform with the current year presentation.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.

Revenues

The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

The following table presents a summary of revenues by service type as a percentage of total revenues:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Patient service revenues:				
Surgical Facility Services	93.3 %	95.8 %	94.1 %	95.9 %
Ancillary Services	4.4 %	2.4 %	4.0 %	2.5 %
Total patient service revenues	97.7 %	98.2 %	98.1 %	98.4 %
Other service revenues	2.3 %	1.8 %	1.9 %	1.6 %
Total revenues	100.0 %	100.0 %	100.0 %	100.0 %

Patient service revenues. This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for

anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.

Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.

The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change.

Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services ("CMS") and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses.

Other service revenues. Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.

The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):

	Three Months Ended September 30,			
	2024		2023	
	Amount	%	Amount	%
Patient service revenues:				
Private insurance	$ 393.2	52.2 %	$ 347.1	52.4 %
Government	318.3	42.3 %	271.6	41.0 %
Self-pay	19.7	2.6 %	16.9	2.6 %
Other [1]	22.0	2.9 %	26.7	4.0 %
Total patient service revenues	753.2	100.0 %	662.3	100.0 %
Other service revenues	17.2		11.8	
Total revenues	$ 770.4		$ 674.1	

	Nine Months Ended September 30,			
	2024		2023	
	Amount	%	Amount	%
Patient service revenues:				
Private insurance	$ 1,152.2	52.2 %	$ 1,024.3	51.8 %
Government	932.0	42.2 %	837.6	42.4 %
Self-pay	60.2	2.7 %	49.6	2.5 %
Other [1]	62.2	2.9 %	65.2	3.3 %
Total patient service revenues	2,206.6	100.0 %	1,976.7	100.0 %
Other service revenues	43.3		31.2	
Total revenues	$ 2,249.9		$ 2,007.9	

(1) Other is comprised of automobile liability, letters of protection and other payor types.

Accounts Receivable

Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals' cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.

Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors.

The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient's coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.

The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected

to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.

The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.

The Company's effective tax rate was 18.9% for the nine months ended September 30, 2024 compared to (7.7)% for the nine months ended September 30, 2023. For the nine months ended September 30, 2024, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company's valuation allowance attributable to interest expense limitations, state tax expense, and a discrete tax expense of $1.5 million related to the valuation allowance impact of the Company's impairment to an equity method investment. For the nine months ended September 30, 2023, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company's valuation allowance attributable to interest expense limitations, and discrete tax benefits of (i) $1.6 million related to the vesting of restricted stock awards and (ii) $15.8 million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.

Goodwill

Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions, disposals and deconsolidations for the nine months ended September 30, 2024 is included in Note 2. "Acquisitions, Disposals and Deconsolidations."

A summary of activity related to goodwill for the nine months ended September 30, 2024 is as follows (in millions):

Balance as of December 31, 2023	$ 4,326.0
Acquisitions, including post acquisition adjustments	495.4
Disposals	(6.0)
Balance as of September 30, 2024	$ 4,815.4

A detailed evaluation of potential impairment indicators was performed as of September 30, 2024, which specifically considered recent changes in interest rates, inflation risk and market volatility. On the basis of available evidence as of September 30, 2024, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company's stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.

Derivative Instruments and Hedging Activities

The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.

The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Non-Controlling Interests—Redeemable

Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of September 30, 2024. The non-controlling interests—redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.

A summary of activity related to redeemable non-controlling interests is as follows (in millions):

	Nine Months Ended September 30,	
	2024	2023
Balance at beginning of period	$ 327.4	$ 342.0
Net income attributable to non-controlling interests—redeemable	19.2	25.6
Acquisition and disposal of shares of non-controlling interests, net—redeemable	121.4	(2.2)
Distributions to non-controlling interest —redeemable holders	(31.6)	(33.2)
Balance at end of period	$ 436.4	$ 332.2

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:

- Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
- Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.

The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate their fair values under Level 3 calculations.

A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):

	Carrying Amount		Fair Value	
	September 30, 2024	December 31, 2023	September 30, 2024	December 31, 2023
Senior secured term loan	$ 1,391.5	$ 1,398.4	$ 1,393.2	$ 1,401.9
6.750% senior unsecured notes due 2025	$ —	$ 185.0	$ —	$ 183.2
10.000% senior unsecured notes due 2027	$ —	$ 320.0	$ —	$ 321.2
7.250% senior unsecured notes due 2032	$ 800.0	$ —	$ 835.0	$ —

The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.

Variable Interest Entities

The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's

("FASB") Accounting Standards Codification 810, "*Consolidation*." The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of September 30, 2024, the Company's consolidated VIEs consisted of nine surgical facilities and 26 physician practices.

The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, were $86.2 million and $65.3 million, respectively, and the total liabilities of the consolidated VIEs were $57.9 million and $41.2 million, respectively.

Recent Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, *Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures*, which requires enhanced disclosures of significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments in this ASU must be applied retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), *Improvements to Income Tax Disclosures*, which establishes new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 and interim periods beginning after December 15, 2025. The amendments in this ASU may be applied prospectively or retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Acquisitions, Disposals and Deconsolidations	**9 Months Ended Sep. 30, 2024**
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]	
Acquisitions, Disposals and Deconsolidations	Acquisitions, Disposals and Deconsolidations

Acquisitions

During the nine months ended September 30, 2024:

- The Company acquired a controlling interest in six surgical facilities and several physician practices for aggregate cash consideration of $291.2 million, net of cash acquired, and non-cash consideration of $1.1 million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $293.2 million, goodwill of $506.7 million and investments and advances to affiliates of $44.6 million related to an acquired surgical facility accounted for as an equity method investment.

During the nine months ended September 30, 2023:

- The Company acquired a controlling interest in two surgical facilities and one physician practice for aggregate cash consideration of $23.1 million, net of cash acquired, and non-cash consideration of $1.3 million, which consisted of non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $20.4 million and goodwill of $39.7 million.
- The Company acquired a controlling interest in two surgical facilities and one in-development de novo surgical facility, which were previously accounted for as equity method investments, for aggregate cash consideration of $26.9 million, net of cash acquired. The Company also amended the operating agreement of a previously non-controlled surgical facility resulting in the Company obtaining a controlling interest in the facility. These transactions resulted in the consolidation of the previously non-consolidated entities. The previously held non-controlling interests were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $27.3 million. As a result of increasing its ownership interest, the Company recognized a net loss of $7.1 million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended September 30, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the consolidation of these facilities, the Company preliminarily recognized non-controlling interests of $55.1 million and goodwill of $106.3 million.
- The Company acquired non-controlling interests in five surgical facilities and two in-development de novo surgical facilities for aggregate cash consideration of $50.2 million. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the condensed consolidated balance sheets. The Company also paid cash consideration of $21.0 million to acquire management rights from the prior management service provider related to four of the aforementioned surgical facilities. Management rights agreements are accounted for and recorded as a component of intangibles assets, net in the accompanying condensed consolidated balance sheets. The cash paid to acquire the management rights is presented as a component of other investing activities on the condensed consolidated statements of cash flows.

Disposals and Deconsolidations

During the nine months ended September 30, 2024:

- The Company disposed of its non-controlling interests in one surgical facility, which was previously accounted for as an equity method investment, for cash proceeds of $2.0 million. In connection with this transaction, the Company recognized a pre-tax loss of $3.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024.
- The Company sold a portion of its interests in one surgical facility for net cash proceeds of $2.5 million. As a result of the transaction, the Company no longer controlled the previously controlled surgical facility but retained a non-controlling interest, resulting in the deconsolidation of the previously consolidated entity. This transaction resulted in a pretax net gain on deconsolidation of $2.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. The net gain was determined based on the difference between the net cash proceeds plus the fair value of the Company's retained interests in the entity and the carrying values of both the tangible and intangible assets of the entity immediately prior to the transaction.
- The Company sold its interests in one surgical facility for a nominal amount of cash proceeds. In connection with the sale, the Company recognized a pre-tax loss of $3.4 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024.
- The Company recognized a pre-tax loss of $10.0 million related to an equity investment previously held at cost, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024.

During the nine months ended September 30, 2023:

- The Company sold its interests in six surgical facilities for aggregate net cash proceeds of $30.4 million, a portion of which was held in escrow pursuant to the purchase agreements for such transactions. In connection with these transactions, the Company recognized a pre-tax gain of $26.9 million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended September 30, 2023.
- The Company disposed of its non-controlling interests in a surgical facility and an in-development de novo surgical facility, which were previously accounted for as equity method investments, for cash proceeds of $1.5 million. In connection with these transactions, the Company recognized a pre-tax loss of $13.7 million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended September 30, 2023.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Long-Term Debt	**9 Months Ended Sep. 30, 2024**
Debt Disclosure [Abstract]	
Long-Term Debt	Long-Term Debt

A summary of long-term debt follows (in millions):

	September 30, 2024	December 31, 2023
Senior secured term loan [(1)]	$ 1,391.5	$ 1,398.4
Senior secured revolving credit facility	98.0	—
6.750% senior unsecured notes due 2025	—	185.0
10.000% senior unsecured notes due 2027	—	320.0
7.250% senior unsecured notes due 2032	800.0	—
Notes payable and other secured loans	212.5	205.2
Finance lease obligations	723.6	693.6
Less: unamortized debt issuance costs and discounts	(34.1)	(27.1)
Total debt	3,191.5	2,775.1
Less: current maturities	97.3	73.3
Total long-term debt	$ 3,094.2	$ 2,701.8

(1) Includes unamortized fair value discount of $1.5 million and $1.6 million as of September 30, 2024 and December 31, 2023, respectively.

Revolving Credit Facility

As of September 30, 2024, the Company's availability on its $703.8 million senior secured revolving credit facility (the "Revolver") was $595.8 million (including letters of credit of $10.0 million). The increase in outstanding borrowings on the Revolver compared to December 31, 2023 was primarily due to the timing of acquisitions completed during 2024.

7.250% Senior Unsecured Notes Due 2032

On April 10, 2024, the Company completed the issuance and sale of $800.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes were issued pursuant to an Indenture dated April 10, 2024 by and among Surgery Center Holdings, Inc., certain subsidiaries of Surgery Center Holdings, Inc., as guarantors, and Wilmington Trust, National Association, as trustee. The 2032 Notes bear interest at an annual rate of 7.250% per year, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2024. Proceeds from the sale of the 2032 Notes were used (i) to redeem all of the outstanding 6.750% senior unsecured notes due 2025 (the "2025 Notes") and the 10.000% senior unsecured notes due 2027 (the "2027 Notes," together with the 2025 Notes, the "Existing Notes"), (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes and (iv) for general corporate purposes, including to fund future acquisitions.

In connection with this financing transaction, the Company recorded debt issuance costs and discount of $12.5 million, and a debt extinguishment loss of $2.8 million, which is included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024.

First Amendment to Credit Agreement

On June 20, 2024, the Company entered into a first amendment (the "Amendment") to its credit agreement, dated as of December 19, 2023, by and among Surgery Center Holdings, Inc., the Borrower, Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time (the "Credit Agreement") to provide for a new tranche of term loans under the Credit Agreement in an aggregate principal amount of $1,400 million (the "2024 Refinancing Term Loans"), which 2024 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), all as further set forth in the Amendment. The 2024 Refinancing Term Loans mature on December 19, 2030. The 2024 Refinancing Term Loans bear interest at a rate per annum equal to (x) the forward-looking term rate based on Secured Overnight Financing Rate ("Term SOFR") plus 2.75% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate plus 0.5% per annum above the federal funds effective rate and (ii) Term SOFR plus 1.00% per annum (which shall not be less than 1.00%)) plus 1.75% per annum. The 2024 Refinancing Term Loans amortize in equal quarterly installments of 0.25% of the aggregate original principal amount of the 2024 Refinancing Term Loans. Voluntary prepayments of the 2024 Refinancing Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except a 1.00% call premium in the case of certain repricing events occurring prior to the sixth month anniversary of the effective date of the Amendment).

In connection with the Amendment, the Company recorded debt issuance costs and discount of $2.4 million, and a debt extinguishment loss of $2.3 million, which is included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. The loss on debt extinguishment includes the partial write-off of unamortized debt issuance costs and discounts.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Leases	**9 Months Ended Sep. 30, 2024**
Leases [Abstract]	
Leases	Leases

The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets.

The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions):

	Classification in Condensed Consolidated Balance Sheets	September 30, 2024	December 31, 2023
Assets:			
Operating lease assets	Right-of-use operating lease assets	$ 297.5	$ 255.3
Finance lease assets	Property and equipment, net of accumulated depreciation	588.6	587.0
Total leased assets		$ 886.1	$ 842.3
Liabilities:			
Operating lease liabilities:			
Current	Other current liabilities	$ 41.4	$ 37.6
Long-term	Right-of-use operating lease liabilities	286.4	248.9
Total operating lease liabilities		327.8	286.5
Finance lease liabilities:			
Current	Current maturities of long-term debt	29.5	25.4
Long-term	Long-term debt, less current maturities	694.1	668.2
Total finance lease liabilities		723.6	693.6
Total lease liabilities		$ 1,051.4	$ 980.1

The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions):

	Nine Months Ended September 30,	
	2024	2023
Operating lease costs	$ 50.1	$ 48.7
Finance lease costs:		
Amortization of leased assets	47.5	29.0
Interest on lease liabilities	40.6	35.9
Total finance lease costs	88.1	64.9
Variable and short-term lease costs	18.1	16.3
Total lease costs	$ 156.3	$ 129.9

The following table presents supplemental cash flow information (in millions):

	Nine Months Ended September 30,	
	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash outflows from operating leases	$ 48.0	$ 47.2
Operating cash outflows from finance leases	$ 38.6	$ 34.1
Financing cash outflows from finance leases	$ 24.4	$ 19.3
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	$ 79.3	$ 39.9
Finance leases	$ 40.8	$ 108.7

Leases

Leases

The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets.

The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions):

	Classification in Condensed Consolidated Balance Sheets	September 30, 2024	December 31, 2023
Assets:			
Operating lease assets	Right-of-use operating lease assets	$ 297.5	$ 255.3
Finance lease assets	Property and equipment, net of accumulated depreciation	588.6	587.0
Total leased assets		$ 886.1	$ 842.3
Liabilities:			
Operating lease liabilities:			
Current	Other current liabilities	$ 41.4	$ 37.6
Long-term	Right-of-use operating lease liabilities	286.4	248.9
Total operating lease liabilities		327.8	286.5
Finance lease liabilities:			
Current	Current maturities of long-term debt	29.5	25.4
Long-term	Long-term debt, less current maturities	694.1	668.2
Total finance lease liabilities		723.6	693.6
Total lease liabilities		$ 1,051.4	$ 980.1

The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions):

	Nine Months Ended September 30,	
	2024	2023
Operating lease costs	$ 50.1	$ 48.7
Finance lease costs:		
Amortization of leased assets	47.5	29.0
Interest on lease liabilities	40.6	35.9
Total finance lease costs	88.1	64.9
Variable and short-term lease costs	18.1	16.3
Total lease costs	$ 156.3	$ 129.9

The following table presents supplemental cash flow information (in millions):

	Nine Months Ended September 30,	
	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash outflows from operating leases	$ 48.0	$ 47.2
Operating cash outflows from finance leases	$ 38.6	$ 34.1
Financing cash outflows from finance leases	$ 24.4	$ 19.3
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	$ 79.3	$ 39.9
Finance leases	$ 40.8	$ 108.7

XML 24 R13.htm IDEA: XBRL DOCUMENT

Derivatives and Hedging Activities

Derivative Instruments and Hedging Activities Disclosure [Abstract]

9 Months Ended
Sep. 30, 2024

Derivatives and Hedging Activities

Derivatives and Hedging Activities

The Company's objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its

interest rate risk management strategy. During 2024 and 2023, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.

The key terms of interest rate swaps and interest rate caps outstanding are presented below:

		September 30, 2024		December 31, 2023		
Description	Effective Date	Notional Amount (in millions)	Status	Notional Amount (in millions)	Status	Maturity Date
Pay-fixed swap	May 7, 2021	$ 435.0	Active	$ 435.0	Active	March 31, 2025
Pay-fixed swap	May 7, 2021	330.0	Active	330.0	Active	March 31, 2025
Pay-fixed swap	May 7, 2021	435.0	Active	435.0	Active	March 31, 2025
Interest rate cap	September 30, 2021	145.6	Active	151.4	Active	March 31, 2025
Interest rate cap	September 30, 2021	8.3	Active	8.7	Active	March 31, 2025
Deferred premium cap	March 31, 2025	396.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	198.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	396.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	198.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	198.0	Active	—	N/A	December 31, 2028
		$ 2,739.9		$ 1,360.1		

As of September 30, 2024, the Company had three interest rate swaps with a total net notional amount of $1.2 billion. The interest rate swaps are pay-fixed, receive 1-Month Secured Overnight Financing Rate ("SOFR") (subject to a minimum of 0.75%) designated in cash flow hedging relationships and have a termination date of March 31, 2025.

As of September 30, 2024, the Company had two interest rate caps designated in cash flow hedging relationships with a total notional amount of $153.9 million. The interest rate caps each have a termination date of March 31, 2025. During the nine months ended September 30, 2023, the Company partially terminated a previously undesignated portion of one of its interest rate caps. In connection with the termination, the Company received $8.6 million, which is included as a component of operating activities in the condensed consolidated statements of cash flows for the nine months ended September 30, 2023.

On April 9, 2024, the Company entered into five deferred premium interest rate cap agreements, each with an effective date of March 31, 2025. The interest rate caps are designated in cash flow hedging relationships with a total notional amount of $1.4 billion. The deferred premium interest rate caps each have a termination date of December 31, 2028. These financial instruments are designed to limit the Company's interest rate exposure on its term loan concurrent with the expected maturity of positions held as of September 30, 2024. As of September 30, 2024, the Company's deferred premium interest rate caps had a total notional amount of $1.4 billion.

The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge.

Within the Company's condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Within the Company's condensed consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the condensed consolidated statements of cash flows.

The Company's interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps is determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company's accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company's variable-rate debt. Over the next 12 months, the Company estimates that an additional $19.0 million will be reclassified as a decrease to interest expense.

The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):

	September 30, 2024		December 31, 2023	
	Assets	Liabilities	Assets	Liabilities
Derivatives in cash flow hedging relationships				
Interest rate caps [1]	$ 2.2	$ —	$ 6.0	$ —
Interest rate swaps [1]	19.5	—	51.4	—
Interest rate caps [2]	—	11.4	—	—
Interest rate swaps [2] [3]	—	7.0	—	17.8
Total	$ 21.7	$ 18.4	$ 57.4	$ 17.8

(1) Amounts were included in other current assets and other long-term assets on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively.
(2) Amounts were included in other current liabilities and other long-term liabilities on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively.
(3) Amounts related to the financing component of the pay-fixed interest rate swaps.

The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statements of operations (in millions):

		Three Months Ended September 30,		Nine Months Ended September 30,	
	Location	2024	2023	2024	2023
Derivatives not designated as hedging instruments					
Loss recognized in income	Other income, net	$ —	$ —	$ —	$ 0.6
Derivatives in cash flow hedging relationships					
Gain (loss) recognized in OCI (effective portion)		$ (11.8)	$ 7.4	$ (2.7)	$ 24.1
Gain reclassified from accumulated OCI into income (effective portion) [1]	Interest expense, net	$ (14.8)	$ (9.2)	$ (44.3)	$ (23.3)

(1) Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million and $16.0 million for the three and nine months ended September 30, 2023, respectively. There were no corresponding amounts for the three and nine months ended September 30, 2024.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Earnings Per Share

9 Months Ended
Sep. 30, 2024

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

Basic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Net loss attributable to Surgery Partners, Inc.	$ (31.7)	$ (4.9)	$ (59.6)	$ (10.9)
Denominator:				
Weighted average common shares outstanding:				
Basic	126,172	125,747	126,093	125,559
Diluted [1]	126,172	125,747	126,093	125,559
Net loss per share attributable to common stockholders:				
Basic	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Diluted [1]	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:				
Stock options	1,187	1,421	1,164	1,412
Restricted shares	281	208	264	202

(1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Other Current Liabilities

9 Months Ended
Sep. 30, 2024

Other Liabilities Disclosure [Abstract]

Other Current Liabilities

Other Current Liabilities

A summary of other current liabilities was as follows (in millions):

	September 30, 2024	December 31, 2023
Right-of-use operating lease liabilities	$ 41.4	$ 37.6
Cost report liabilities	20.7	23.9
Amounts due to patients and payors	29.4	23.9
Interest payable	29.9	17.8
Interest rate swaps	7.0	—
Accrued expenses and other	113.8	100.9
Total	$ 242.2	$ 204.1

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended
Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Professional, General and Workers' Compensation, and Cyber Liability Risks

The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation and cyber liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of September 30, 2024 and December 31, 2023 were $18.1 million and $18.2 million, respectively. Expected insurance recoveries of $10.2 million as of both September 30, 2024 and December 31, 2023 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Segment Reporting

9 Months Ended
Sep. 30, 2024

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

The Company currently operates in two major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment includes the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of amounts attributable to the Company's corporate general and administrative functions.

The following tables present financial information for each reportable segment (in millions):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenues:				
Surgical Facility Services	$ 735.4	$ 657.3	$ 2,158.5	$ 1,956.5
Ancillary Services	35.0	16.8	91.4	51.4
Total	$ 770.4	$ 674.1	$ 2,249.9	$ 2,007.9
Adjusted EBITDA:				
Surgical Facility Services	$ 149.6	$ 138.6	$ 419.3	$ 384.1
Ancillary Services	0.7	(1.2)	(0.6)	(2.7)
All other	(21.7)	(31.9)	(74.3)	(85.6)
Total	$ 128.6	$ 105.5	$ 344.4	$ 295.8
Reconciliation of Adjusted EBITDA:				
Income before income taxes	$ 10.9	$ 32.8	$ 72.9	$ 82.3
Net income attributable to non-controlling interests	(38.1)	(34.6)	(118.7)	(99.5)
Interest expense, net	50.0	49.8	148.8	144.3
Depreciation and amortization	50.2	28.9	118.7	87.0
Equity-based compensation expense	7.1	4.4	27.1	13.2
Transaction, integration and acquisition costs [1]	31.5	13.0	71.2	38.8
Net loss on disposals, consolidations and deconsolidations	14.7	5.8	21.5	7.5
Litigation settlements and regulatory change impact [2]	1.6	4.2	1.5	13.9
Loss on debt extinguishment	—	—	5.1	—
Undesignated derivative activity	—	—	—	0.6
Other [3]	0.7	1.2	(3.7)	7.7
Adjusted EBITDA	$ 128.6	$ 105.5	$ 344.4	$ 295.8

(1) This amount includes transaction and integration costs of $29.4 million and $12.8 million for the three months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $2.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively.
This amount includes transaction and integration costs of $66.1 million and $37.3 million for the nine months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $5.1 million and $1.5 million for the nine months ended September 30, 2024 and 2023, respectively.
(2) This amount includes a litigation settlement loss of $0.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $1.1 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively.
This amount includes a litigation settlements gain of $0.8 million and a loss of $8.1 million for the nine months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $2.3 million and $1.4 million for the nine months ended September 30, 2024 and

2023, respectively. Additionally, the nine months ended September 30, 2023 includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.

(3) For the three months ended September 30, 2024, this amount includes hurricane-related impacts. For the three months ended September 30, 2023, this amount includes estimates for the net impact of a cyber event.

For the nine months ended September 30, 2024, this amount includes hurricane-related impacts in the third quarter of 2024, net of insurance proceeds related to cyber event losses predominantly incurred in 2023. For the nine months ended September 30, 2023, this amount includes estimates for the net impact of the same cyber event and losses from a divested business.

	September 30, 2024	December 31, 2023
Assets:		
Surgical Facility Services	$ 6,935.7	$ 6,347.4
Ancillary Services	85.1	36.3
All other	513.6	493.0
Total assets	$ 7,534.4	$ 6,876.7

	Nine Months Ended September 30,	
	2024	2023
Cash purchases of property and equipment:		
Surgical Facility Services	$ 62.5	$ 68.4
Ancillary Services	1.9	0.6
All other	3.7	—
Total cash purchases of property and equipment	$ 68.1	$ 69.0

XML 29 R18.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
Pay vs Performance Disclosure				
Net Income (Loss) Attributable to Parent	$ (31.7)	$ (4.9)	$ (59.6)	$ (10.9)

XML 30 R19.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 31 R20.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies (Policies)	9 Months Ended Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Basis of Presentation	**Basis of Presentation**

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company's fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report on Form 10-K").

Reclassification — Certain prior year amounts have been reclassified to conform with the current year presentation.

Principles of Consolidation — The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.

Revenues

Revenues

The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

Patient service revenues. This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.

Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.

The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change.

Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services ("CMS") and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses.

Other service revenues. Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.

Accounts Receivable

Accounts Receivable

Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals' cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.

Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors.

The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient's coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.

The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.

Income Taxes

Income Taxes

The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected

to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.

The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.

Goodwill

Goodwill

Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives

depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.

The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Non-Controlling Interests—Redeemable

Non-Controlling Interests—Redeemable

Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of September 30, 2024. The non-controlling interests—redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:

- Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
- Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.

The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate their fair values under Level 3 calculations.

The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.

Variable Interest Entities

Variable Interest Entities

The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "*Consolidation*." The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, *Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures*, which requires enhanced disclosures of significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments in this ASU must be applied retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), *Improvements to Income Tax Disclosures*, which establishes new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 and interim periods beginning after December 15, 2025. The amendments in this ASU may be applied prospectively or retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.

Leases

LeasesThe Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets.

Earnings Per Share

Earnings Per ShareBasic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenues

The following table presents a summary of revenues by service type as a percentage of total revenues:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Patient service revenues:				
Surgical Facility Services	93.3 %	95.8 %	94.1 %	95.9 %
Ancillary Services	4.4 %	2.4 %	4.0 %	2.5 %
Total patient service revenues	97.7 %	98.2 %	98.1 %	98.4 %
Other service revenues	2.3 %	1.8 %	1.9 %	1.6 %
Total revenues	100.0 %	100.0 %	100.0 %	100.0 %

The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):

	Three Months Ended September 30,			
	2024		2023	
	Amount	%	Amount	%
Patient service revenues:				
Private insurance	$ 393.2	52.2 %	$ 347.1	52.4 %
Government	318.3	42.3 %	271.6	41.0 %
Self-pay	19.7	2.6 %	16.9	2.6 %
Other [1]	22.0	2.9 %	26.7	4.0 %
Total patient service revenues	753.2	100.0 %	662.3	100.0 %
Other service revenues	17.2		11.8	
Total revenues	$ 770.4		$ 674.1	

	Nine Months Ended September 30,			
	2024		2023	
	Amount	%	Amount	%
Patient service revenues:				
Private insurance	$ 1,152.2	52.2 %	$ 1,024.3	51.8 %
Government	932.0	42.2 %	837.6	42.4 %
Self-pay	60.2	2.7 %	49.6	2.5 %
Other [1]	62.2	2.9 %	65.2	3.3 %
Total patient service revenues	2,206.6	100.0 %	1,976.7	100.0 %
Other service revenues	43.3		31.2	
Total revenues	$ 2,249.9		$ 2,007.9	

(1) Other is comprised of automobile liability, letters of protection and other payor types.

Schedule of Rollforward of Goodwill

A summary of activity related to goodwill for the nine months ended September 30, 2024 is as follows (in millions):

Balance as of December 31, 2023	$ 4,326.0
Acquisitions, including post acquisition adjustments	495.4
Disposals	(6.0)
Balance as of September 30, 2024	$ 4,815.4

Schedule of Rollforward of Non-Controlling Interests - Redeemable

A summary of activity related to redeemable non-controlling interests is as follows (in millions):

	Nine Months Ended September 30,	
	2024	2023
Balance at beginning of period	$ 327.4	$ 342.0
Net income attributable to non-controlling interests—redeemable	19.2	25.6
Acquisition and disposal of shares of non-controlling interests, net—redeemable	121.4	(2.2)
Distributions to non-controlling interest —redeemable holders	(31.6)	(33.2)
Balance at end of period	$ 436.4	$ 332.2

Schedule of Carrying Amounts and Fair Values of Long-Term Debt

A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):

	Carrying Amount		Fair Value	
	September 30, 2024	December 31, 2023	September 30, 2024	December 31, 2023
Senior secured term loan	$ 1,391.5	$ 1,398.4	$ 1,393.2	$ 1,401.9
6.750% senior unsecured notes due 2025	$ —	$ 185.0	$ —	$ 183.2
10.000% senior unsecured notes due 2027	$ —	$ 320.0	$ —	$ 321.2
7.250% senior unsecured notes due 2032	$ 800.0	$ —	$ 835.0	$ —

XML 33 R22.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

A summary of long-term debt follows (in millions):

	September 30, 2024	December 31, 2023
Senior secured term loan [1]	$ 1,391.5	$ 1,398.4
Senior secured revolving credit facility	98.0	—
6.750% senior unsecured notes due 2025	—	185.0
10.000% senior unsecured notes due 2027	—	320.0
7.250% senior unsecured notes due 2032	800.0	—
Notes payable and other secured loans	212.5	205.2
Finance lease obligations	723.6	693.6
Less: unamortized debt issuance costs and discounts	(34.1)	(27.1)
Total debt	3,191.5	2,775.1
Less: current maturities	97.3	73.3
Total long-term debt	$ 3,094.2	$ 2,701.8

(1) Includes unamortized fair value discount of $1.5 million and $1.6 million as of September 30, 2024 and December 31, 2023, respectively.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended
Sep. 30, 2024

Leases [Abstract]

Schedule of Components of Right-of-use Assets and Liabilities Related to Leases

The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions):

	Classification in Condensed Consolidated Balance Sheets	September 30, 2024	December 31, 2023
Assets:			
Operating lease assets	Right-of-use operating lease assets	$ 297.5	$ 255.3
Finance lease assets	Property and equipment, net of accumulated depreciation	588.6	587.0
Total leased assets		$ 886.1	$ 842.3
Liabilities:			
Operating lease liabilities:			
Current	Other current liabilities	$ 41.4	$ 37.6
Long-term	Right-of-use operating lease liabilities	286.4	248.9
Total operating lease liabilities		327.8	286.5
Finance lease liabilities:			
Current	Current maturities of long-term debt	29.5	25.4
Long-term	Long-term debt, less current maturities	694.1	668.2
Total finance lease liabilities		723.6	693.6
Total lease liabilities		$ 1,051.4	$ 980.1

Schedule of Lease Expense and Cash Flow Information

The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions):

	Nine Months Ended September 30,	
	2024	2023
Operating lease costs	$ 50.1	$ 48.7
Finance lease costs:		
Amortization of leased assets	47.5	29.0
Interest on lease liabilities	40.6	35.9
Total finance lease costs	88.1	64.9
Variable and short-term lease costs	18.1	16.3
Total lease costs	$ 156.3	$ 129.9

The following table presents supplemental cash flow information (in millions):

	Nine Months Ended September 30,	
	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash outflows from operating leases	$ 48.0	$ 47.2
Operating cash outflows from finance leases	$ 38.6	$ 34.1
Financing cash outflows from finance leases	$ 24.4	$ 19.3
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	$ 79.3	$ 39.9
Finance leases	$ 40.8	$ 108.7

XML 35 R24.htm IDEA: XBRL DOCUMENT

Derivatives and Hedging Activities (Tables)

9 Months Ended
Sep. 30, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding

The key terms of interest rate swaps and interest rate caps outstanding are presented below:

		September 30, 2024		December 31, 2023		
Description	Effective Date	Notional Amount (in millions)	Status	Notional Amount (in millions)	Status	Maturity Date
Pay-fixed swap	May 7, 2021	$ 435.0	Active	$ 435.0	Active	March 31, 2025
Pay-fixed swap	May 7, 2021	330.0	Active	330.0	Active	March 31, 2025
Pay-fixed swap	May 7, 2021	435.0	Active	435.0	Active	March 31, 2025
Interest rate cap	September 30, 2021	145.6	Active	151.4	Active	March 31, 2025
Interest rate cap	September 30, 2021	8.3	Active	8.7	Active	March 31, 2025
Deferred premium cap	March 31, 2025	396.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	198.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	396.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	198.0	Active	—	N/A	December 31, 2028
Deferred premium cap	March 31, 2025	198.0	Active	—	N/A	December 31, 2028
		$ 2,739.9		$ 1,360.1		

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):

	September 30, 2024		December 31, 2023	
	Assets	Liabilities	Assets	Liabilities
Derivatives in cash flow hedging relationships				
Interest rate caps [1]	$ 2.2	$ —	$ 6.0	$ —
Interest rate swaps [1]	19.5	—	51.4	—
Interest rate caps [2]	—	11.4	—	—
Interest rate swaps [2] [3]	—	7.0	—	17.8
Total	$ 21.7	$ 18.4	$ 57.4	$ 17.8

(1) Amounts were included in other current assets and other long-term assets on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively.

(2) Amounts were included in other current liabilities and other long-term liabilities on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively.

(3) Amounts related to the financing component of the pay-fixed interest rate swaps.

Schedule of Effect of Interest Rate Swaps

The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statements of operations (in millions):

		Three Months Ended September 30,		Nine Months Ended September 30,	
	Location	2024	2023	2024	2023
Derivatives not designated as hedging instruments					
Loss recognized in income	Other income, net	$ —	$ —	$ —	$ 0.6
Derivatives in cash flow hedging relationships					
Gain (loss) recognized in OCI (effective portion)		$ (11.8)	$ 7.4	$ (2.7)	$ 24.1
Gain reclassified from accumulated OCI into income (effective portion) [1]	Interest expense, net	$ (14.8)	$ (9.2)	$ (44.3)	$ (23.3)

(1) Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million and $16.0 million for the three and nine months ended September 30, 2023, respectively. There were no corresponding amounts for the three and nine months ended September 30, 2024.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

9 Months Ended
Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share

A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Net loss attributable to Surgery Partners, Inc.	$ (31.7)	$ (4.9)	$ (59.6)	$ (10.9)
Denominator:				
Weighted average common shares outstanding:				
Basic	126,172	125,747	126,093	125,559
Diluted [1]	126,172	125,747	126,093	125,559
Net loss per share attributable to common stockholders:				
Basic	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Diluted [1]	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:				
Stock options	1,187	1,421	1,164	1,412
Restricted shares	281	208	264	202

(1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Other Current Liabilities (Tables) — **9 Months Ended Sep. 30, 2024**

Other Liabilities Disclosure [Abstract]

Schedule of Other Current Liabilities

A summary of other current liabilities was as follows (in millions):

	September 30, 2024	December 31, 2023
Right-of-use operating lease liabilities	$ 41.4	$ 37.6
Cost report liabilities	20.7	23.9
Amounts due to patients and payors	29.4	23.9
Interest payable	29.9	17.8
Interest rate swaps	7.0	—
Accrued expenses and other	113.8	100.9
Total	$ 242.2	$ 204.1

XML 38 R27.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables) — **9 Months Ended Sep. 30, 2024**

Segment Reporting [Abstract]

Schedule of Segment Revenue and Operating Income

The following tables present financial information for each reportable segment (in millions):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenues:				
Surgical Facility Services	$ 735.4	$ 657.3	$ 2,158.5	$ 1,956.5
Ancillary Services	35.0	16.8	91.4	51.4
Total	$ 770.4	$ 674.1	$ 2,249.9	$ 2,007.9
Adjusted EBITDA:				
Surgical Facility Services	$ 149.6	$ 138.6	$ 419.3	$ 384.1
Ancillary Services	0.7	(1.2)	(0.6)	(2.7)
All other	(21.7)	(31.9)	(74.3)	(85.6)
Total	$ 128.6	$ 105.5	$ 344.4	$ 295.8
Reconciliation of Adjusted EBITDA:				
Income before income taxes	$ 10.9	$ 32.8	$ 72.9	$ 82.3
Net income attributable to non-controlling interests	(38.1)	(34.6)	(118.7)	(99.5)
Interest expense, net	50.0	49.8	148.8	144.3
Depreciation and amortization	50.2	28.9	118.7	87.0
Equity-based compensation expense	7.1	4.4	27.1	13.2
Transaction, integration and acquisition costs [1]	31.5	13.0	71.2	38.8
Net loss on disposals, consolidations and deconsolidations	14.7	5.8	21.5	7.5
Litigation settlements and regulatory change impact [2]	1.6	4.2	1.5	13.9
Loss on debt extinguishment	—	—	5.1	—
Undesignated derivative activity	—	—	—	0.6
Other [3]	0.7	1.2	(3.7)	7.7
Adjusted EBITDA	$ 128.6	$ 105.5	$ 344.4	$ 295.8

(1) This amount includes transaction and integration costs of $29.4 million and $12.8 million for the three months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $2.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively.

This amount includes transaction and integration costs of $66.1 million and $37.3 million for the nine months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $5.1 million and $1.5 million for the nine months ended September 30, 2024 and 2023, respectively.

(2) This amount includes a litigation settlement loss of $0.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $1.1 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively.

This amount includes a litigation settlements gain of $0.8 million and a loss of $8.1 million for the nine months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $2.3 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, the nine months ended September 30, 2023 includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.

(3) For the three months ended September 30, 2024, this amount includes hurricane-related impacts. For the three months ended September 30, 2023, this amount includes estimates for the net impact of a cyber event.

For the nine months ended September 30, 2024, this amount includes hurricane-related impacts in the third quarter of 2024, net of insurance proceeds related to cyber event losses predominantly incurred in 2023. For the nine months ended September 30, 2023, this amount includes estimates for the net impact of the same cyber event and losses from a divested business.

Schedule of Reconciliation of Assets from Segment to Consolidated

	September 30, 2024	December 31, 2023
Assets:		
Surgical Facility Services	$ 6,935.7	$ 6,347.4
Ancillary Services	85.1	36.3
All other	513.6	493.0
Total assets	$ 7,534.4	$ 6,876.7

Schedule of Financial Information by Reportable Segment

	Nine Months Ended September 30,	
	2024	2023
Cash purchases of property and equipment:		
Surgical Facility Services	$ 62.5	$ 68.4
Ancillary Services	1.9	0.6
All other	3.7	—
Total cash purchases of property and equipment	$ 68.1	$ 69.0

XML 39 R28.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Narrative (Details) — **Sep. 30, 2024 state facility**

Product Information [Line Items]

Number of surgical facilities owned	166
Number of states in which entity operates | state	33
Number of surgical facilities owned, majority interest	89
Number of surgical facilities owned, consolidated	123

Facilities, Ambulatory Surgery Centers

Product Information [Line Items]

Number of surgical facilities owned	147

Facilities, Surgical Hospitals

Product Information [Line Items]

Number of surgical facilities owned	19

XML 40 R29.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) - Revenue Source - Revenue

	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	100.00%	100.00%	100.00%	100.00%

Total patient service revenues				
Revenue from External Customer [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	97.70%	98.20%	98.10%	98.40%
Surgical Facility Services				
Revenue from External Customer [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	93.30%	95.80%	94.10%	95.90%
Ancillary Services				
Revenue from External Customer [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	4.40%	2.40%	4.00%	2.50%
Other service revenues				
Revenue from External Customer [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	2.30%	1.80%	1.90%	1.60%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Revenues by Sources (Details) - USD ($) $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Disaggregation of Revenue [Line Items]				
Total revenues	$ 770.4	$ 674.1	$ 2,249.9	$ 2,007.9
Total patient service revenues				
Disaggregation of Revenue [Line Items]				
Total revenues	$ 753.2	$ 662.3	$ 2,206.6	$ 1,976.7
Total patient service revenues | Customer | Revenue				
Disaggregation of Revenue [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	100.00%	100.00%	100.00%	100.00%
Private insurance				
Disaggregation of Revenue [Line Items]				
Total revenues	$ 393.2	$ 347.1	$ 1,152.2	$ 1,024.3
Private insurance | Customer | Revenue				
Disaggregation of Revenue [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	52.20%	52.40%	52.20%	51.80%
Government				
Disaggregation of Revenue [Line Items]				
Total revenues	$ 318.3	$ 271.6	$ 932.0	$ 837.6
Government | Customer | Revenue				
Disaggregation of Revenue [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	42.30%	41.00%	42.20%	42.40%
Self-pay				
Disaggregation of Revenue [Line Items]				
Total revenues	$ 19.7	$ 16.9	$ 60.2	$ 49.6
Self-pay | Customer | Revenue				
Disaggregation of Revenue [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	2.60%	2.60%	2.70%	2.50%
Other				
Disaggregation of Revenue [Line Items]				
Total revenues	$ 22.0	$ 26.7	$ 62.2	$ 65.2
Other | Customer | Revenue				
Disaggregation of Revenue [Line Items]				
Revenue by service type as a proportion of total revenues (percent)	2.90%	4.00%	2.90%	3.30%
Other service revenues				
Disaggregation of Revenue [Line Items]				
Total revenues	$ 17.2	$ 11.8	$ 43.3	$ 31.2

XML 42 R31.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Income Taxes (Details) - USD ($) $ in Millions	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Organization, Consolidation and Presentation of Financial Statements [Abstract]		
Effective tax rate	18.90%	7.70%
Tax expense (benefits) related to vesting of restricted stock awards	$ 1.5	$ (1.6)
Effective income tax rate reconciliation, disposition of business, amount		$ 15.8

XML 43 R32.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details) $ in Millions	**9 Months Ended**
	Sep. 30, 2024 USD ($)
Goodwill [Roll Forward]	
Goodwill, beginning of period	$ 4,326.0
Acquisitions, including post acquisition adjustments	495.4
Disposals	(6.0)
Goodwill, end of period	$ 4,815.4

XML 44 R33.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Non-Controlling Interests - Redeemable (Details) - USD ($) $ in Millions	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Non-Controlling Interests - Redeemable [Roll Forward]		
Balance at beginning of period	$ 327.4	$ 342.0
Net income attributable to non-controlling interests—redeemable	19.2	25.6
Acquisition and disposal of shares of non-controlling interests, net—redeemable	121.4	(2.2)
Distributions to non-controlling interest —redeemable holders	(31.6)	(33.2)
Balance at end of period	$ 436.4	$ 332.2

XML 45 R34.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details) - USD ($)			
	Sep. 30, 2024	**Apr. 10, 2024**	**Dec. 31, 2023**

$ in Millions			
Secured Debt | Senior secured term loan | Carrying Amount			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	$ 1,391.5		$ 1,398.4
Secured Debt | Senior secured term loan | Fair Value | Fair Value, Inputs, Level 2			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	1,393.2		$ 1,401.9
Senior Notes | 6.750% senior unsecured notes due 2025			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Stated interest rate		6.75%	6.75%
Senior Notes | 6.750% senior unsecured notes due 2025 | Carrying Amount			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	0.0		$ 185.0
Senior Notes | 6.750% senior unsecured notes due 2025 | Fair Value | Fair Value, Inputs, Level 2			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	0.0		$ 183.2
Senior Notes | 10.000% senior unsecured notes due 2027			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Stated interest rate		10.00%	10.00%
Senior Notes | 10.000% senior unsecured notes due 2027 | Carrying Amount			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	0.0		$ 320.0
Senior Notes | 10.000% senior unsecured notes due 2027 | Fair Value | Fair Value, Inputs, Level 2			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	$ 0.0		321.2
Senior Notes | 7.250% senior unsecured notes due 2032			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Stated interest rate	7.25%	7.25%	
Senior Notes | 7.250% senior unsecured notes due 2032 | Carrying Amount			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	$ 800.0		0.0
Senior Notes | 7.250% senior unsecured notes due 2032 | Fair Value | Fair Value, Inputs, Level 2			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Long-term debt	$ 835.0		$ 0.0

XML 46 R35.htm IDEA: XBRL DOCUMENT

Organization and Summary of Accounting Policies - Variable Interest Entities (Details) $ in Millions	**Sep. 30, 2024 facility**	**Sep. 30, 2024 physician_practice**	**Sep. 30, 2024 USD ($)**	**Dec. 31, 2023 USD ($)**
Variable Interest Entity [Line Items]				
Number of facilities included in VIE	9	26		
Assets			$ 7,534.4	$ 6,876.7
Variable Interest Entity, Primary Beneficiary				
Variable Interest Entity [Line Items]				
Assets			86.2	65.3
Liabilities			$ 57.9	$ 41.2

XML 47 R36.htm IDEA: XBRL DOCUMENT

Acquisitions, Disposals and Deconsolidations - Acquisitions (Details) $ in Millions	**9 Months Ended**					
	Sep. 30, 2024 USD ($) surgical_facility	**Sep. 30, 2023 USD ($)**	**Sep. 30, 2023 USD ($) surgical_facility**	**Sep. 30, 2023 USD ($) physician_practice**	**Sep. 30, 2023 USD ($) de_novo_surgical_facility**	**Dec. 31, 2023 USD ($)**
Business Acquisition [Line Items]						
Total cash consideration, net of cash acquired	$ 291.2	$ 48.8				
Goodwill	$ 4,815.4					$ 4,326.0
Equity Method Investments						
Business Acquisition [Line Items]						
Number of non-controlling interests in in-development de novo surgical facilities acquired			5		2	
Surgical Facilities and Anesthesia Practice						
Business Acquisition [Line Items]						
Number of business entities acquired | surgical_facility	6					
Total cash consideration, net of cash acquired	$ 291.2					
Noncash consideration	1.1					
Recognized non-controlling interests	293.2					
Goodwill	506.7					
Investments and advances to affiliates	$ 44.6					
Surgical Facilities and Physician Practices						
Business Acquisition [Line Items]						
Number of business entities acquired			2	1		
Total cash consideration, net of cash acquired		23.1				
Noncash consideration		1.3				
Recognized non-controlling interests		20.4	$ 20.4	$ 20.4	$ 20.4	
Goodwill		39.7	$ 39.7	39.7	$ 39.7	
Surgical Facilities And In-Development De Novo Surgical Facility						
Business Acquisition [Line Items]						
Number of business entities acquired			2		1	
Total cash consideration, net of cash acquired		26.9				
Recognized non-controlling interests		55.1	$ 55.1	55.1	$ 55.1	
Goodwill		106.3	106.3	106.3	106.3	
Non-controlling interest, fair value		27.3				
Net loss on fair value of non-controlling interest		7.1				
Surgical Facilities and In-Development De Novo Surgical Facilities						
Business Acquisition [Line Items]						
Total cash consideration, net of cash acquired		50.2				
Surgical Facilities and In-Development De Novo Surgical Facilities | Management Rights Agreement						
Business Acquisition [Line Items]						
Intangible assets acquired		$ 21.0	$ 21.0	$ 21.0	$ 21.0	
Surgical Facilities and In-Development De Novo Surgical Facilities | Equity Method Investments | Management Rights Agreement						
Business Acquisition [Line Items]						
Number of non-controlling interests in surgical facilities acquired | surgical_facility			4			

XML 48 R37.htm IDEA: XBRL DOCUMENT

Acquisitions, Disposals and	**9 Months Ended**

Deconsolidations - Disposals and Deconsolidations (Details) $ in Millions	Sep. 30, 2024 USD ($) surgical_facility	Sep. 30, 2023 USD ($) surgical_facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]		
Proceeds from sales of equity investments	$ 4.0	$ 1.0
Loss on sale of equity method investment	10.0	
Proceeds from disposals of facilities and other assets	$ 1.5	$ 25.8
Surgical Facility, Equity Method Investment | Disposed of by Sale		
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]		
Number of interests sold | surgical_facility	1	
Proceeds from sales of equity investments	$ 2.0	
Loss on sale of equity method investment	$ 3.7	
Surgical Facility With A Retained Interest | Disposed of by Sale		
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]		
Number of interests sold | surgical_facility	1	
Proceeds from disposals of facilities and other assets	$ 2.5	
Pre-tax gain (loss) on disposal	$ 2.7	
Surgical Facility | Disposed of by Sale		
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]		
Number of interests sold | surgical_facility	1	
Pre-tax gain (loss) on disposal	$ (3.4)	
2023 Disposals | Disposed of by Sale		
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]		
Number of interests sold | surgical_facility		6
Proceeds from disposals of facilities and other assets		$ 30.4
Pre-tax gain (loss) on disposal		26.9
Surgical Facilities and In-Development De Novo Surgical Facilities | Disposed of by Sale		
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]		
Proceeds from sales of equity investments		1.5
Loss on sale of equity method investment		$ 13.7

XML 49 R38.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2024	Apr. 10, 2024	Dec. 31, 2023
Debt Instrument [Line Items]			
Finance lease obligations	$ 723.6		$ 693.6
Less: unamortized debt issuance costs and discounts	(34.1)		(27.1)
Total debt	3,191.5		2,775.1
Less: current maturities	97.3		73.3
Total long-term debt	3,094.2		2,701.8
Secured Debt | Senior secured term loan			
Debt Instrument [Line Items]			
Long-term debt	1,391.5		1,398.4
Unamortized fair value discount	1.5		1.6
Secured Debt | Senior secured revolving credit facility			
Debt Instrument [Line Items]			
Long-term debt	98.0		0.0
Senior Notes | 6.750% senior unsecured notes due 2025			
Debt Instrument [Line Items]			
Long-term debt	0.0		$ 185.0
Stated interest rate		6.75%	6.75%
Senior Notes | 10.000% senior unsecured notes due 2027			
Debt Instrument [Line Items]			
Long-term debt	0.0		$ 320.0
Stated interest rate		10.00%	10.00%
Senior Notes | 7.250% senior unsecured notes due 2032			
Debt Instrument [Line Items]			
Long-term debt	$ 800.0		$ 0.0
Less: unamortized debt issuance costs and discounts		$ 12.5	
Stated interest rate	7.25%	7.25%	
Notes payable and other secured loans			
Debt Instrument [Line Items]			
Long-term debt	$ 212.5		$ 205.2

XML 50 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Narrative (Details) - USD ($) $ in Millions	Jun. 20, 2024	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023	Apr. 10, 2024	Dec. 31, 2023
Debt Instrument [Line Items]							
Debt issuance costs and discount		$ 34.1		$ 34.1			$ 27.1
Loss on debt extinguishment		$ 0.0	$ 0.0	$ 5.1	$ 0.0		
7.250% senior unsecured notes due 2032 | Senior Notes							
Debt Instrument [Line Items]							
Stated interest rate		7.25%		7.25%		7.25%	
Original balance of debt						$ 800.0	
Debt issuance costs and discount						$ (12.5)	
Loss on debt extinguishment				$ 2.8			
6.750% senior unsecured notes due 2025 | Senior Notes							
Debt Instrument [Line Items]							
Stated interest rate						6.75%	6.75%
10.000% senior unsecured notes due 2027 | Senior Notes							
Debt Instrument [Line Items]							
Stated interest rate						10.00%	10.00%
2024 Refinancing Term Loans | Secured Debt							
Debt Instrument [Line Items]							
Original balance of debt	$ 1,400.0						
Loan amortization rate	0.25%						
Debt instrument, call premium percentage	1.00%						
Debt issuance costs and discount	$ 2.4						
Loss on debt extinguishment				2.3			
2024 Refinancing Term Loans | Secured Debt | Term Rate Based Secured Overnight Financing Rate (SOFR)							
Debt Instrument [Line Items]							
Debt instrument, basis spread on variable rate	2.75%						
2024 Refinancing Term Loans | Secured Debt | Federal Funds Effective Swap Rate							

Debt Instrument [Line Items]			
Debt instrument, basis spread on variable rate	0.50%		
2024 Refinancing Term Loans | Secured Debt | SOFR			
Debt Instrument [Line Items]			
Debt instrument, basis spread on variable rate	1.00%		
Debt instrument, basis spread on variable rate, floor	1.00%		
2024 Refinancing Term Loans | Secured Debt | Base Rate			
Debt Instrument [Line Items]			
Debt instrument, basis spread on variable rate	1.75%		
Revolving Credit Facility | Senior secured revolving credit facility | Secured Debt			
Debt Instrument [Line Items]			
Outstanding balance on debt		$ 703.8	703.8
Revolving Credit Facility | Credit Facility | Secured Debt			
Debt Instrument [Line Items]			
Outstanding balance on debt		595.8	595.8
Letter of Credit | Credit Facility | Secured Debt			
Debt Instrument [Line Items]			
Outstanding letters of credit		$ 10.0	$ 10.0

XML 51 R40.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details) - USD ($) $ in Millions	**Sep. 30, 2024**	**Dec. 31, 2023**
Assets:		
Operating lease assets	$ 297.5	$ 255.3
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net of accumulated depreciation of $558.8 and $454.4, respectively	Property and equipment, net of accumulated depreciation of $558.8 and $454.4, respectively
Finance lease assets	$ 588.6	$ 587.0
Total leased assets	$ 886.1	$ 842.3
Operating lease liabilities:		
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Current	$ 41.4	$ 37.6
Long-term	286.4	248.9
Total operating lease liabilities	$ 327.8	$ 286.5
Finance lease liabilities:		
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current maturities of long-term debt	Current maturities of long-term debt
Current	$ 29.5	$ 25.4
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt, less current maturities	Long-term debt, less current maturities
Long-term	$ 694.1	$ 668.2
Total finance lease liabilities	723.6	693.6
Total lease liabilities	$ 1,051.4	$ 980.1

XML 52 R41.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Lease Expense and Cash Flow Information (Details) - USD ($) $ in Millions	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Leases [Abstract]		
Operating lease costs	$ 50.1	$ 48.7
Finance lease costs:		
Amortization of leased assets	47.5	29.0
Interest on lease liabilities	40.6	35.9
Total finance lease costs	88.1	64.9
Variable and short-term lease costs	18.1	16.3
Total lease costs	156.3	129.9
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash outflows from operating leases	48.0	47.2
Operating cash outflows from finance leases	38.6	34.1
Financing cash outflows from finance leases	24.4	19.3
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	79.3	39.9
Finance leases	$ 40.8	$ 108.7

XML 53 R42.htm IDEA: XBRL DOCUMENT

Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details) - USD ($) $ in Millions	**Sep. 30, 2024**	**Dec. 31, 2023**
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	$ 2,739.9	$ 1,360.1
Pay-fixed swap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	435.0	435.0
Pay-fixed swap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	330.0	330.0
Pay-fixed swap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	435.0	435.0
Interest rate cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	145.6	151.4
Interest rate cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	8.3	8.7
Deferred premium cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	396.0	0.0
Deferred premium cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	198.0	0.0

Deferred premium cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	396.0	0.0
Deferred premium cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	198.0	0.0
Deferred premium cap		
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]		
Current notional amount	$ 198.0	$ 0.0

XML 54 R43.htm IDEA: XBRL DOCUMENT

Derivatives and Hedging Activities - Narrative (Details)	**9 Months Ended**			
	Sep. 30, 2024 USD ($) interest_rate_swap	**Sep. 30, 2023 USD ($)**	**Apr. 09, 2024 USD ($) interest_rate_swap**	**Dec. 31, 2023 USD ($)**
Derivative [Line Items]				
Current notional amount	$ 2,739,900,000			$ 1,360,100,000
Amount estimated to be reclassified as a reduction to interest expense over next 12 months	$ 19,000,000.0			
Interest rate swaps				
Derivative [Line Items]				
Number of interest rate swaps held | interest_rate_swap	3			
Interest rate swaps | Minimum				
Derivative [Line Items]				
Variable interest rate of derivative instrument (percent)	0.75%			
Interest rate swaps | Derivatives in cash flow hedging relationships				
Derivative [Line Items]				
Current notional amount	$ 1,200,000,000			
Interest rate caps (2)				
Derivative [Line Items]				
Number of interest rate swaps held | interest_rate_swap	2			
Current notional amount	$ 153,900,000			
Interest rate caps (2) | Derivatives not designated as hedging instruments				
Derivative [Line Items]				
Gain on termination		$ 8,600,000		
Deferred premium cap				
Derivative [Line Items]				
Number of interest rate swaps held | interest_rate_swap			5	
Current notional amount	$ 1,400,000,000		$ 1,400,000,000	

XML 55 R44.htm IDEA: XBRL DOCUMENT

Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) - USD ($) $ in Millions	**Sep. 30, 2024**	**Dec. 31, 2023**
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]		
Derivative asset, notional amount	$ 21.7	$ 57.4
Derivative liability, notional amount	18.4	17.8
Derivatives in cash flow hedging relationships | Interest rate caps (2)		
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]		
Derivative asset, notional amount	2.2	6.0
Derivative liability, notional amount	11.4	0.0
Derivatives in cash flow hedging relationships | Interest rate swaps		
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]		
Derivative asset, notional amount	19.5	51.4
Derivative liability, notional amount	$ 7.0	$ 17.8

XML 56 R45.htm IDEA: XBRL DOCUMENT

Derivatives and Hedging Activities - Schedule of Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details) - USD ($) $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]				
OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest expense, net	Interest expense, net	Interest expense, net	Interest expense, net
Amortization of accumulated OCI related	$ 0.0	$ 5.3	$ 0.0	$ 16.0
Derivatives not designated as hedging instruments				
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]				
Loss recognized in income	0.0	0.0	0.0	0.6
Derivatives in cash flow hedging relationships				
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]				
Gain (loss) recognized in OCI (effective portion)	(11.8)	7.4	(2.7)	24.1
(Gain) loss reclassified from accumulated OCI into income (effective portion)	$ (14.8)	$ (9.2)	$ (44.3)	$ (23.3)

XML 57 R46.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Numerator:				
Net loss attributable to Surgery Partners, Inc.	$ (31.7)	$ (4.9)	$ (59.6)	$ (10.9)
Weighted average common shares outstanding:				
Basic (shares)	126,172	125,747	126,093	125,559
Diluted (shares)	[1] 126,172	125,747	126,093	125,559
Net loss per share attributable to common stockholders:				
Basic (in USD per share)	$ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Diluted (in USD per share)	[1] $ (0.25)	$ (0.04)	$ (0.47)	$ (0.09)
Stock options				
Net loss per share attributable to common stockholders:				

Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)	1,187	1,421	1,164	1,412
Restricted shares				
Net loss per share attributable to common stockholders:				
Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)	281	208	264	202

[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.

XML 58 R47.htm IDEA: XBRL DOCUMENT

Other Current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Other Liabilities Disclosure [Abstract]		
Right-of-use operating lease liabilities	$ 41.4	$ 37.6
Cost report liabilities	20.7	23.9
Amounts due to patients and payors	29.4	23.9
Interest payable	29.9	17.8
Interest rate swaps	7.0	0.0
Accrued expenses and other	113.8	100.9
Total	$ 242.2	$ 204.1

XML 59 R48.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]		
Professional, general and workers' compensation insurance reserve	$ 18.1	$ 18.2
Estimated insurance recoveries	$ 10.2	$ 10.2

XML 60 R49.htm IDEA: XBRL DOCUMENT

Segment Reporting - Narrative (Details)	9 Months Ended Sep. 30, 2024 segment
Segment Reporting [Abstract]	
Number of operating segments	2

XML 61 R50.htm IDEA: XBRL DOCUMENT

Segment Reporting - Schedule of Segment Revenue and Operating Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]				
Revenues	$ 770.4	$ 674.1	$ 2,249.9	$ 2,007.9
Adjusted EBITDA	128.6	105.5	344.4	295.8
Reconciliation of Adjusted EBITDA:				
Income before income taxes	10.9	32.8	72.9	82.3
Net income attributable to non-controlling interests	(38.1)	(34.6)	(118.7)	(99.5)
Interest expense, net	50.0	49.8	148.8	144.3
Depreciation and amortization	50.2	28.9	118.7	87.0
Equity-based compensation expense	7.1	4.4	27.1	13.2
Transaction, integration and acquisition costs	31.5	13.0	71.2	38.8
Net loss on disposals, consolidations and deconsolidations	14.7	5.8	21.5	7.5
Litigation settlements and regulatory change impact	1.6	4.2	1.5	13.9
Loss on debt extinguishment	0.0	0.0	5.1	0.0
Undesignated derivative activity	0.0	0.0	0.0	0.6
Other	0.7	1.2	(3.7)	7.7
Transaction and integration costs	29.4	12.8	66.1	37.3
Start-up costs	2.1	0.2	5.1	1.5
(Loss) gain on litigation settlement	(0.5)	(3.6)	0.8	(8.1)
Other litigation costs	1.1	0.6	2.3	1.4
Additional interest expense for Florida LOP regulation change				4.4
Operating Segments | Surgical Facility Services				
Segment Reporting Information [Line Items]				
Revenues	735.4	657.3	2,158.5	1,956.5
Adjusted EBITDA	149.6	138.6	419.3	384.1
Operating Segments | Ancillary Services				
Segment Reporting Information [Line Items]				
Revenues	35.0	16.8	91.4	51.4
Adjusted EBITDA	0.7	(1.2)	(0.6)	(2.7)
All other				
Segment Reporting Information [Line Items]				
Adjusted EBITDA	$ (21.7)	$ (31.9)	$ (74.3)	$ (85.6)

XML 62 R51.htm IDEA: XBRL DOCUMENT

Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) - USD ($) $ in Millions	9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]			
Total assets	$ 7,534.4		$ 6,876.7
Total cash purchases of property and equipment	68.1	$ 69.0	
Operating Segments | Surgical Facility Services			
Segment Reporting Information [Line Items]			
Total assets	6,935.7		6,347.4
Total cash purchases of property and equipment	62.5	68.4	
Operating Segments | Ancillary Services			
Segment Reporting Information [Line Items]			
Total assets	85.1		36.3
Total cash purchases of property and equipment	1.9	0.6	
All other			
Segment Reporting Information [Line Items]			
Total assets	513.6		$ 493.0
Total cash purchases of property and equipment	$ 3.7	$ 0.0	

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

<7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71%
B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8]*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M %F";%FQX+) W 4 -T> 8 >&PO=V]R:W-H965T&UL MM9EK;]LV%(;_"N$-PP;$L4CYDG2.
<=)NF!MZL;9BF[8!UJB;:&2J%&4'? [M'4JVE&34L2'47Q+=SFL^/+R\)(<;J;ZE*R$T>8["-UJK;1.WG4ZJ;<2$4 / M92)B>+.0*N(:;M6RDR9<#\BL(. _^JY9@2B5!XVDAP^+<6$Q&&1@G*\>].
MM%7^]@E\>;U7O\OA 6;.4S&1X9? UZNKUD6+^&+!LU _RLUO8@?4,WJ>#-/\ M+]D4WW:[+>)EJ9;1+AA*$ 5Q\9_[RKB98!3$\!V >Q- *W[!7<7X.:@129X^(\[B;V"[9:P74Q]=".]#+JH)D_;1-
A(\7#]M# _; MD-"HADB]$JEW'-+GC"LM5+@ECR*12MOP<"FM,ENE3-"HAGC]$J] '-Y4J$#Z MIA<2& >LR<.5RGY7V_'0^(:<@Y)S<&3+5!RFD'P&J,\CKK7@86I-)!K6$/"B M!+Q
"W4;ZT!OR5T0"O*017.A;&"XAN/0MCOH#?HV.#2T(=QE"7=Y#-RC6 9F M&(4T/0(VD9QG5FFED)MR12ZD;N8^_<1HQJ-*2E3C6G.L?P0N&D@;*_* M37,)(S,-'9-(128RBS5@3*1OK80#ZC>W-
F(\]"GR"QM!CT%^XL_DWH>.&BP" M+^=&6O,!R>Z@[?:9<\E<*R\:W)275;SL&-ZQ[X,Z-,3=!?D WY%/L3VON*3; M==]QK%6!ZC:MBLHA4=23_*\]N8.FOF3 MW,36:L#EKA4TGXV4OA7U%/:
(5OZ(X@[G+6K9I:=*KH/8LZ<=UWQZL(*>PC31 MRC51W.N\!9W*5/.0_!4D]:,6KN@.'#:PDI["/]'*0%'<]^2M=0PKX'HP7*!/ M>U:L4]@E6ODEBIN<#]*#?$U7,L;\Q
$1YG;;O<4;HE6=HGB7NO5J]Y3V"=6V2>&&YQ],LGM ML[?B\5+4VL4#0@_CV66)IDRD]UN09.G$B:4S+H-6L7!([RB7=Q[#R+C;LS.J4[\&MG+AB>"_ $2ZFL8]$!G0\
<%CAD['D"A$#&+R2MQ*=P0JQR0NPH)S2+>!B2ZRR%UZF] MW>(ZM8MQ/*XI7V6 V%$&Z#82:FDZYGM0T"OP"%'"8WMJ<<%ZT%/X'U;Y'X;; MEWTB5P(2B>'A,O5XI _!!K/)!#+[R:=,@ZN-
S1QJ)?Y.#F=7 M#X5:+UD[:QMD98;849M*$QA2%;B^^]@7S^1W8<_CH3TD MA _;=BPO7NNC&@YLFLS(\#/ M5@%N[@X?VD06<7JSU?.(7Y<2OS MXQ[8W7G#N-O8K:4\(/?9FD<\"EC97]P-
W"^T*9 M#^#]0DJ]OS$_4)YHC_X#4$L#!!0 (%F";%E!V,C YP8 &0< 8 M>&PO=V]R:W-H965T&ULK9G[;]LV$,?_%<(+N@WP0R3U;!,# M:9*M!=HTJ-
OM9T:F8Z&2Z(JTD^ROWU%2)+FDF!1H@"1Z'$_?X^,^/.GT7E3? MY)9SA1Z*O)1GDZU2N]>+A4RWO&!R+G:\A#L;415,P6EUMY"[BK-UW:C(%\3S MPD7!LG*R/*VOW53+4[%7>5;RFPK)?
5&PZ0$MS\7]V01/GBY\SNZV2E]8+$]W M[(ZON/]ZNZG@;-%Y66<%+V4F2E3QS=GD'+^^H(%N4%O\D_%[.3A&.I1;(;[I MD_?KLXFG%?&?^K#AZ"N6627XC\ MWVRMMF>3>(+6?,/VN?
HL[M_Q-J!:8"IR6?]%]ZVM-T'I7BI1M(U!09&5S7_V MT';$H 'V1QJ0M@%Y:0/:-J!UH(VR.JQ+IMCRM!+WJ-+6X$T?U'U3MX9HLE/ MXTI5<#=FIY\>GZ\NIZ=76)&XCU2Y"DTQW5S>MQ\
8%WT9,N>E+[HV/1[ZN*EPHQ*;F2KVWQ- Y\NP.]R%[+ M'4OYV016D>35@4^6KW[#H??&%MTOIV(,L2!(I M!XVW.;!4^+X\0+^)*N/6OFL:!X-G MQN0'68$A*PKFQ*XJ[%2%3E4W%=^Q;(WX
Z1X:9<6FMTQ?&XC+C3T4VR7%G72 M(J>T3VK+*\AFP\5FDQ<9\K!/C3$UK6!([O"N%,8.Q5^$8KE+U 8FPH]&A@+ M(S:G0#*B,.D4)L\,+Z"[4H_U$M:K=P!{9(\5> MSR3/&>O?
0JSO@3&U9%%/GJQ4K+S+(!FTHU-';@609T[R.,2&=IL=C;W!6!ZK M'Q 5/\I-*C(S4L=0QL?6!ERD52 K'-)LMA<.PKM/4]5$6P;TPPBQF._?G(M.L4]#[$30CU2G41FEUO,@F!.1U3W M9,-
NM'T0Y=U,\:K0&S@.:WB-%'MPZ:5F DZ,1&BQBI.Q3(-[OF$WX)ILF'>: M'3(M^,*#06YEFE:0E$9[M:<<=F.NR8D.=3:*47] UU:?:1?&43B:)GK@X?!% MNS=83;>PI!3PV+J%PTYP_NP>
[E=Y.PZZ1REVL[3;'NW8J)C>"%M &GEF$K&9 MX=$$V+,4NV$*$JL]K$%06(DVBD]_RDF^RD8ED4C7TYXDW^#'FO-DDHJ/*>\9B M-V2/-RJ#>665;=*/P!;4R"(6,V\T59,>DL0-R:?
9#Z7LOJI%:M;G@U1X:^4C M,;D'J9K^H-IB%8WF%-*SD;C9>=S/>J:#B0FY(#+WJZW9<+<5D#&E@\K03<(/ M1QTY!01*V0GO^]RJV\0<]1+?%&[!8>2-+D#2\Y"X>>BD^',=;D*/Q*&1U&UF M?
CQ6^Y$>CN3GX/B<6I-]U#,G\S,25_KPL* M]6A_ ?)+Z?FKO!U'W=.3N.D)17*[090Z_BDZ\>8>!E)5Z,#R/7^#Y);!@Q'; MJRU4^/^!Y0P1;TJQ-P4.=?BW51F&Q2^)H-(K!RUTW\I]C
M$>2EF9M'U"0Z)C@P@&2S_QH;$W2'0W4C?YF(%[+;868OGQ> 3D/[^]I%5=UDI8<^W@8;>/ (_ M5?-)GJ[SE18E=_%;H52HFB/MQR!K*U =S?"*&>3O2'IN[#XO) 4$L#!!0 (M %F";%FQ1>AD40,
!<+ 8 >&PO=V]R:W-H965T&ULMK99K;]HP%(;_BI554RMUYZ.:U@T@4F#:I%U2Z[<.T#VXPQ*H39[8#ZW[]CITT M2]J40C6$($[.>?V\)\>)AULN[F5B* 8Y;(D14IE9[9M@PC$F/9XBE)X,J*
MBQ@K&(JU+5-!\-(DQQV@8[G M6)!1431+,3] %]74S1\=$).D(T09>4,;@G0[I\ASO'9#^F1W^I2$D.Z:=+^>;D,ARFIX934\H^>_A*.P(M"D"O$5^D03 MG(04,S3GDIJF^S&^DTI
Z_ULLIIKMYNU]7H\DRD.R)V! K>/ _[3H? MFXS_)[%:&?RR#/XN]6 <$$DA&T]4D3>R[?KU Y+<=]@OY*4(V\4Y)W#B,W MC!+A3$5 M0N^*J-'V2MK>FVCA?2<5-#A-UCN1>Z\B[XJH(?=+Y/Y.Y
F/8UB&;^SK_CY] M_4I0#7M08@\.P#ZLJ0?/:N@[Q><)^3Z1-7S7^?>>= XWL$=7%()5)M?KP7?P MK.Z-H=W.P.JYO1?P*Z]Y]W#\?=N\T-[+0U-HLP>[LFO16\9++-8TD8B1%>0Z
MK1Z(B'P7E@\43\U&YHXKV!:9PPAVKD3H +B^XEP]#O3>J-P+!W\!4$L#!!0 M (%F";%EYR+J!B @ -TG 8 >&PO=V]R:W-H965T&ULK5I=IN9!L>68:HP\ M2$ZZ]]?OY2/&H(N2V74_=
P<73CW2T>"\Q>9?U,;(33YODTS=3'8:+T[&X_5 MN)K\31Q8GQ]'S\'G\1"Z-]W]3D*1BJ4N3'#X M\RRN19H6EN Y_JZ-#@[W+ 8>_WZU/B_) YE'KL2U3/(5GIS,0@'9"76?) J MK_+E7Z(F5#
[@4J:J_)^\U%AG0)9[I>6V'@Q/L$VRZB__7COB: !U>P:P>@#K M#O!['KCU +<[P.L9X-4#O/?>P:\'^.^]PZ0>,"E]7SFK]/2,:SX]S^4+R0LT M6"M^E.$]1X.#DZS(K(7.X6H"X_3T^N[+++/ZRB&<$?
BWN;F]FEP]PL'B /Y_C M+P\+I[&)9]EIC>*Q-E*K)#QL7U\9!D_!L\ MW7/-K 878CC\?W>?_\]W;SG#/>2*6]IS>^S=9$NY M%62AN1;07#3Y_)1Z1R:PU]8J"MC'FZLZ)AG:L>7XF(+5&)_%D,IK_\1"?.
MKYB?3VDL/J6Q^8F,M2+B'2+BV:Q/OXIGD>T%6FG5R$DYLIA?GJ=!X(P@C9Z/ M_6JB)H$WHFU4;*(8\Z)1U(;-$9CC!$>P%DG_0-*WIMW=3N1<)]D3$=]A0E5' MG6%_5.FRF-
Q:::ER60R"CN)9Z+\B!W=K\4V.+ -[&SWNUV:X,45F 0= M:A T432(1JQ#T43YH5E;" HJ,.0IA@>*H97B?2[70A4JD:=E4+=BE2SA]UK@ MO$,C9%&G5\Q"XT$#"
(5S]* ;74RC;#+IT#>M,AKU=9;H0#^RTK\5H$E?NPI& M-S+OZG8C,T- U.B@)F@2C#K)/D= WLC%.5*G47B.E>6=WHB<2*.+HO+,,1[! M"[L9.\-0SJ@3LAA!42\8!1W2&
(P%1];:M(^$+;72OI9*$[F&Y4__'%F;Z#:. M;H0QF!,>1:8F;,)HX 9&*=>X5N/S_9YN15E#F%D)_P8-:_KF*]@K9 4XJQ8 MN-E#SLS\-9K4#$&Y1A^.$11UF!ER9CK <7KX-
^J46J76="9@RELFO%JQ%D[8 MREPG_RE/H,Q=)*PF)[!%*"*OKC/&@<(*);U.DFA>'J: MA*FPAKY9*@C*[9*,,10DE=OU!0*+^C0=;40=M:NZVT0G3U5M**%U6JYD<+>OU2 >-2"9RCJ;.&S$QF!$4-
M\8ZB'+/O(S#WR%A[,;N\:W8%JFBCE$U!-G$,=8>@0C;R+;-7C QAT,Z[44=A MDSYIRQJEQ^Q*[P8F>%C=Z]=X]V8ZX,Y76T._6,S-%V[*UM*PY(S *BX-N&\-Q MO>L8UN@[9M=W]?;CHUC+7-
11)YI_[TEW1) AL3=1KJEO$!2L:2/+FG:.# E9 MKP\:J#Y@V"[O$9BC,,Q0-!L/6.Q@NBOHD M+6M4'+.KN(/.[_IDL<^?1/Z#W/-JSU:.R1NBZU5O<1Q1K&33ODSC4[:97E=T558T#IVD8U/-
J%!=^V)XOR@FW$Q M;L^)NGLIN#W?[TO-HR\"WMAS?:WE?M)7;YCHJV!SIQ1W%8;#7(7:0UR%VNMW
M52'=VV<:3>O:-2TP)P\;6,IL(2G+=Q4[J46F$YZF/\BJ<&VQ>:_$+EIG(E2(O7($*U.7^9@)3NBA>RR[Y7L&4#X;%>BW \(OOZ=F,(N=C>C;' MSE^ZWEGL>N@5'ZZ4GT>-
FT>J/GS[S/.G)%,D%6MX&<4@,/SZENRZD#+7?GM MTZ/46F[+GQO!P5,% *ZO)7B\/BAN&PO=V]R:W-H965T&ULK5==;^(X%/TK M5K9:M5*;+(Q)(6$!J24:#5*!J.K,/JWTP8"":)&9M
^V_W^LDS8;$19U9>""V M<\ZQS_6-/P9'RG[P+2$"O:9)QH?:5HA=WS#X&Y[C MS5;(!F,TV.$-B8CXMGMB4#,JE56_Z-CB34UM-QS0=.2#"-(XZQX MXM_9P-\8HSF2>18/
V!IX8C>>S()Q%88"@%,T?)\']"U2B%WA,P]E+ MA.9?X-7TZ3G\"KC))Q!-9E /T?7C(/INTWZ%@7H^NH&7:$X0],X22 !^, 0 M,#K9A[$L1_)0C,3^8"0=-*69V'(49BNR4O"#\WS_#-^]%2AL=]#\V"?
%8S(M3D<=\Q;9INTHQC/^/+VCLO/ >@]_N?>38'2J/.GD>IV/] 06!-8'@>@:C6D* MB])6KA8'@B;9DJ8$_76_X(+!A_^W:NX+=4>M+A?#/M_A)1EJ(,P).Q!M]/MO M5M?
\0Q7X2XH%EQ0++R1V,D5.-47..?71#':5.)\+U004W&[.E9O'8=35(:\. M];BV,;:OJTY!01OD^KIU"@K;(,_37;_^JQ@G9MW*K'LV'^=B2QA:GB3B=4(Y MOREC<(LRDB>KP*]]54#<2V;D)
<6"2XJ%%Q([F:1N-4G=LQD9$!8?L#P)% >" M6+S5IT4^KDS5W!2RO5KZW-E=O=M(5P7*TKU&NA8@MPYR&BD=MH7,FLZ)]5YE MO7?6^OCCS%09[BD,F[&[=-
Q&V3W=;QAN@RR[]7VV09ZO.V;M9ZG]>Y5_[ZS_ M1\)YO[%1%/81%H+%B[W BX0@05%&L[LE;-V,PM$AVP!,$,A%H3Q#>.U =;RF MO;$*Y33S)U"@+,HK+GBA N;[NJN.CU_%Q_^)_)#IT8I+M&
<;PM[0$V8B(XS? MRIU65P7%;ZVV=ZZG=QI!4:"ZK=5= ;+,UJ<7*F%Z,V>,VKDT)>!&7@@XK-K[M3!1'CZJUNG/(_^>*",\5L$V<<)60-79EZ#U8 M5EP:BHJ@N_Q4O* "SMAY<0OW+,(D -
ZO*17O%=E!=7,; .0M02P,$% @ M68)L6:3=8\F[@]P< !@ !X;"]W;W)K:.>PH*M$W?+--53UG&N^B">R<)) -Y6L9)%)Q=,*C!FD+"O_ M=%OU80^ /,T NP+8+P'N*P"G CCOC>!6 />]$-
,ZGBGH=P3=$ M:&]DTXNB^P4:^\4R_4Y")?"4(4YY@\G8#\9AX!-$H%9"H&Q2*:G) OY#[TR?'1"3DB M+",CEB3X(&3'5)BMCFE&56;],C/[E@/]>JOGV0,(3\C#C6*;$MVVW(9_!^N--4SO]%#_XY^K-
F./6[<0H^YS4^116@ M7BC"%V3 4Q2I6*O'&L@PBW@#Y&=O)I5 (?C5=/U/B)/,_DBSX(+)G5^365^0>8O=\$&Q-M0Z7K_';WKX;WH$ASS*$LT])4M!+(L1(DG$5YDJ'V>]6T^I M7B'.+_;
[K?:@U;#OXU0KA]!?^G(DCJA8LDR2!!88RCK[B8(KRC%3&HKGA8[. MN$)5+I8Q3F80V@'/%YRKG:$#U+/>^P:02P,$% @ 68)L66\1^?[?" P MEW, !@ !X;"]W;W)KZ':2B+4MK*6TNQ^^Z-
LUS+%$2,9D[8O M&CLA?T-QAD]_C^33QWS]I;A+T]+[<[E8%6>#N[*\?W5R4LSNTF52C/+[=*7_ M\^K,]/X=RD:W2#VNO M>%@ND_5?%^DB?
SP;D,&W7UQEMW=E]8N3\]/[Y#:]3LM/]Q_6^MW)GC+/ENFJ MR/*5MTYOS@:OR2LEHJK"IL2_LO2Q.'CM59?R.<^_5&_>S,\&?M6B=)'.R@J1 MZ!]?TTFZ6%0DW8X_=M#!WF95\?#U-
[K<7+R^F,])D4[RQ;^S>7EW-A@/O'EZ MDSPLRJO\\?=T=T&BXLWR1;'YWWO>3R_?3 M^/UU//7TJ^O+MV^FKS_J-I^NI]^+EJ@[/7K;RWF6+A8ZMXO2DU,VJX^>S71,NMDV@+4WXF)?) M
J@V<5>;Y,NECN7K,I]] 6I/W;5?S^=9-1:2A?9#?063Y#Z#6Q(_P9K- M'I8/BZ1,Y]YE>9>N/=TV/3'<52/V:^J]>)L7Q4OOS6J6+U, +]WXJ[344XIF M3].;;):5 $&Y">_SU7'2K\IUKGVTNM4M*=-
U6I3%+S^:*:&_>56!JW2>ZFGN M\Z+1Q!,=4?NPHONPHAN+O,7B17J;K5:5K8MDD:QFNA.*NT3;?.DEI;Z0V/^1I" >.$5[/SJ^(>F:5G]W+1;K^F@[.?_F)!/YO4!AM86(#JV;FK^>$ MBB@@ON^?
GGP]#!E,LS$F3&+"%!+," RV#PS6,S"ZQ,.6&1RXD$;<'T6F_R9V M,3)B#1]ORT2'*!Z.S4*Q#0J#$34+2;O04(BP:5#9Q2).1^&^E-&-?-^-?%.-
MM72CGDOTQJ/0PTKWW>;5RVH2WDR&=_EBGJX+/5' \9"5?WG_O=+#WM,+]V.R MGO\/ZEZ..=PP85-,6(P)DY@PA00S0DGL0TDX1^1[O=]]L=BL4%G;"G6Q182' ML1X"
MK729[+9P:$M^W9H^5;I= A\"RNI$'(]*(F?3^D:!;7'(1D%C MH&-:E)@P!718U+8S)WZMJ/A.]TZSHEQGGQ\]Q9>F;=[;)9.)N8%\GH])B5)I$I:DGN]>,B .-C;@7Z]6\30IYEZSW1U\& MNMR)
[KN!V],,23@8]_>Q*$:CE%I$ED!FL&AF=-12&7%K98WHZ!04U I46JD* MHCD1T Z*' 3CX;BY78W9M+381 M]AUE$N*4MGH/14S:%)46H](D*DUATJ5(9* MBU%IZ+1D1!JRXJ)H7*DVB
MTA06S8R)6D@C1RII8"@$]EBV%UI,86G:Q62,.E*BTA06S?1OK8T1MSAVE(A" M;-&*,.LC)K?EWH[&I,6=KD"BVE18--/3M5I&W'+9-3^:1+4I46D*ZC72KJC4>AEQ"V;/J:@ $A9ES5Z?
N!O8V].8M!B5)E%I MZLGN-;-+:HV-NC4VAZ+R]X>5/CS[[8=G-[IW=HD/*B$H1L+]#-1RCTB0J36'1 MS.BH]3;:2V_K%!0$4%3&U)H(=N7=H*B!ZE<]#N**!0WMPN3-
D6EQ:@TB4I36#0SI&I=CKJSP#J)*#N&,8J8 M]7F6VU+O"$"5T5!$NB/(6_N2=6NU.%Z1-N6VUKTHF[1ZS@1Q0WM/=1M#6G(M@446509#I4E4FL*BF3%1"VOT2&$-# 4[(P_E#B9C5),2E::P:*9_
M:Y&,ND6RHT04:BM70V)OHE#5,E1:W.D*)*I-A44S/5W+9=0MESV7B$(!XU(Z)6U:A;57-H*-?I_1/'94R5:+*C65DI0&HQJN$8E291 M:0J+9MZF4RMLK)?"UB4H=D3S-IUQ8.WS@'+ ?
3IV+A;ED;V#8[;^%C;6& FP MAB(8-_/F%% N&I.#(Y;9E[4>Q=QZ5/>[X>!^!9.V1,1"VEQ-VXH"!R5WF_N. M)%2:1*4I+)KI_5H_8WWOA>SD=#MUB_G,/C0!Y8#!!*5X1:&5J@N4$V'3I 1*
MZ>$4V!6H!BSY'Y8%;YNUV9I?P MQ\!BBYK:A4J3J#2%13.#HE:M&&)J%X/RK*SAC"I6=3$9HYJ4J#2%13/]6VM5 M[!E2NQB@"@E[)X6J1*'2XDY7(%%M*BR:Z>E:L&(_)K6+ 6E6@256N1O7.Q@
M"K-2CVPS*[&)1Z%%GZL[N!O1V-*D^ATB0J33W9 MO>9S36K=B1^=V75X6Q2'7.Y&]JW;<2BS*R0^M;=WJ(9C5)I$I2DLFAD=M9+& M^V9V/1T4=EH4\UEH[?-XE\PN
$9Y)"PAA=LZG&@^/PA@#<68-%D**$?\T&]+ M[.*U,,6_9V(71TWL0J5-46DQ*DVBTA06S0RI6IGC"(E='$A1\INC$55&0Z7% MJ#3)@;0N8NWM%5",B;8[9/G!<\2>([/+#>]TJUNW,+@HMLJA*&"I-
HM(4%LV, MB5I8XXB971QXU)6PLC3=%GL/YRXV8U2;$I6FLxBFAVN5C#]#;A>',J-LOK49.[NEV"1#6JL&BFKVO%C/^8["X.Y"GQT!)2W*WK'0ZV4=_*[D(U*5%I
MJJ77>,LZ7JME_(>E=W$H_RBRGF;@;F!O1Z.F=Z'2)"I-/=F]9D34TAH_.KWK M\&XH^,R,FM[%H?2ND% @*075<(Q*DZ@TA44SG_E:RVRB;WK7DT$A[.PH1L+ M>LZ@Z)+>!
<"H(,3:Q$%&PV8I"90:BL@JIX!RA%+6EN$E:EU*D.\HI0C49WZA MTJ:HM!B5)E%I"HMFAE2MS@EWVEBWYS+;#[>WAB.JDH9*BU%I4@[Y:H11\S&YD[:B0"*QN\&]?8JJBZ'2%!;-
='TMGXE>\EDGCT?6(&>$ M$.L3$J <()#8A:@@S+K_#8+Y5F8H4&H84.M90PJB42(L??KDX!L'JZ^L?)>L M;S,];2[2&UW1'X4ZEM?;;X'I8F>+JL"^N\W>5Y^ M>U-]K^'^NSC/_P]02P,$% @
68)L656_V-EC!P -A\ !@ !X;"]W M;W)KUG6J)MWLJB2]+);G]]AYZ2LATDQSD7R(9;DX?C,@W-FJ,L7(?]26\8T M^K[+_I5>]
MR"!B&4NT44'AXYG=LBPSF@#'WZ727O6;9F'S^JC]LS4>C%E1Q6Y%]B=/]?:J M-^NAE*WI(=._BY=?66G0V.A+1*;L?_12RD8]E!R4%KMR,2#8\;SXI-]+1S06 M@!['_ E(N(*<+1AT+XG)!;
TMD%FS[JBFBTLI7I TT]#-7%C?V-5@#<]-&)=: MPK</7N_NOR_L[!%?+QR^_W5U_@YOE-_AXN/_Z;8D>/Z/;Z^6OZ/.7 MQS^7J(_^6-ZA#S]]1#\AGJ,'GF40#74YU #&J!PFY0_?
%#],.GYXCAY$KK<* MW>!^#$E6-CJR_N;YILA<(SAO(*O'EN[A(3 MT+T4SQSR%:U^G!_1\7M&])V4M;PUJ;PU"4;TCH'2A-.B .&8,2C]AW8#WE3<.I@Y#, M!^0H=H,ACY(NRZ;.]G:%<-QP?
@LMCFI&BUZM.YE0 M"@'"E*N]4#13GP!YKD3&4PM=V?1-6?NAE\4BUQ(\&)8XI&:-H3:EC2X&0IA:<^!J:\]5%RIV0(P=GY="S=T6=> D-4[R2EU8,RDA.XX5DWYG M?F<2-
^+1(#Z%Z$KU0:PCC7'-R#A(=V4BF[:%49F#,\&Y:W3(ZR0 $^AZS3,H M<4S9C6@D((FTY*M#D3A0 1ETGJG7OMA![C'/%>J304?%PS7;XE&XX=C2?,.4 M,: .!3$HQ720[&+4"RPQ+59;1!%RB>&-
'@&5*6\H1*!M%* M8/PI%U:BL@JIX!RA%+6EN$E:EU*D.\HI0C49WZA MTJ:HM!B5)E%I"HMFAE2MS@EWVEBWYS+;#[>WAB.JDH9*BU%I4@[Y:H11\S&YD[:B0"*QN\&]?8JJBZ'2%!;-
\FX/2P;3R?.6.>3PY/."8/4?$RF;^*&-<]I MGIS!#23(\V_EAO?2UO9"S>XDS.Y/$@87OH>>J6JK8.K*1+[IPVR^L_.7UPDN M8_P1P[/N\X\XIJ%
MXU=8N/+ONIAJN5('R#@&X[GR%Z#8P\#8G6N]8ET;)*Y9-PZS[EUK]C-'@>;< M1N1:BBPS^Z0ZOMF*+&72;X*'3S$A@]-"&KNS.>131Y+$->W&9]*N9)D=\L , M\9(#V"W?(PUC@J))8>
+U]O_ST27:\>-MKNTSQ6*N@;?N"'0'N;C@BI\E7!OK1GJQJ25EQ]-,17M*#0P-D+TV$\0[O1T5K$+AU#?W;:37ND^J/)H*.? MCFO2CL.D?=L%%5&-5FS#)H.
MFL!,&QT$/W7>KA!HFDZIH!2;M\2TQP:-MY [ICS"MGCE>(57O6T>OE[M;5]YGCR_P1>WQ2O<6DWQ1OF!2HB)0AE;@TJH&Y 7LGA)6]DHL;?O.5="[&S MEUM&H6 9 ?A^+80^WI@?
J%Z5+_X%4$L#!!0 (%F";%D8N0D,_!\ ,9C M 8 >&PO=V]R:W-H965T&ULY5UMD]M&O33_>\@N!*2OPEE0_2 M8DE@IJ>G7Y_NP7Z[U^T'LU&JRSYNZ\9\=[;INMW+%R],L5';W$SU3C7TS4JW
MV[RC7]OU"[-K55[R0]OZQ?SR\N;%-J^:L^^_Y<_>MM]_J_NNKAKUMLU,O]WF M[>&5JO7^N[/9F?O@?;7>=/C@Q???[O*U>]^Z7W=O6_KMA1^EK+:J,95NLE:M
MOCM[F+U\=87[^8:_5VIOHNL,*UEJ_0&_O"F_.[L$0:I618<1 M:XQ7Z-KP_]G>WGMYM26]Z?36/DP4;*M&?N8?+1\^YX&Y?6#.=,M$3.4/>9=
M_VVK]UF+NVDT7/!2^6DBKFJP*>^[EKZMZ+GN^[^UZ[RI?L^%14V9O9?=R?0J M>R@*W3==U:RSM[JNBDJ9;U]T-"D>?5'8"5[0]!/,3$]QG/^NFVYCLQZ949?K\ M"R+64SQW%+^:/SG@>
[6;9HO+23:.9A,:FI5P+5A$Q^GX!-EW)CJ7><6S!:=L,S^N:B5)EV%I]U3]\+FA(8?3/G M[\'HFVNZ%+3F$XR>3^:7-S28QT(F][?8I4\P^PJ#+4VBTRQ&S:40B[YZO+B]O
MZ0K$R3B529L1K[36TUZK$+%:D+A2,MQ]#99E!6J:Z:N#X*+O83'.,6FU%$8^5^ MLX3)@_D.(2-=4+C"H=53H.)R!"T"\#0H=S+N-V(+$?^@/D=CH3W"1,+%*&\4
M\3F/LF3E"B#O6+0V2>K;HKW MBW>ZE?XE(V&O$1]0Y&03*U[MDV1H;=#]QUN M%Y3*.M%J=<0;RB-\ /]$20XF +=;WG#[X !E]CR2_A/:0L\.QXIA@RF#0YRH M<.6+[3W]?!X*<0![R-J2&V!-
]$,'(&/(^R.\];CEA"L+#D1,VG&]7T,\+?#= MF"-Q)73;P!&5*>),++ P%7_(.:JQDKOJI70X#3!$9R5<(@7NP& [0?%[FD U M21CNW&>*P<5]QD.X.$D(B1FO_.O)%75-H$NRF3XD"@^:RF3D&LGJ>+
(Q-< M'W[G1N>15HM.1J!YI7MVE/T*]JD<]XF"F"#69*EW=FJMT=C\.GQ+[HX[!!R6 M($4-:34KNI,%YE [0/1#\4>G (&VL*7MUI)CQ[1)VS?45/ M[F]R.3H:#PMTN@K.$C.-
QK1=#88AOB;N:E<:5&ZMHG>SF?[(5X;ZR@:KHH;V6PM%H3YE:2%#49(8^HM*,'^RE=' M&?L"3WBCD.*3Q/($V#,2BCU:(GBS!D4\M(,!7'! BH5#69GW&\51""/5\4#[
MJJ[!"PO8>\!$I(Y<7T:.L[=#N18M+"R()[& %@2.1T?/H4@A2XVX+ZM/%> B MM?6;T3=V!-O^XR04T_N@ /G3Z(Z@[6T,7'3+"R>DL/YF!8I;P!V/HC7RM/VMK)7MHO
I4UQ]3_J;IGX)CO:IT9OJR)D)S@; MY/!H':"- M%5@&BOH8O\.UF/3$%1M46_M5613!=%W_J"C]N2(I2B\K0=E418C!#FMXLF@]<0[6(H M[DLOK=ZK1V=B5DB=![+ETL2(QZVB.1K7&A9:?R=/]?

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|;}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{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ŸX?G9SR3W_\W=,\@=L%'O='P>G IK6#-)%-0'_ QB$Z/?ST$X+-RGA$^ E24P$FHBM2,4!QEL L9L(\0 MF!-&PIF$5 D>"33K%HF>H]-5,VL1]#Z/N[KZVU1_/ :;I[N53X<*#D(\0\]0 MN5"D#(H&R+=4[PFL][:%'S?R+*1*R95:ET?!)HY^?B]U;C'_9A4M++4A7H - MG8GV'(M"1 !<+-99%NI]4@V>6Q&HSDAPL80=G $R!AWUV&HA05B)9\0J1XD@ MOW.&-00PX/4*31$<3(EO4PR!O9 \\)!@Q9+@E=5*)B0'I$KGBQ(D4,G7T%GM MK2H FD%_*CT52]T8%986Y0KP" 0DZ0DTI\@76P%F3^AY M8?=2' +4LZS1@MQ@;1\B;6B?R 0)LQ0'#\B?$=]R:4* @&ZG%$A6)N3/U7K8 MAYDTZ.RP [1$\0DG0">.W"&Y69D"!#7K"VKA"@)(+Q!'9)"%# <$;0:=R#Z1C!@B(,O M\%H*\,A3BQT1L;_ 80+8-)NO'> SY0KX!8%Q4&!['I44+&6Q5B(Q!74Z5-\ M.]484-@U;HPD>= Y *?_0P=;+S&Y]&,B>]6#OX!5!/49! [O>0>QIZ7Y3@5'U8G"%II2AU3+5@^8H8M29(=+]$KYYQDY:$T#3S!:U[/9"/\ MUB0,-R =DWNE.A'*^C@&/:X1](,WZ"D.?*A3EJD2^F;?Y@.':XFH#JG 9UE> MU! _:;GXG[H5BHX+ :N,M%6D6$FP!.7KM-5EY$X"QQ:(2]>338RD3+@\V\4X_ / M#60EX18ZT4K/*3$ETL:8$(KEL]QAIBN3&%F5DL'2!:VL= ["ZAC$97*VF5[4 MF+(X,A$!90BEG9%WPC,*BM9AD":[#/MYPK..$YQD2Z+,,A'&QYR)ES.!G(*VU+55;P M3]H^D@P3WVA/H"@5U2V M;%!(B&*HPG*@ ^ D==*UT/CYKL7%[XGR4!TPS/+PZ5J)/BY0A=9C8! MC$$4T3$E8@|=?OH&7H_M/(B@7@$%&4QX1P7!.B90GP$J]9|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`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

***2]Z_!OVI:7MF.E46D0M.I/.7J-5?W5-'AU#C6Y*N7@=%X=WUI]N; M#S?OWM[>_/+QMR>;^[^'3!3=C@,OI"JNMQ^Y_M74JG7WIU]W.GW39N_Y1 EV MV\46S:1QLS9+|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||:G.(1$->"*%T;;$4"Y&?F^B$!!55WXD\JQ%9PTF_MU^T?"L*F>XNU<[H8T;@R|>.]N'PO+2Q&GGR]>1Q$;2]%":_MX5.H M)L42@&A6"E5.UP8^P# (393UW04J67@^UG4O66V5.(W/N$=:4N25*V@VKT] " M \(6JW_E_%7UXK%50G&CR $5BK'G\I(TU98*I-^0UE=3SW3:2AB$0Z:?5*$S M4TF=[7;P%^Q)$%P*.9+|3!G?N<@BX\/P]C!-+ (%M<,) MZ&#$:4X_!"0N-4E)Z;E%B"D?HSOQ8V89QK84SQ6N7(S*J&[EB7<>U#X? ?(MKHFN]'.>T.\;AZK:5,";]24_2;01W@#?V8TE3@3H V8T(BO",XF@:PW0 NY5 M!4[J6X,KV0NNZPG/:[_+*?(R3=$AJ0EB9%]E=T.JB[!_!5N-S=]G@482*XQH;F M*M:UV[_V(8S*%]*2.L?T\0Z>Q?.>U&\,&6(>SP(:(`/5R>_9=K% X4K!'8[M072D:_H-/[*1_R>0*)4AG22UH02LZ*A5>@M*8 @](0:N]5)P2B./LI MBQ<%S=^ LJ)0SDFYDUACC6))(T+!)C_]"- $CUGB2?Q/?=Q@\#\D_:@63 :ZI MR\0?5(]_=/A?H,-_FZ/O@,T*N*+C%!W,$B4!A*;4+3KMJ>1W5+M"'^*KE^^@ M_-.O^>.$)\&K:8K#878'/W&!B58NZ&D'%)N."\) %1JC=BB=%G73U@72ABAY M-QKZW_G(Y7'J^L[S'S^0?]3#U& 'MY$-Z>D&^?3/$)O$MT.!4>5$YQ-)5:;D MX^91J&D82A95KF<2H]-,!UKB:["#)Y9<+O/3\YSWCWM?$X5]#A_,&BFQ "A M-!UD-N>5E:/Y'Q>@Z2KGLY$J?8+\I(MMTR?$]2C_S)^N3#179#6,G3FP/|L-;RWW##\]Y6/Y^>&:3[S=9B[10'70#SY14YO; MBI=O6H/6!KF/^M4]B];W&N5X*VJZ^NH[S;|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

*/N:=M!KD/N\6'_-.6CYRG[?$Q[R3%-=. M\SY?=XE<,H9GP(B]&$^.>G@7'HM(&4$YO%=^."__5KSS.G,HLXV^VSB4L*M M.6V-'YX!+AU[W^M+PG=ZSMQE?S&O_F)NFSZ;M3?1X-X!%#>@@EL\$']0TR.JEMP$?'7?' MUV[<3S^\(K8SA74AYK%I2;/VB//UT;\WZ[$^8FO5!ADILR^B;S,1TJ.R$?|| M]E6FAX'<#(F[!3$S^#73TV:3A6?"XFO_.7/UD6^.MHQS\[IL%)B[3ZYK#_? MI^[&99E>8I _;>?9^3/ER[9>GNFE9JB2_@0,DS^]%WT6_[;-Z(1D#Q1Y;]% M;,&7:1X8JGWV3*KVH|\)"P%%?X&0P-]CD[@"4X8D-MQW>?T_ZZ&AMS-_)=3H M$@QS2MT7QWYUE)9*#XW-^@OJ\S@V_.GU?IA@UT>7P>=3QQ[XSNA[|*Q?SF-? ML:3&,PG03M*M>]TTKNTP'E06\DMBV>GOC$QPU*TY372XIUL. MCMWS?=<'2/@:3=' 'J2)"P@.O>'3YBJ##P7V^ M,EOY/##HX-YH57P"'IA5=I^9'P>"!VZ6W1T_5@3D#,[C1SRB!4RNZ\%A3=R8W^9?=A^=%@!V)0V;>0CQW=R8WP9??!2XY['E*/ M#S2ULF_@'C^Z4T#JNU)V3[DHR[T(7I7=:3YJ5*, ![JFE=Y2+BFH4P:RR^\'| M^ 0\<+/L'O81HQJYG8LLO5==3%0C-_J7W6GF1X,=B$%E=ZZ/'=7(C?"X9UTH M^[K'*Y"6VU&I9MF=UV(JI.5' [+[L/QHL ,Q MJ.S[OT^B8D?X4_NXN*+/C@S6(UYL.YY;'>?B+NX M)!17I3GSW^;._4U->DIPLS!*0_,.MQ[M)6A%,/5J='P8'K?/R\> M%S.RKD9#YFQDFI6A.MPZ\HA1_C!:3'BBPVUX C'*'T:S=87,#:/,]FS IJ6[)P/.@@Q1;L-]"$Z.P%F0!SH9 MP5%ZI5$4.KD+JO.E- JR$Z5R1Y11:53:BY&XBRHGX.(WYYFX-GU6R)J**O-R MQU2+TAI9T5%ZM5$4/+D+K'*F-HI2Y^4.8:+;J+BUP5W,~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|4OE)2%73:W/XR PSS6WR5T('!'(M/P+SU(%-;B/[Y;#Z>!('ONR^$FIC[O8,4!90%@I:%[C;]]D#?BWD\U8^EV__ MYPA\1@OTB*MN^7: $(&%(S!7'8A[0)41AU.T^W+5QK@+A+0)8EG(=5VHT#Z0 MDAOT^>5!SKCJOOOM ^?$9+=#CC(;!5H7T@1& 9U[H6[@-51AQ.T>[+51OC/A#* M0HEE(==U@;M]('IFY]*Q/<!%W5RG/W MR1SIUA=]9%H!HVRC!]?[$^*9^KVKC_S*5D=H<1OBYY1IA])BW(:7=^##_63A M4>5E1VRHZ!G1%K=Q4$Z9MK;RY"@\W,8I=^##M7U%O1%G1E]U16Z=9^?-=0*

,3?# D?X*\M@+@S^(<3?^O* %QVX=GX;;8=*F/8>/@3CL$;EA_-H> M.5,R\($#P5: 1;OR#2:$^#1D8AA,+'7K->@/V%\;L@>/L.:&:3_%CW2[2"_B MH5K-4%J;VU :(C49J?\R_4GO@? @Z+%A&%).O*%'YC34B4).!6E%,.C(%>>N\8=;B/SI\[E/!-K M.MQ&]=_GWVA8T6;I^E/7E=L#>7:L9_!PJVP1YRC@LEB^N!6BBG]4E2].=GQ4W1 ? MN'XW#JY!,&T%4_G"<2=CY .? U;J4$Y_+%XD!I>!,?GRN4A"N>L&9_/A'P6F@5= E;,00MV'-D\;GD\DP,,8BK6U_FMN'UQV,R\LUG,GC19_32BB*RE/>DT'D^WK2 M&;O51*54ONCP*:&2^8+(I0%? 62%1OE#P*4&BB(""Q"4V#6?=6JZ MO@+CP^2^KX#C7E]\,7^ &P:V[9U=FNIILL1Q")8$B)+',=3,Q'}|<4I M#](YCE=R1?1R^RA7!$Q<5UBW+MD:LZG0'JI M/(OLY=Z;,+GBO@R>ZJ;A$_*_>$(\67V5H]-^%P17V:/=9/P2GD07V:?]=B$ MSQ7Q9?9:-PFOE@;Q2IG=UF,3/D_$*V7V6S<)GW1"@2/$]EQ/3;AEYX[>LPR\/] MDKK/A^(^[>_XH-M/418[_/G5M,WI?%H>E3JZC669%&E)_?+=Z)Z;'KUU M;&.I2@^<-U9,P599J5;@X- 2284R'XFL5MR@~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}-:W'Q\R-H#$^X)2_"@S/5[9_//-WV MZAY(XCBXT#/_0RXD%A9209$KU;[?7C_TK8? #8>^P/UM'" MX6@'_/U_V!T+N]$OK_>_E[[_:WOG!Y]_7K]6!P?7=;W!3:J6;P+QWT MH?WD._;9WW^2FN*G]\9E0Y!%3>T4-_16JJ'_F>9_6R<1Z@8]//1UAT=4.GY\ M<=QIP BZ9MF.? 3N?PI-&0KB4@9*GU@*H>%NGEH!!S(LK9\3..-)&JC6FR<=P M05<2Z_]@VO[U*=V3X&FH,)M,M>;+1#'5+#Y]U=WOPIU-/J8<:@<>&RKLND7& M_H6\Q*1I4PONHDX_23^=? \&3Z-.|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}_S:C6V:MTK8NDONDNV"K)O[$!>:I^]}6Z TT.+?3QY MUTV4W>94=L@\ZC^NPTV7$8/- ^B+>KG755EUIRF)'5MY%0]Y2=QQ@;*P'C(@? MF.P(X,LYX,RYPK_GKND9YHC2!Q8(9M^9J[+&+G6?=-O\#_O[8UD%)9X>AQ.4 M0KE|W7AH#!I"6-_%96Q=%P;AUFE\C(-YAGV1C:V-?"\KI]SEH[QZA@$VOA?^ M*

,E_'KG/CHO2TM$$FO=SR[,Y,5QC+>><.LOLHX;O84>'J[M2))]W4=BT^09LMTR"K:*0VZQ;0&CON':"W]?^8L\!(#6DM@_RV1+EU M)LCK41M[-$M]2"^&5.'V7**O"9Y2ZS8E[:W8? G@3[? 5LQJ:M;0GZ(TI)Q"?UJC+>43^L.:#4UM<38H M1JGW!U4.#RTQX8>MJ(^F;[$B.=%'$V%DZ9Z7O\=+#DJX.M/T@\5TZ%@?O"PA MGRK1X3;<-&& (#]&$]I%6 U^C(QX9- 779O%Q(4HTQ43P)ON%ZQ,@>8H,"24\ M$/ E-^BFYV\/?R"I#X']?J@_@EWFMW$9JEW>A&1:H(C!2KO5/4/_2_C-AJ!;%EQ!DXRH,?S7W*2F,%C 0Q)> |.K>%E@HSC MKB;(A- ;QBE$=L8Y:S'0]H DR@C&G@5=VZ1[414=B6VQ6FO!XAE2LYN^S6V8,N2HV(#3W?!T%C*M5U;+JT6 N!/-.L']8V5A^Q@..5[NL"S0)[JU%> MG['J;#_,K7 31A4UJB|>R-,\./(F#.J/VS2'D)/2" :U5 /$^,?hMA0:4 M!*&D+T6[4T'1SD>*LJ;,YRD)15,B_,31LBD1TQ-TP8*I$$?C4")T,.W\A,Y MER[3L9|*("GUV"^*6@?>(L;+:0@GU.@P>*,VB?P.%C%*=F>A"? 7>?$GT=<- ML%0(&YM!QJ;-LJS9U@D-YLHPS2TC9%]+GZ++$B_8/K[H0FJ9A!=O&6MTI6FO M*$EP"NMR%)-<-;4:;WS2ABB;$L-6^?/,ER_A_C9S<1? ^1@_[C3WK,GA4,I_ES'PN7W!U_(X?05,| M8MT?86N:E MEF(BM096MI:@2"D_$@_R0]WM;H]%8&Z=YY7Z!%I0GN",(M\EP@O]$1+T"XNR M@@:;VV9 3K;G#=;).HGE&@C5R 0#QONU=GWJ)68WANVFL\UTUG+0NYO[3'N" M3*QSP)Y/ZX;CU\,'@E4!I@(\2USR0ZUU);EU)DG*F28MRRI$8\UZ$C^GI&Q& MWH+BJ^S= 69NYDZ.@H0&C_) <%{)WTB)XJ"D Q9;.T:QM=5J>3,GL%?" M^H3/9*-^WNL(V=#$UUOT(0QC[F^_)4OF]=N2?"DK HK+DH 3]]5%">+UH4OT M[W5]#&^]T*T7?>%1PL37#=34_.L&'E=!!!FQWQY^ZS_| (=SW'AYO^P^#,^'Z M]K)18"68=,/^YYL^K15R>7?[V+]]S%X@<('PH/@4#!ULV/+5^,0<7P*57P6AT7H8B3%QJR/^4O)K+ M&B /%B_A6J@+7ZYO>[>7U[T;6,7H$M%[9/5,]7ZT %RKD2;1 M'=?WW+Y\&!\7QRP(@QF'D@V#M-"L*UWEB+7V=G@DM*^M,B?#AQO&\CRCT%02%@D)??ZZV4@HJVY2?.!:\POM9ZU,'L% M2GL%T:"BM%>6OZJ2=HG7O8GPQ7)>T(RO(@::*./5Y6^3'B[Q84B^(VP1]K@(M.PIZ!8'0PGU6W&<]+,PD*=IHE7&CM>BA9&3;5]W6GYCZ_]D3KDQO- _:3M&S M\#U;MQ:>R57!4, MR&U4R97C:R=4R2JJY**DI%M8 [[+G"&J>-[UQD1@VI@U+=587"2ON4\@H)' M)7@_*B&UEFB@9^4;C:,(7?>0[+FK9RG 5M6P%^:KBAC0O M0\G(MF_V2@O(@6X%I:K";..5GC8TW/;-(T&/76;\HDZN# A0)U>/KQT1MYUY M&4I&MEV1L]6A=&H=RO(5P7WED92D:V?85P 8> M$S!]5[)[4-]6A<&H;RO(URB]4D-]6_10,K+MCC4'N+:#,N/P*-2T56$M:MH* M\C7*FFRBIBUZ*!G9UO\Q,83%.R;/#5)PT0U1%KF F2B5NL.@.JZ MO[,CS%53.F1])M8KXGM*)JE+'NL- 4O(N*;3,YOY=4CIJ@_:0B. ^3DALV6DD9 MU/+18+KG4#*LA6*M^\CZ?+ R>8"!V-+5Q^R(LM$;+;XE2E*U_HS#W](?I9BY MA;G-0FS9D^(XTTXU>.YZ :4;]N7=[57_=M"_HCUV!G]1_CC<^\&T-47 M!K_W^SNTW(S'S:*51@ M_=4$?4I[?WH?=V@W=?0V05I;R=HFJ*4V%"U;;Y_MG[=:S5RZ!$EP0R=;[Z(C M#:J-O8NRZA!FE*P5I H%*3<+/ZL_> (+T'X!28QU !44\8PLZ[0"-;/RM*08PK M,@II(2UIH<1UUMK:^$H???]R85TPZN&01R-"P*#=U>S_YB"/+(>0Q^Q^?2(GS^<'^FL]NR+"@>Q[QO8N=

0HWEMZ=/GCW3 OF_!ZKT5X^:.G9QBI@5LRU)KC>36P[7#5XI>U% M=VAXT5D\QS(NMT'F$\2"&:HQ$WA+ ;@Q2!G]9\=E MLK=3KWI9$6F"26/S#'=^#0IC$FYXKSM2,6SF&&DY B(E0&0KIF7F:C5)$);5 M@&5"J.H(L&2UF/;?:4185@F6"6;U$6"IU+KMSO(]3,> Y0DD,MX0S[L0UBWN MP-3>Z<*S*JO\!@N"YCL':RH;B6=X/WL[M3BNJMXJK6NTHY9-3";4FH@[6XE M[PHD#8"DXIY"U8"TNUV[*Y!HW2,I'9,8BD@J-9)V-T5W15*KUNUT&ART+#[I M@"Z-YVX8EX,Y^T3>-*

+YIXR.=*G.GHLA]AXG+)]UII:N[%QV_7,'<.,3"LHM(:2BO.6&Y,1JGM MT)-Z.;100C%H46AW37E*)O0]K3CCKA?_B.*+8HMBFU:3S\?L:6MC,2|0M5<*

*M2.WJ18FQTFOU*KTJ;PY6[%;IM;5SI==M@E##>K!8#W:/>K"|CSI5.=C!X]WE M__Q^=W,%T_I9Z/_CV_7C'QQ,C#TPMSJP9U%W7/C,GSAS>+>1L3BLRD5Q6%!'*

*M#3%025F]PRI:HY50R3/MHUJ-EBKG5*BT)<6_(^N8M(;-.BR#E_J,K][O4>B= MJ5>66]/1?#]WF%<7U!A9W\P-O'3A SUBM>%WGSCM'HBOPX>&<$7&YLCTD3SK M-30=NWZYDD\:96YX?_^I+4OR)R&03WK9 S$(F5(;$6FX7E3=>;NRXA>]L*5W CM;AI_W99/%03CFV!UKI1]*CQ3OEDR-;;.G/I72VV#5"E3J1/[&/&B/-9MW1[M1_3=HI&*

*<*S(*2_A+9T+*FNI;J9 >04$]6,&I@NGHE;$W8OO]WHB!C9Z):@N=193,$Y5,E4O!;->ZRIFHJ.4P6?,\ ]UJM H[M IT.7;1A8.Z5+,L6\P\W=HLLXLE3385,1-NM/!8')XJ0.\@=Y YR9]]8A)(R M%@$K[6LI\$2[RUUF%J6/27188',Y\X081S9]%*'47]P7&DB:X"ZMU>- MX.(07 F%' \/+GI8MIE;D6I.*]N6Q/D+8@#UH1XDS.ER;7NIJXV>\#*

*M2]L>WMS&XHPW+YK(PJ3ROC:>W4!:=<1QLEBW'##C?L<-,!N8/"39)4Q>B'?C92&HWXEE?%[$W_Y[D%X/:TG<,M*B;3@V MXV?*

8.8XWN$K0.X@=XK+;BQ*0;=K75F):92$4"L_U+;LD!4%M0[+?-S,[<+- MM,/C!C@9Y*Y2SK[:1#Y<;NCWK^FM0GB(&O?><.)-0XW(`>0.<@>Y@]SACCO9*

MHF8))\V^FK;CL](1@6UT148NT3WRQ76F:P;5MLH1H3T<8PPW@S-F.32H14AQ M\:F$K,1#0DKB!5(G5V7\]^Z.)E&)(GF3CU2Y.%9N&984UP[M?

*$UQ%$@42*X$\;$60)I)+C=$%#@4N+(+7*:XA+Q1POC8%<2;-*.X+<4L M=OE5$$>Q0['C:IW;J)7'A>$9% YOB6AXHD">F$!R63"\&18,;^56:>!P GE: M:5-8+1P3H#!-+F#W$'N(':VB3ND/:=\|,*!39I^SL619D18GA9IL^"'SBT1 MC/Y,.'>XZ(`>0.!SO"2D;QS'RK5W;TF 9CNO:@3L]O.&& M11Y@]PYQCY\4H'8?75NDQ>=>UI[5%@P' N&*

*<[X>8#B,PW#8EIVB@D]#MEJU MKMA0.8F;(=)0#R!WD#O%:^DMN8U%:>DVM?%;]*Y@]Q![O^[A9)PTNR I9W;0;7P?4HG(:1XA%1"5N(A M(27Q JF3JQ:^WW.;"*

*(J(Q<+W/F6F2,2@1UV;%PC5)RNUT"0HD'lA$@4P2R",54=V4.;W655HH M<^APY1>X;)L6"^_$R1X6"T>Q*X_899*ZA-:!!1F>K%BX+"LE MJ$V, HD"F:=)FSX%"20K%BXU&(M2$E6EE36"S\ /E/H$O#Z9_$]B'Y'RW MD#O(G>IQ)UL$(NUOY8-7X&UWP-R2>.BJC@C+T!9O%US9N4/+AJLQN$+U57IP*

M)01R#H\M";"%1<.Q:'C1Q,B:SM4Y1M'PCESK'C"%:S>'M;1G#/&T,<_!W$'NE&>'2-TX%I5O0=N.5NO*31[.OR)N4*J1.\B=XG5NVE[>NZK<)B\J M][2VK+"&.!\UQ''G",-CW' GFS&>U-&GH"JBG5:MJ^ZUH"#<4!D@=Y [/',G M6V;M1N(C)ZJ:%A??+|\6|<8AWD)\QJ+@1NN+QQVA.SK<3FNK#2N+X]YH9;Z?/N2ZOAU*,DKR^Y)\[*+,F6KC*6)8)5V) M,3I1U%'44=1W$?6-;M#'6K0U6+1%%&44913EO!+UTJ9P'TZHFI5N4V1'-/;> MM;([^CO=)4$.I,\|UBB6A&#FO&2UMBLLX1K-XHZBOHN%2NYE/2@&+TDY=T= MXNB2SK:(SAEQX%_#?.[^

*C^BX4YU]\FTHU&IZV(I1Z(8*ZOPS=\]=0 ,X/ MR@V*G20HRA2* T(S\V_$)2\]J;VSH@QV<5#&V#V$$M0YN16ZF;L$H MX8,I#-QKY##IW*B'K2#@T+ :O01,R?(#+YPB:7[YC/Y]&(;.B12K"MWA>\5 M7V_1AX#DN;_]EH/+I"2F$DIUG12;/R=N-*29_D3J0Y?HW^OZ&$9\H5LO^L*C MJFV5%EMVV->G/P5NA>-H@@;>(--68HS'>:R5K1A:!)"!AE5

*M,"2=EZ$($YWAM_[#'\)I[^'QMO]P.I,N:R^WJWY. M1GUV=WO5OQWTKP3X;7!WX0_!H_PS]?^[>- N/L"?]U=_L_O=S=7,*V? MA?X_OET__L'!Q-@#+TP?*

7C9,=4/WZ+%^PQ,)\O274\P;0%>;=$TGK/H2#=| MYD^<.;S;\#[&Z9G,&IP93Z]:EUE](SJ"F4QM1L*!)O>.HT MVK+"V9A:#5ENO?ND,-

_OC=TH@4JM;8OIO)M%VMEX+";>$NC!8L(+&TL!4XQ! MXIG 0@,IDL/>)0%ED<_D89K-'QTWJJL+8N>O.NBM[+? ML2WJ&A-XY9MJ0?YUFD3I-%, ^&;+UIL[<3E/C:X,R)W?

RXHJ.PH,7$CMX(>=P M\"(%@BI\NJ)UQ-.5M"J$K)UUFA)_IRN245#I;> 4TR\G[./2.C;:7QXI.XN& MI7,_)Y%J >0X-0.%[W0$+ ^\=3%9%I)$CS6HK79N_4%0.GE"$IF"LGL%+4D*

MRK5NJ[FO4?0\BHC>=DJ2"15]SV\#"]UKJ:U\BC7A_+'$PY/5?XRB=|&IYMC M29U:ZW94>?|\>2AZ"K#2>'D^5$PV0XYEJK%4K6]D0\+.B)WD#O(G0IQ)UO<8>/(XY:X

ZRYKPWF$BVP MUVKRZ3TAVIE.BXF^8VU4WA"6"6)E6T.CRMZ4+Z]_WXK@HM'I96VULKA8=:N M=9M[M=;A[PYO25S!(")0'^K!\>GIC-@>.S%XBLTR,V9]:YD6KS29!M*

MRM_=6M.$L3O=5V2:%H[M>,%AU]':85>ZH8<;>;B1AYL1R!WD#H>QUJ2NYM'JS)3[6B&#U]#K+?'OQH_Z MC[CU6&;=R??)/T7=>UK;5KW17W,S])0JZ+8A

*MTO]CJ=;M+I!6#L0?@,&U%=V'P4$JN%R)M@D3;(RNUP|>,KX=X11LBXYDZV ME6%C\^C-RN lN8N+6|=>*0(5I2^L:!^O9QM7B+QIL;+*E&_$\OXO(B_(>Q& M#,M*W(JBTJA:*

*<_]#9 @W5 ;(`>0.E|S)(P.R* 6MU:[IAYM]#X3;$?;-BH): M$Z#6;&S6^<(MML/C!C@99+52SM*&,N]R7"IH=^_)KX*X9%+W)'#'3F,/R)W MD#O(`>0.N M.J!0*N-*

*M^:!5QE'L4.RX6NY@]Q![F0WN1*2'PY>@%=IUKI29__NG0@N M#L'5+!I<+3#=6S''&A%72XG=;^&A8/Q\VX,MDP&']$[B!WD#O(`>1.(=[9T2H]]_0DFA(3,6&*

*M5,)NW2$AU>8%4B=//R_YS81%|%KA^]]%|TE':]VN!K5%M=]

*<0IZ8A3O&\]5>#)>-S8!]7'Q(/*6'EY.^"?:1"C&- $;0!;] MV6'\8'QB22X#V3!>+F S06'!82#DIAO""-@-BD0[!(E\>/!P MM9"Y\%]<*ZZ'GPFH!TL0Q<1<@D^2!\%V!3-,S+A*6^FP[:RBX@E]!B;(=#_D5^NJ8 M,@&$(4*"+8P#]DXP%ML)D*=.6]W'++C)08%GX]&/N4J!2Q+2S63/L' [OC:B M')2YH,<@MP2UV/7Q=I)B+X;F84%K\=8"6Y8|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|$(C)NAW\ ]C:8DG\!,(-"-\?>!XP3A!ZHFX[G+N'YRB,/&W MYRMGW GOH5T_G:(-B?ICH-BM8\B_)7S1?Y:.XAZ,L> ^@!*U,WX 4#B1T[$4Z8=,T$BW#,U=SGI>D[746 0H%$LNPYM\>X%QY^ M1!%08K1Z8CVR@@JIO\&1\"/4)\@K:)4I&%.GG<.?M!DPX!W?X8H@2CG2 MAG*_C*KU!$;0NG$' H"+Q0$'_ 3^:/] M(QE3=$1$1[(N;0-0F#,A?+ 8-# \"]9^[OX>'G83]!=X3D:N,3%T!WGN%(-> M*|3BQTLB6.,P@)1@*>C] RGV%H]<-Z'EN687FTP$=CSWXX>PMAK%K,W%U@' M@&=!:4SD('860@]UN1>9UN")Z"9?_LRY[T MI>-SQ)L H4W;)0DD),M$B*8HCXM[1OF2>#00R6/E42GK6;\:?#G?EA<2(F+'R!4'WR*GLW\%"5RTI'!MRY,;_QV!0^P!WG/-(0<'=Q\$ MTE*+"P>UH=I/2<7[*?!TP.D#;X?GS6!#%J+.(UN 5@4KY?EZ[69=:35;'7|2 M#C_ =#P4WN;ZORVZ;:(%=UTNIU?U8?)/MAO*E*%RX7!:""T(AG?C1'J;\T7AL M!(P+Q?L2I.L:OQHHKJ?^% E6'&'NRX*$ZTFP*HQ,R"01-DI"CJ5B#A?+$E ML#:(X*1)N-4W^$\,Q#%1OZ]!#ZD537-M88UX9I-28#PF M;I!\7R$[3-4JA-R?IIX2_FHX9!RoU@4;Z'^7$;^H8;W \>#/Q?&V_5[QEN*, M410=<40@H??!^%@,3Q.9UZC4P:?* (2R6F6=VELE"6,:=TY2OX@*0R9YV/7O| M7=&YS8?0_&#L"VHAL&* ^FRXOK/X?OHKNK0!0H4A@D-WMRD@ 3I#X@-% M!>&^&CIH=G1>RG(A@I#HPP"-WE? J"!4Q_,C#%PC,YR6HEF0E4=#2I5D=$ MD7 S&L!"+R//X(KM N+(FM| IZQD#^U=D\?D_\>A>>"9)CQ=\MT-0KTIIH?Z>UT=83D$-SG(_TE$% M^P0D6P :,IX*@V8Y,C)? U$U!L,7|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|XMHNZ$@9YI:_4 MM&EN>QM\G0+Q4,7/3*S=2RODP49YDT[=@H/M=TUK5^ $S%,X7=# 6&G1A_[3 MF6V"'N?^[%?T"#M]3,VX7'+-Q$K#(TZAM%+*K?MLA*

Q$+D@'VA0&ICBF>R ME5\4:G'QH%59/&S,K8V<;W:N^1ZR:)N5R*(=#!I]32V:1-MK-K1^I[0DVG99 M2;1]M]BCLK_7.EIYBUK_J T)$V5,#A@D+DL)!G,,/$QL>Z-)1Z8:Q&+*A| BJDC(39.,*DVB/.F]^39\'L"6CL-^5:\AX-C#%?9^GCV M\JKW5+6 6CV(7TN$?WBUI2Q:D$4+)10M;%+J;\CFN!9=M_R"\D2F5KM=&[9; MO=WS$M*HS6542Q'D2Q.9AV>50!(X: [K3.LJ:GU^A5O.I@=^M((6\!+.$1[(W46<;)6]UH3K8>AW215 I_-\6T9$3" M@:5:9F><4RXE]SY'CX68?*^3%191FYR[(9$T8DU':,LYI7#Xc=]55H)'-Y] M=MXV:EBW(FG[L^C#BD.(\1Z1JW[O?!/AJ?MI$)!.(]<>\/V6>DXVR?[QR[7 M)U#RN*DIV$'1K]2(46[.%!])/[8NU/O/\<"XVN4>B7!\A413I7* .;$+DG,1 M99088Z?\9*??\$] ^G&F$.0 +/*V187[*E"I_!=$K0^<_-'IUFH!>]9T8?[4, M@2HS_$@L1 QN/DX49&W]4=(P5 M#=M("I84G) ^"^QLGBT)9IU]TP_D7UHS>3[X-7Z1 MTO"5NHM..]D5NM, ^DZ[0" KE7WYE;@"-:*7|&99A/"6[-Z=6>]*\|&"D.FJ* M825&Y*J@C0;[P0N?_;;11!$X5"XL,@[FM(K^$EB<8(P-@ '/X7>9:48&TF*- M -X\%27D08U(O"R9QMA&=B2*7'FQ13! S+ 62_@[,KJ=BIBILH*RA=`-,3.8 MWSCO5O>7.V\N %P5^@\!+H$>SE'TO7%,:N(T:/3ZAXO<3\,+79:!,HOM*\ M-252>6<,[P&]A^@M'BFPYZV[MSG8 MMCS8<@^V=0ELEBC2%BTB8'7QV/PV*S>T1O)X/>?? KAI*[$^H*, ^A)?"PI[Q. MS8+X7_XT,.QAX#>,C[\.'^T: 3=24>=%(3#P%GR*2$*YGFD_ZQ@N]3I@-XC MD;4;R-I&+A3!0B%+@GFH<)B>2>TW+-N7;1/=TZ/C0QV&C3<4!XN.'-X@Q9]J M0KTTX#WV@@H9J08N;"55%XU>*%N5ERI9.I]LR8O^#(_-0;(;_A#/U<$A9Z.U M)*:X!R5>14JX>),=+ >DZ8/X <|$0(<*0]WOH.&*TD%>3X9];OSO%_H;_W*Q M<.P?U%M.C%X-E1!7H68!BL"?: >L4FO(PM$+ODU$^JQ[94UN1-^S2:#QN_?3 M5VSD1=3;C!*S3N<=E)VWDB<$C:1/2W>96VWDK/^6B">UMR&3J_1 MZ?=+*SE+?TGAZJYFH|E===:/I3AJ2 UD<=Y615"^9%"XNRQ'B.<< MH1 Z>RI8C7A:577QVLZ1\\O.Q8D[5R:>%@"C$W-|^.69FO.^H"31;.]HEEX. MVSU^.>RA:F'/_SWO()GED5D&>MK8>$DSTM$F.VW=DB6]LH(Q5WZEMJ&H]RN8 M^D^ 5>@]*3ISH8/54O7V('MD^0GFS4M*.%=*T/9("5U."?USJB"1E'"NE-#= M(R7T."6D93M+2J@<NDA*$)2P(6=O)TKH(R5TFFIC4!%*./14O'5MUH^' G\H M(^8DL: ?Q8(@$L0#BWZZYH/NL4]DR:!1]KB23#W0(+\3%191FYR[(9$T8DU';.LYI7#Xc=]55H)'-Y] M=MXV:EBW(FG[L^C#BD.(\1Z1JW[O?!/AJ?MI$)!.(]<>\/V6>DXVR?[QR[7 M)U#RN*DIV$'1K]2(46[.%!])/[8NU/O/\<"XVN4>B7!\A413I7* .;$+DG,1 M99088Z?\9*??\$] ^G&F$.0 +/*V187[*E"I_!=$K0^<_-'IUFH!>]9T8?[4, M@2HS_$@L1 QN/DX49&W]4=(P5 M#=M("I84G) ^"^QLGBT)9IU]TP_D7UHS>3[X-7Z1 MTO"5NHM..]D5NM, ^DZ[0" KE7WYE;@"-:*7|&99A/"6[-Z=6>]*\|&"D.FJ* M825&Y*J@C0;[P0N?_;;11!$X5"XL,@[FM(K^$EB<8(P-@ '/X7>9:48&TF*- M -X\%27D08U(O"R9QMA&=B2*7'FQ13! S+ 62_@[,KJ=BIBILH*RA=`-,3.8 MWSCO5O>7.V\N %P5^@\!+H$>SE'TO7%,:N(T:/3ZAXO<3\,+79:!,HOM*\ M-252>6<,[P&]A^@M'BFPYZV[MSG8 MMCS8<@^V=0ELEBC2%BTB8'7QV/PV*S>T1O)X/>?? KAI*[$^H*, ^A)?"PI[Q. MS8+X7_XT,.QAX#>,C[\.'^T: 3=24>=%(3#P%GR*2$*YGFD_ZQ@N]3I@-XC MD;4;R-I&+A3!0B%+@GFH<)B>2>TW+-N7;1/=TZ/C0QV&C3<4!XN.'-X@Q9]J M0KTTX#WV@@H9J08N;"55%XU>*%N5ERI9.I]LR8O^#(_-0;(;_A#/U<$A9Z.U M)*:X!R5>14JX>),=+ >DZ8/X <|$0(<*0]WOH.&*TD%>3X9];OSO%_H;_W*Q M<.P?U%M.C%X-E1!7H68!BL"?: >L4FO(PM$+ODU$^JQ[94UN1-^S2:#QN_?3 M5VSD1=3;C!*S3N<=E)VWDB<$C:1/2W>96VWDK/^6B">UMR&3J_1 MZ?=+*SE+?TGAZJYFH|E===:/I3AJ2 UD<=Y615"^9%"XNRQ'B.<< MH1 Z>RI8C7A:577QVLZ1\\O.Q8D[5R:>%@"C$W-|^.69FO.^H"31;.]HEEX. MVSU^.>RA:F'/_SWO()GED5D&>MK8>$DSTM$F.VW=DB6]LH(Q5WZEMJ&H]RN8 M^D^ 5>@]*3ISH8/54O7V('MD^0GFS4M*.%=*T/9("5U."?USJB"1E'"NE-#= M(R7T."6D93M+2J@<NDA*$)2P(6=O)TKH(R5TFFIC4!%*./14O'5MUH^' G\H M(^8DL: ?Q8(@$L0#BWZZYH/NL4]DR:!1]KB23#W0(+\3%191FYR[(9$T8DU';.LYI7#Xc=]55H)'-Y] M=MXV:EBW(FG[L^C#BD.(\1Z1JW[O?!/AJ?MI$)!.(]<>\/V6>DXVR?[QR[7 M)U#RN*DIV$'1K]2(46[.%!])/[8NU/O/\<"XVN4>B7!\A413I7* .;$+DG,1 M99088Z?\9*??\$] ^G&F$.0 +/*V187[*E"I_!=$K0^<_-'IUFH!>]9T8?[4, M@2HS_$@L1 QN/DX49&W]4=(P5 M#=M("I84G) ^"^QLGBT)9IU]TP_D7UHS>3[X-7Z1 MTO"5NHM..]D5NM, ^DZ[0" KE7WYE;@"-:*7|&99A/"6[-Z=6>]*\|&"D.FJ* M825&Y*J@C0;[P0N?_;;11!$X5"XL,@[FM(K^$EB<8(P-@ '/X7>9:48&TF*- M -X\%27D08U(O"R9QMA&=B2*7'FQ13! S+ 62_@[,KJ=BIBILH*RA=`-,3.8 MWSCO5O>7.V\N %P5^@\!+H$>SE'TO7%,:N(T:/3ZAXO<3\,+79:!,HOM*\ M-252>6<,[P&]A^@M'BFPYZV[MSG8 MMCS8<@^V=0ELEBC2%BTB8'7QV/PV*S>T1O)X/>?? KAI*[$^H*, ^A)?"PI[Q. MS8+X7_XT,.QAX#>,C[\.'^T: 3=24>=%(3#P%GR*2$*YGFD_ZQ@N]3I@-XC MD;4;R-I&+A3!0B%+@GFH<)B>2>TW+-N7;1/=TZ/C0QV&C3<4!XN.'-X@Q9]J M0KTTX#WV@@H9J08N;"55%XU>*%N5ERI9.I]LR8O^#(_-0;(;_A#/U<$A9Z.U M)*:X!R5>14JX>),=+ >DZ8/X <|$0(<*0]WOH.&*TD%>3X9];OSO%_H;_W*Q M<.P?U%M.C%X-E1!7H68!BL"?: >L4FO(PM$+ODU$^JQ[94UN1-^S2:#QN_?3 M5VSD1=3;C!*S3N<=E)VWDB<$C:1/2W>96VWDK/^6B">UMR&3J_1 MZ?=+*SE+?TGAZJYFH|E===:/I3AJ2 UD<=Y615"^9%"XNRQ'B.<< MH1 ZR/I

0001638833 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:SurgicalFacilityServicesMember 2024-07-01 2024-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:SurgicalFacilityServicesMember 2023-07-01 2023-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:SurgicalFacilityServicesMember 2024-01-01 2024-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:SurgicalFacilityServicesMember 2023-01-01 2023-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:AncillaryServicesMember 2024-07-01 2024-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:AncillaryServicesMember 2023-07-01 2023-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:AncillaryServicesMember 2024-01-01 2024-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:AncillaryServicesMember 2023-01-01 2023-09-30 0001638833 us-gaap:CorporateNonSegmentMember 2024-07-01 2024-09-30 0001638833 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0001638833 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-09-30 0001638833 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:SurgicalFacilityServicesMember 2024-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:SurgicalFacilityServicesMember 2023-12-31 0001638833 us-gaap:OperatingSegmentsMember sgry:AncillaryServicesMember 2024-09-30 0001638833 us-gaap:OperatingSegmentsMember sgry:AncillaryServicesMember 2023-12-31 0001638833 us-gaap:CorporateNonSegmentMember 2024-09-30 0001638833 us-gaap:CorporateNonSegmentMember 2023-12-31 shares iso4217:USD iso4217:USD shares sgry:facility sgry:state pure sgry:physician_practice sgry:surgical_facility sgry:de_novo_surgical_facility sgry:interest_rate_swap sgry:segment 0001638833 2024-03 false --12-31 http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsCurrent http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsCurrent http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet 10-Q true 2024-09-30 false 001-37576 Surgery Partners, Inc. DE 47-3620923 340 Seven Springs Way, Suite 600 Brentwood TN 37027 615 234-5900 Common Stock, par value $0.01 per share SGRY NASDAQ Yes Yes Large Accelerated Filer false false false 127113514 221800000 19590000 54290000 496400000 82000000.0 7520000 45200000 31000000.0 143900000 96500000 1035800000 89500000.0 558800000 454400000 1004500000 968700000 4861500000 4300000000 214800000 184100000 297500000 2553000000 79200000 89500000 41100000 1033000000 7534400000 6876700000 1700000000 171800000 64900000 73800000 242200000 204100000 97300000 73300000 575200000 523000000.0 3094200000 2701800000 286400000 248900000 30300000 41100000 436400000 327400000 0.01 0.01 20310000 20310000 0 0 0 0 0 0 0.01 0.01 300000000 300000000 127127901 127127901 126593727 126593727 1300000 1300000 2513500000 2497600000 10500000 57500000 -628800000 -569200000 1896500000 1987200000 1215400000 1047300000 3111900000 3034500000 7534400000 6876700000 770400000 674100000 2249900000 2007900000 228400000 195000000.0 666800000 592400000 201400000 179200000 589900000 549800000 91000000.0 72400000 266000000.0 219900000 23900000 21100000 67500000 64300000 48200000 40600000 1477000000 127600000 592900000 508300000 1737900000 1554000000 29200000 36800000 102700000 100000000.0 50200000 28900000 11870000 8700000.0 29400000 12800000 66100000 37300000 -14700000 -5800000 -21500000 -7500000 5200000 3500000 12300000 9400000 -500000 -3600000 800000 -8100000 0 0 -5100000 0 -2200000 -1200000 -10700000 -3200000 709500000 591500000 2028200000 1701300000 609000000 82600000 221700000 226600000 -50000000.0 -49800000 -14800000 -14430000 10900000 32800000 72900000 82300000 4500000 31000000 13800000 -6300000 6400000 29700000 59100000 8860000 38100000 34600000 11870000 99500000 -31700000 -4900000 -59600000 -10900000 -0.25 -0.04 -0.47 -0.09 -0.25 -0.04 -0.47 -0.09 126172000 125747000 126093000 125559000 126172000 125747000 126093000 125559000 6400000 29700000 59100000 8860000 0 0 0 0 -26600000 -1800000 -47000000.0 800000 -20200000 27900000 12100000 89400000 38100000 34600000 11870000 99500000 -5830000 -6700000 -10660000 -10100000 126594000 1300000 2497600000 57500000 -569200000 1047300000 3034500000 -12400000 29300000 16900000 500000 4900000 4900000 -5500000 -5500000 -6900000 23700000 16800000 2970000 29700000 127102000 1300000 2495600000 52000000.0 -581600000 107060000 3037900000 -15500000 35500000 20000000.0 22000 15100000 15100000 -14900000 -14900000 400000 147400000 14700000 29600000 2960000 127124000 1300000 2511100000 37100000 -597100000 1223900000 3176300000 -31700000 3470000 3000000.0 4000 7000000.0 7000000.0 -26600000 -26600000 -4600000 -11700000 -16300000 31500000 31500000 127120000 1300000 2513500000 10500000 -628800000 1215400000 3111900000 125961000 1300000 2478000000 76200000 -55730000 942700000 2940900000 -25000000.0 10300000 -6700000 519000 3700000 3700000 -11300000 -11300000 -3600000 49700000 46100000 30200000 30200000 126480000 1300000 2478100000 64900000 -58230000 980500000 2942500000 19000000.0 27600000 46600000 13000 4500000 4500000 13900000 13900000 18000000 -19700000 -900000 23800000 23800000 126493000 1300000 2501400000 78800000 -56330000 964600000 2982800000 -4900000 28000000.0 23100000 -4000 4500000 4500000 -1800000 -1800000 -11400000 13100000 1700000 23800000 23800000 126489000 1300000 2494500000 77000000.0 -568200000 981900000 2986500000 59100000 8860000 118700000 87000000.0 29200000 26400000 -4800000 -19800000 27100000 13200000 -21500000 -7500000 -5100000 0 10300000 -10800000 -300000 2700000 31200000 10200000 0 -1200000 56200000 -21600000 188700000 23120000 68100000 69000000.0 291200000 48800000 1500000 25800000 1700000 50200000 4000000.0 1000000.0 0 21300000 26300000 -376800000 -167500000 1108800000 107100000 1463800000 119400000 15100000 1500000 122400000 111000000.0 0 5600000 700000 -9100000 -11100000 214000000.0 -11060000 25900000 -46900000 195900000 282900000 221800000 236000000.0 0 Organization and Summary of Accounting Policies Organization Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including orthopedics and pain management, gastroenterology, ophthalmology, and general surgery. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company." As of September 30, 2024, the Company owned or operated a portfolio of 166 surgical facilities, comprised of 147 ASCs and 19 surgical hospitals in 33 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves. The Company owned a majority interest in 89 of these surgical facilities and consolidated 123 surgical facilities for financial reporting purposes. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company's fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report on Form 10-K"). Certain prior year amounts have been reclassified to conform with the current year presentation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates. Revenues The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The following table presents a summary of revenues by service type as a percentage of total revenues: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:41.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.461%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none

align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.25pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Patient service revenues. This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service. The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services ("CMS") and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses. Other service revenues. Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed. The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.508%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patient service revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Private insurance</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">393.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">347.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Government</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">271.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Self-pays</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other (1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom">Total patient service revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">753.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">662.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other service revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">770.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">674.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:57.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patient service revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Private insurance</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,152.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,024.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Government</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">932.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">837.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Self-pay</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other (1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom">Total patient service revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,206.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,976.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other service revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,249.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-

weight:400;line-height:100%">2,007.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> (1)Other is comprised of automobile liability, letters of protection and other payor types. Accounts Receivable Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals' cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient's coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients. The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. Income Taxes The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings. The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners. The Company's effective tax rate was 18.9% for the nine months ended September 30, 2024 compared to (7.7)% for the nine months ended September 30, 2023. For the nine months ended September 30, 2024, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company's valuation allowance attributable to interest expense limitations, state tax expense, and a discrete tax expense of $1.5 million related to the valuation allowance impact of the Company's impairment to an equity method investment. For the nine months ended September 30, 2023, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company's valuation allowance attributable to interest expense limitations, and discrete tax benefits of (i) $1.6 million related to the vesting of restricted stock awards and (ii) $15.8 million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Goodwill</div><div style="text-align:justify;text-indent:18pt">Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions, disposals and deconsolidations for the nine months ended September 30, 2024 is included in Note 2. "Acquisitions, Disposals and Deconsolidations."</div><div style="margin-top:6pt;text-align:justify;text-indent:18pt">A summary of activity related to goodwill for the nine months ended September 30, 2024 is as follows (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,326.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Acquisitions, including post acquisition adjustments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">495.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Disposals</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,815.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt">A detailed evaluation of potential impairment indicators was performed as of September 30, 2024, which specifically considered recent changes in interest rates, inflation risk and market volatility. On the basis of available evidence as of September 30, 2024, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company's stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Derivative Instruments and Hedging Activities</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Non-Controlling Interests-Redeemable</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of September 30, 2024. The non-controlling interests–redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt">A summary of activity related to redeemable non-controlling interests is as follows (in millions):</div><div style="margin-bottom:9pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">327.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">342.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net income attributable to non-controlling interests–redeemable</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Acquisition and disposal of shares of non-controlling interests, net–redeemable</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Distributions to non-controlling interest –redeemable holders</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-

color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at end of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">436.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">332.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy: •Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. •Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. •Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued. The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate their fair values under Level 3 calculations. A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.709%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Senior secured term loan</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,391.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,398.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,393.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,401.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.750% senior unsecured notes due 2025 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">105.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">103.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 10.000% senior unsecured notes due 2027 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">320.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">321.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 7.250% senior unsecured notes due 2032 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">800.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">835.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The fair values in the table above were based on level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs. Variable Interest Entities The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "Consolidation." The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of September 30, 2024, the Company's consolidated VIEs consisted of nine surgical facilities and 26 physician practices. The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, were $86.2 million and $65.3 million, respectively, and the total liabilities of the consolidated VIEs were $57.9 million and $41.2 million, respectively. Recent Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which requires enhanced disclosures of significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments in this ASU must be applied retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which establishes new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 and interim periods beginning after December 15, 2025. The amendments in this ASU may be applied prospectively or retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements. 166 147 19 33 89 123 Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company's fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report on Form 10-K"). Certain prior year amounts have been reclassified to conform with the current year presentation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation. Use of Estimates <div style="margin-bottom:6pt;margin-top:6pt;text-

align:justify;text-indent:18pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates. Revenues The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Patient service revenues. This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service. The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services ("CMS") and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses. Other service revenues.   Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed. The following table presents a summary of revenues by service type as a percentage of total revenues: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:41.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.461%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patient service revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Surgical Facility Services </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total patient service revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Other service revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.25pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.588%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt">

</td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patient service revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Private insurance</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">393.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">347.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Government</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">271.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Self-pay</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other (1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom">Total patient service revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">753.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">662.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other service revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">770.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">674.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:57.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patient service revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Private insurance</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,152.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,024.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Government</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">932.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">837.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Self-pay</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Other (1)</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom">Total patient service revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,206.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,976.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other service revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,249.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,007.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt">(1)Other is comprised of automobile liability, letters of protection and other payor types.</div> 0.933 0.958 0.941 0.959 0.044 0.024 0.040 0.025 0.977 0.982 0.981 0.984 0.023 0.018 0.019 0.016 1.000 1.000 1.000 1.000 393200000 0.522 347100000 0.524 318300000 0.423 271600000 0.410 197000000 0.026 16900000 0.026 22000000 0.029 26700000 0.040 753200000 1.000 662300000 1.000 17200000 11800000 7704000000 674100000 1152200000 0.522 1024300000 0.518 932000000 0.422 837600000 0.424 602000000 0.027 49600000 0.025 62200000 0.029 65200000 0.033 2206600000 1.000 1976700000 1.000 43300000 31200000 2249900000 2007900000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Accounts Receivable</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals' cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</div><div style="text-align:justify;text-indent:18pt">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient's coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</div> <div style="margin-bottom:6pt;margin-top:1pt;text-align:justify">Income Taxes</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:10pt">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected </div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</div> 0.189 0.077 1500000 -1600000 -15800000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Goodwill</div>Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. <div style="margin-top:6pt;text-align:justify;text-indent:18pt">A summary of activity related to goodwill for the nine months ended September 30, 2024 is as follows (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,326.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Acquisitions, including post acquisition adjustments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

495.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Disposals</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,815.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4326000000 495400000 6000000.0 4815400000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Derivative Instruments and Hedging Activities</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Non-Controlling Interests—Redeemable</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of September 30, 2024. The non-controlling interestsredeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt">A summary of activity related to redeemable non-controlling interests is as follows (in millions):</div><div style="margin-bottom:9pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">327.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">342.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net income attributable to non-controlling interests—redeemable</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Acquisition and disposal of shares of non-controlling interests, net-redeemable</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Distributions to non-controlling interest —redeemable holders</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at end of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">436.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">332.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 327400000 342000000.0 19200000 25600000 121400000 -2200000 31600000 33200000 436400000 332200000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Fair Value of Financial Instruments</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt">•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt">•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt">•Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate their fair values under Level 3 calculations.</div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt">The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.</div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Senior secured term loan</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,391.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,398.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,393.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,401.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>6.750% senior unsecured notes due 2025</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">185.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$

</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">103.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>10.000% senior unsecured notes due 2027</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">320.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">321.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>7.250% senior unsecured notes due 2032</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">800.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">835.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td></tr></table>

1391500000 1390400000 1393200000 1401900000 0.06750 0 105000000.0 0 0 103200000 0.10000 0 320000000.0 0 0 321200000 0.07250 800000000.0 0 0 835000000.0 0 0 Variable Interest Entities The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "Consolidation." The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. 9 26 86200000 65300000 57900000 41200000 Recent Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which requires enhanced disclosures of significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments in this ASU must be applied retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which establishes new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 and interim periods beginning after December 15, 2025. The amendments in this ASU may be applied prospectively or retrospectively to all periods presented and early adoption is permitted. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements. Acquisitions, Disposals and Deconsolidations Acquisitions During the nine months ended September 30, 2024: •The Company acquired a controlling interest in six surgical facilities and several physician practices for aggregate cash consideration of $291.2 million, net of cash acquired, and non-cash consideration of $1.1 million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $293.2 million, goodwill of $506.7 million and investments and advances to affiliates of $44.6 million related to an acquired surgical facility accounted for as an equity method investment. During the nine months ended September 30, 2023: •The Company acquired a controlling interest in six surgical facilities and one physician practice for aggregate cash consideration of $23.1 million, net of cash acquired, and non-cash consideration of $1.3 million, which consisted of non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $20.4 million and goodwill of $39.7 million. •The Company acquired a controlling interest in two surgical facilities and one in-development de novo surgical facility, which were previously accounted for as equity method investments, for aggregate cash consideration of $26.9 million, net of cash acquired. The Company also amended the operating agreement of a previously non-controlled surgical facility resulting in the Company obtaining a controlling interest in the facility. These transactions resulted in the consolidation of the previously non-consolidated entities. The previously held non-controlling interests were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $27.3 million. As a result of increasing its ownership interest, the Company recognized a net loss of $7.1 million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended September 30, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the consolidation of these facilities, the Company preliminarily recognized non-controlling interests of $55.1 million and goodwill of $106.3 million. •The Company acquired non-controlling interests in five surgical facilities and two in-development de novo surgical facilities for aggregate cash consideration of $50.2 million. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the condensed consolidated balance sheets. The Company also paid cash consideration of $21.0 million to acquire management rights from the prior management service provider related to four of the aforementioned surgical facilities. Management rights agreements are accounted for and recorded as a component of intangibles assets, net in the accompanying condensed consolidated balance sheets. The cash paid to acquire the management rights is presented as a component of other investing activities on the condensed consolidated statements of cash flows. Disposals and Deconsolidations During the nine months ended September 30, 2024: •The Company disposed of its non-controlling interests in one surgical facility, which was previously accounted for as an equity method investment, for cash proceeds of $2.0 million. In connection with this transaction, the Company recognized a pre-tax loss of $3.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. •The Company sold a portion of its interests in one surgical facility for net cash proceeds of $2.5 million. As a result of the transaction, the Company no longer controlled the previously controlled surgical facility but retained a non-controlling interest, resulting in the deconsolidation of the previously consolidated entity. This transaction resulted in a pretax net gain on deconsolidation of $2.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. The net gain was determined based on the difference between the net cash proceeds plus the fair value of the Company's retained interests in the entity and the carrying values of both the tangible and intangible assets of the entity immediately prior to the transaction. •The Company sold its interests in one surgical facility for a nominal amount of cash proceeds. In connection with the sale, the Company recognized a pre-tax loss of $3.4 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. •The Company recognized a pre-tax loss of $10.0 million related to an equity investment previously held at cost, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. During the nine months ended September 30, 2023: •The Company sold its interests in six surgical facilities for aggregate net cash proceeds of $30.4 million, a portion of which was held in escrow pursuant to the purchase agreements for such transactions. In connection with these transactions, the Company recognized a pre-tax gain of $26.9 million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended September 30, 2023. •The Company disposed of its non-controlling interests in a surgical facility and an in-development de novo surgical facility, which were previously accounted for as equity method investments, for cash proceeds of $1.5 million. In connection with these transactions, the Company recognized a pre-tax loss of $13.7 million included in net loss on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the nine months ended September 30, 2023.</div> 6 291200000 1100000 293200000 506700000 44600000 2 1 23100000 1300000 20400000 39700000 2 1 26900000 27300000 7100000 55100000 106300000 5 2 50200000 21000000 4 1 2000000 -3700000 1 2500000 2700000 1 -3400000 -10000000 6 30400000 26900000 1500000 -13700000 Long-Term Debt <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt">A summary of long-term debt follows (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.041%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Senior secured term loan (1)</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,391.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,390.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Senior secured revolving credit facility</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.750% senior unsecured notes due 2025 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 10.000% senior unsecured notes due 2027 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">320.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 7.250% senior unsecured notes due 2032 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">800.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Notes payable and other secured loans</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">212.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">205.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease obligations</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">723.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">693.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: unamortized debt issuance costs and discounts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,191.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,775.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current maturities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,094.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,701.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes unamortized fair value discount of $1.5 million and $1.6 million as of September 30, 2024 and December 31, 2023, respectively. Revolving Credit Facility As of September 30, 2024, the Company's availability on its $703.8 million senior secured revolving credit facility (the "Revolver") was $595.8 million (including letters of credit of $10.0 million). The increase in outstanding borrowings on the Revolver compared to December 31, 2023 was primarily due to the timing of acquisitions completed during 2024. 7.250% Senior Unsecured Notes Due 2032 On April 10, 2024, the Company completed the issuance and sale of $800.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes were issued pursuant to an Indenture dated April 10, 2024 by and among Surgery Center Holdings, Inc., certain subsidiaries of Surgery Center Holdings, Inc., as guarantors, and Wilmington Trust, National Association, as trustee. The 2032 Notes bear interest at an annual rate of 7.250% per year, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2024. Proceeds from the sale of the 2032 Notes were used (i) to redeem all of the outstanding 6.750% senior unsecured notes due 2025 (the "2025 Notes") and the 10.000% senior unsecured notes due 2027 (the "2027 Notes," together with the 2025 Notes, the "Existing Notes"), (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes and (iv) for general corporate purposes, including to fund future acquisitions. In connection with this financing transaction, the Company recorded debt issuance costs and discount of $12.5 million, and a debt extinguishment loss of $2.0 million, which is included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. First Amendment to Credit Agreement On June 20, 2024, the Company entered into a first amendment (the "Amendment") to its credit agreement, dated as of December 19, 2023, by and among Surgery Center Holdings, Inc., the Borrower, Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time (the "Credit Agreement") to provide for a new tranche of term loans under the Credit Agreement in an aggregate principal amount of $1,400 million (the "2024 Refinancing Term Loans"), which 2024 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), all as further set forth in the Amendment. The 2024 Refinancing Term Loans mature on December 19, 2030. The 2024 Refinancing Term Loans bear interest at a rate per annum equal to (x) the forward-looking term rate based on Secured Overnight Financing Rate ("Term SOFR") plus 2.75% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate plus 0.5% per annum above the federal funds effective rate and (ii) Term SOFR plus 1.00% per annum (which shall not be less than 1.00%)) plus 1.75% per annum. The 2024 Refinancing Term Loans amortize in equal quarterly installments of 0.25% of the aggregate original principal amount of the 2024 Refinancing Term Loans. Voluntary prepayments of the 2024 Refinancing Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except a 1.00% call premium in the case of certain repricing events occurring prior to the six month anniversary of the effective date of the Amendment). In connection with the Amendment, the Company recorded debt issuance costs and discount of $2.4 million, and a debt extinguishment loss of $2.3 million, which is included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. The loss on debt extinguishment includes the partial write-off of unamortized debt issuance costs and discounts.</div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt">A summary of long-term debt follows (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Senior secured term loan (1)</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,391.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,390.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Senior secured revolving credit facility</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.750% senior unsecured notes due 2025 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 10.000% senior unsecured notes due 2027 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">320.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 7.250% senior unsecured notes due 2032 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">800.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Notes payable and other secured loans</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">212.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>

<td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">205.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease obligations</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">723.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">693.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: unamortized debt issuance costs and discounts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,191.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,775.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current maturities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,094.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,701.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes unamortized fair value discount of $1.5 million and $1.6 million as of September 30, 2024 and December 31, 2023, respectively.</div> 1391500000 1398400000 98000000.0 0 0.06750 0 185000000.0 0.10000 0 320000000.0 0.07250 800000000.0 0 212500000 205200000 723600000 693600000 34100000 27100000 3191500000 2775100000 97300000 73300000 3094200000 2701800000 1500000 1600000 703800000 595800000 10000000.0 0.07250 800000000.0 0.07250 0.06750 0.10000 -12500000 -2800000 1400000000.0 0.0275 0.005 0.0100 0.0100 0.0175 0.0025 0.0100 2400000 -2300000 Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification in Condensed Consolidated Balance Sheets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Operating lease assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">297.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">255.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Finance lease assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net of accumulated depreciation</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">588.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">587.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total leased assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">886.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">842.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">37.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Long-term</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total operating lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">327.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current maturities of long-term debt</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Long-term</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, less current maturities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">694.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">660.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total finance lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">723.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">693.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,051.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">980.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Operating lease costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">50.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">48.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease costs:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Amortization of leased assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest on lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total finance lease costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Variable and short-term lease costs</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total lease costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">156.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents supplemental cash flow information (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash outflows from operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">47.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash outflows from finance leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">38.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Financing cash outflows from finance leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">19.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for lease obligations:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">79.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">39.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">40.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$

</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">108.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Leases The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification in Condensed Consolidated Balance Sheets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Operating lease assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">297.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">255.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Finance lease assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net of accumulated depreciation</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">588.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">587.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total leased assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">886.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">842.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">37.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Long-term</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total operating lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">327.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current maturities of long-term debt</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Long-term</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt, less current maturities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">694.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">660.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total finance lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">723.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">693.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,051.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">980.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Operating lease costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">50.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">40.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease costs:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Amortization of leased assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest on lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total finance lease costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Variable and short-term lease costs</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Total lease costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">156.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The following table presents supplemental cash flow information (in millions):</div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash outflows from operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">47.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash outflows from finance leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">38.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Financing cash outflows from finance leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">39.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">40.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">108.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> LeasesThe Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification in Condensed Consolidated Balance Sheets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Operating lease assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">297.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">255.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Finance lease assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net of accumulated depreciation</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">508.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">587.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px

</td></tr></table> </td></tr></table> </td></tr></table>

style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents supplemental cash flow information (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash outflows from operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">47.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash outflows from finance leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">38.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Financing cash outflows from finance leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">19.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for lease obligations:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">79.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">39.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">40.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">100.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 50100000 48700000 47500000 29000000.0 40600000 35900000 88100000 64900000 18100000 16300000 156300000 129300000 48000000.0 47200000 38600000 34100000 24400000 19300000 79300000 39900000 40800000 108700000 Derivatives and Hedging Activities The Company's objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2024 and 2023, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt. The key terms of interest rate swaps and interest rate caps outstanding are presented below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Effective Date</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount (in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Status</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount (in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Status</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-fixed swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">May 7, 2021</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">435.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-fixed swap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">May 7, 2021</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">330.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-fixed swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">May 7, 2021</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate cap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2021</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate cap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2021</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred premium cap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">396.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2028</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred premium cap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2028

weight:700;line-height:100%">Liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Assets</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Liabilities</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives in cash flow hedging relationships</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gain (loss) recognized in OCI (effective portion)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(11.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(2.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Gain reclassified from accumulated OCI into income (effective portion) (1)</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(14.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(9.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(44.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(23.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million and $16.0 million for the three and nine months ended September 30, 2023, respectively. There were no corresponding amounts for the three and nine months ended September 30, 2024. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:10pt">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Effective Date</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount (in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Status</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount (in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Status</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-fixed swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">May 7, 2021</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-fixed swap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">May 7, 2021</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">330.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-fixed swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">May 7, 2021</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate cap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2021</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate cap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2021</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-

weight:400;line-height:100%">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred premium cap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">396.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred premium cap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2024</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred premium cap</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2025</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">396.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Active</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest rate caps (2) </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest rate swaps (2) (3) </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">57.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Amounts were included in other current assets and other long-term assets on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively. (2)Amounts were included in other current liabilities and other long-term liabilities on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively. (3)Amounts related to the financing component of the pay-fixed interest rate swaps. 2200000 6000000.0 19500000 51400000 11400000 0 7000000.0 17800000 21700000 18400000 57400000 17800000 The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statements of operations (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives not designated as hedging instruments</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss recognized in income</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives in cash flow hedging relationships</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gain (loss) recognized in OCI (effective portion)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(11.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(2.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Gain reclassified from accumulated OCI into income (effective portion) (1) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(14.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(9.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-

align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(44.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(23.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million and $16.0 million for the three and nine months ended September 30, 2023, respectively. There were no corresponding amounts for the three and nine months ended September 30, 2024. 0 0 0 -600000 -11800000 7400000 -2700000 24100000 14800000 9200000 44300000 23300000 5300000 16000000.0 0 0 0

Earnings Per ShareBasic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. Earnings Per Share Basic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:46.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to Surgery Partners, Inc.</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(31.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(4.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(59.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(10.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average common shares outstanding: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Basic</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126,172 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,747 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126,093 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,559 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Diluted (1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126,172 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,747 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126,093 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,559 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share attributable to common stockholders:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Basic</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.47)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt">Diluted(1)</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.25)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.47)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.09)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3"

style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,107 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,421 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,164 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,412 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted shares</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">281 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">208 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">264 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">202 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:46.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to Surgery Partners, Inc.</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(31.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(4.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(59.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(10.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:bottom">(0.25)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.47)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.09)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,107 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,421 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,164 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,412 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted shares</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">281 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">208 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">264 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">202 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(1)The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.</div> -31700000 -4900000 -59600000 -10900000 126172000 125747000 126093000 125559000 126172000 125747000 126093000 125559000 -0.25 -0.04 -0.47 -0.09 -0.25 -0.04 -0.47 -0.09 1187000 1421000 1164000 1412000 201000 208000 264000 202000 Other Current Liabilities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">A summary of other current liabilities was as follows (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:74.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.280%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">41.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">37.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost report liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amounts due to patients and payors</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest payable</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and others</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">242.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">204.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">A summary of other current liabilities was as follows (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:74.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.280%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use operating lease liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">41.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">37.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost report liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amounts due to patients and payors</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest payable</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and others</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">242.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">204.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

height:100%">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">242.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">204.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 41400000 37600000 20700000 23900000 29400000 23900000 29900000 17800000 7000000.0 0 113800000 100900000 242200000 204100000 Commitments and Contingencies Professional, General and Workers' Compensation, and Cyber Liability Risks The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation and cyber liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of September 30, 2024 and December 31, 2023 were $18.1 million and $18.2 million, respectively. Expected insurance recoveries of $10.2 millionas of both September 30, 2024 and December 31, 2023 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. 18100000 18200000 10200000 10200000 Segment Reporting<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The Company currently operates in two major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment includes the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of amounts attributable to the Company's corporate general and administrative functions.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">The following tables present financial information for each reportable segment (in millions):</div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:46.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">735.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">657.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">2,158.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,956.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">770.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">674.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">2,249.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,007.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Adjusted EBITDA:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">149.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">138.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">419.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">384.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">All others</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-

</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative activity</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other (3) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Adjusted EBITDA</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128.6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">105.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">344.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">295.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)This amount includes transaction and integration costs of $29.4 million and $12.8 million for the three months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $2.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. This amount includes transaction and integration costs of $66.1 million and $37.3 million for the nine months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $5.1 million and $1.5 million for the nine months ended September 30, 2024 and 2023, respectively. (2)This amount includes a litigation settlement loss of $0.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $1.1 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount includes a litigation settlements gain of $0.8 million and a loss of $8.1 million for the nine months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $2.3 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, the nine months ended September 30, 2023 includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.</div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(3)For the three months ended September 30, 2024, this amount includes hurricane-related impacts. For the three months ended September 30, 2023, this amount includes estimates for the net impact of a cyber event. </div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify">For the nine months ended September 30, 2024, this amount includes hurricane-related impacts in the third quarter of 2024, net of insurance proceeds related to cyber event losses predominantly incurred in 2023. For the nine months ended September 30, 2023, this amount includes estimates for the net impact of the same cyber event and losses from a divested business. </div><div style="margin-bottom:1pt;margin-top:9pt;padding-right:-11.25pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.051%"><tr><td style="width:1.0%"></td><td style="width:72.074%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,935.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,347.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">All other</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">513.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">493.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,534.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,876.7 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash purchases of property and equipment:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">62.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">60.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">All other</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total cash purchases of property and equipment</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-

bottom;3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">68.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">69.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 2 The following tables present financial information for each reportable segment (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:46.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenues:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">735.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">657.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,158.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,956.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">770.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">674.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,249.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,007.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Adjusted EBITDA:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">149.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">138.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">419.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">304.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">All other</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(21.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(74.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(85.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">120.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">105.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">344.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">295.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td

colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reconciliation of Adjusted EBITDA:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">32.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">72.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">82.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income attributable to non-controlling interests</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(110.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(99.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">148.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">144.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equity-based compensation expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Transaction, integration and acquisition costs (1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss on disposals, consolidations and deconsolidations</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Litigation settlements and regulatory change impact (2) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on debt extinguishment</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Undesignated derivative activity</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other (3) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Adjusted EBITDA</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double

*#000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">120.6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">105.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">344.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">295.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)This amount includes transaction and integration costs of $29.4 million and $12.8 million for the three months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $2.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. This amount includes transaction and integration costs of $66.1 million and $37.3 million for the nine months ended September 30, 2024 and 2023, respectively. This amount further includes start-up costs related to de novo surgical facilities of $5.1 million and $1.5 million for the nine months ended September 30, 2024 and 2023, respectively. (2)This amount includes a litigation settlement loss of $0.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $1.1 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. This amount includes a litigation settlements gain of $0.8 million and a loss of $8.1 million for the nine months ended September 30, 2024 and 2023, respectively. This amount also includes other litigation costs of $2.3 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, the nine months ended September 30, 2023 includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.</div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(3)For the three months ended September 30, 2024, this amount includes hurricane-related impacts. For the three months ended September 30, 2023, this amount includes estimates for the net impact of a cyber event. </div>For the nine months ended September 30, 2024, this amount includes hurricane-related impacts in the third quarter of 2024, net of insurance proceeds related to cyber event losses predominantly incurred in 2023. For the nine months ended September 30, 2023, this amount includes estimates for the net impact of the same cyber event and losses from a divested business. 735400000 657300000 2150500000 1956500000 35000000.0 16000000 91400000 51400000 770400000 674100000 2249900000 2007900000 149600000 138600000 4193000000 3841000000 700000 -1200000 -600000 -2700000 -21700000 -31900000 -74300000 -85600000 128600000 105500000 344400000 295800000 1090000000 32000000 72900000 82300000 38100000 34600000 118700000 99500000 -50000000.0 -49800000 -148800000 -144300000 50200000 28900000 118700000 87000000.0 7100000 4400000 27100000 13200000 31500000 13000000.0 71200000 38800000 -14700000 -5800000 -21500000 -7500000 -1600000 -4200000 -1500000 -13900000 0 0 -5100000 0 0 0 0 -600000 700000 1200000 -3700000 7700000 128600000 105500000 344400000 295800000 2940000 12000000 2100000 200000 66100000 37300000 5100000 1500000 -500000 -3600000 1100000 600000 800000 -8100000 2300000 1400000 4400000 <div style="margin-bottom:1pt;margin-top:9pt;padding-right:-11.25pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,935.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,347.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">All other</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">513.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">493.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,534.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,876.7 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6935700000 6347400000 85100000 36300000 513600000 493000000.0 7534400000 6876700000 <div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash purchases of property and equipment:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Surgical Facility Services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">62.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">60.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ancillary Services</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">All other</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total cash purchases of property and equipment</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">68.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">69.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 62500000 68400000 1900000 600000 3700000 0 68100000 69000000.0 false false false false* *The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.*

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~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k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~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});;U _ 4IC4!J'T@2* M9NJM\2=^IT MG>!H$/JP3-MWI*_S[T5MMV"<*81\IA'VF$/:A0G^%C>(U-HIGMV'Z]>T=6<9IFK6* MSN\F.JAS J51*(U!:1Q*$RB:*;K&8O& %DMAK)PAI80Z)U :A=(8E,:A-(&BFQ)&30IA|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

!LEXAZQLMUG8+6PH-.YV]+&'M)M((P/^%$/KEQKR@6>3G_P-02P,$% M @ 68)L64([]B2\! K"$!D
!X;"]W;W)K&ULS5K;CMLV$/T50@V*!&BLJV];V\#&1I$%$F2Q1MJ'H@]H&GC=R,XAS9S$KKSW2Q8P4/,4Y>J2 M%5D&Z?,[KQ>>\';'Y05W,=O#+5HC_G7_2,69VZ D.$,YPR0'%&WF
MSKU_MPQ#F5!&_([1D;6.@6SEF9!O\N0AF3N>K BE*.82 HJO UJB-)5(HHY_ M:E"G^9\RL7W\BOY;V;QHYADRM"3I'SCAN[DS<4""-K!(^1,Y?D1U0T.)%Y.4 ME7_!L8[U'!
7C).L3A859#BOON%+340KP8\Z$H(Z(;@V(:P32N;! MTHLY%I??@[403U*D") ->,@YHHAQ\ 0Y NLCW%>)^O6EO/REX(R+>Q+O[0IQ MB%/V3L!]7:_ VS?OP!N <_
9IZF8)YNY7+0CBW+CNO0/5>E!1^EKM!^ T/L% M!%X074A?FM-7*!;I?ID>ZNFN(+%A,FB8#$J\L /O"<4I9 QO< Q+A=XG?XOY M",?U*\QO^\P+
(%IK4Z:5BMM#T=ENFS+\1%=>%V*+-$II. MFW)@OM&M]%%RC61^%?]'D%ZE,CV^V?4T3IE*IQQWR-F(T7LNEM#TCI5]\J-; MD;-5(V8+3:=-63'?:%MZR;E"&K>-;S0VR6T/25#66_
N]&U!Y8M7&VT'3: ME(T+C'ZGC]IK),TV3T]?WO">.IQUT%JU,GNF:_5LAND]F/JCV2E0%BP(;T7/ M5GV<+32=-N7C O,Z6!\]1V=2]:>34SV?!W7I69FFP&R:KM:SU?4G6VAZT\I_ M!:-
;T;-5$V<+3:=-F;C O"[61_C:][/YT%=>E:.*3 [IJOU;'4]RA::WK0R M6<'T5O1LU:;90M-W4Y1-"\VK9'WV4[PKWL\7@CKT"'I/%)H]T;5Z-L/T'8PM M-+UI9;+"6]D;#*W:-%MH.FVM[4%
[^X,5TM2LY_.@4SV[K:UT^3N&SY!N<<[,O=]6?".&PO=V]R:W-H965T1YK4.^,J>'7'R3&P!%GM,DDS>] MC5+;:\^3RPVD3%[F6\CT)ZM)1WQ]Y*>-9;S8MKCV* MV33?
J81G\"B(W*4I$__<09(?;GI!['WCA$U]OE+G@S:9;MH8G4)^WCT*?>34E MYBEDDN<9$;"ZZ=T&UQ$=F@;%'5\X'.3),3%#6>3Y-W-R']_T?-,C2&"I#(+I
M/WN80Y(8DN['WQ6T5\#U8!9,PCQ/_N"QVMSTKGHDAA7;)>I3 M?O@ U8"*#B[S1!;_DT-UK]\CRYU4>5HUUCU(>5;^9<]5(DX:#()7&M"J 3UK M0.DK#?I5@_Y;
(PRJ!H.W1AA6#8JA>^78B\2%3+'95.0'(LS=FF8.BNP7K76^ M>&:.^*$]*Z$^Y;J=F(0B^9T8L25@6DP\0KWFV)K=&0*ZXOOP+^:8VDD19#+'=WM.]KKM.CUV_HT[@$VPO
M2=__F5"?#LCGIY!<_/B.\$R! *F^ZA[#5WE@VY:NSM].[A_)+9C0C;G=BDOB M3[ZG@Y&;',)2=S!P==!*:;_^-O0+;O]_OPWDS]_U9^1>02K_:A.[! W:0::\ M7VF0!)3(%NS[(1T+4"8L!
3%B'!+"7&M1)CK.E@C*D&)BSA5(,$N- MJUJ-*^=S\7&7+G3]R5=-86J>$+*!)";_OFUU<5<&&IY4J/Y9:7)VI:L$F+ (M"69),*DEF'0M33KG#SSCZ2YM2[03U_6QP(2%F+ ("69I$OB-
A?&QRE1%0A($ ME1:BTB(LFJW)B:T,G$_*%R8X6R1P5JMT\8H;M7@FE=BE9HU[L06QU ?MQK+R ML,%)P?(O?7\\/*M:[DYU%@23%F'1;$%H(PC]CM)U:O]Y1I9,;L@JT>Q-]1Y
M0,+,>EAN>/LRS!VV\Q.%20M1:1$6S1:PL>8!FC,HYIT+)J=\<;(!VXG;Y>QI:EB%[1]TL TQ'-46HA* MB[!HMB2-70]&:(4)U;2CTD)46H1%LS5IC'O@=**87KK&*=&H6Z7F]0C7LJ+0(
MBV8+T7CVP&W:N\P05R]GB&&_]1VN.VCGA*/Z[C25I7^VB&GI46HA*B[!H]D[C:>G:)Z>HGIZ5%J(2HNP M:+8FC:>G;D__&],6T?PT B+E66$+6_7 M,WSBG9:%:]&+34QI
T;8='L5#=N MG;K=>@KT!-'3#0]Y;O4%++67*.Z;U1:B$J+L&BV((W[IFCNFZ*Z;U1:B$J+ ML&BV)HW[IF[WC;C(=4?JK!FJ?Z]HIPOPL_>>$59 6XC&E%.W*>^PR*4M/XX/ M7GD-
XH[:.8UOCQQA12[SZ9ULSTI!K(M]<9(L38[*[4[UU7KOW6VQX^SL^EUP M/2]WT#68@"BW"-7GJA\6VP"6^1*Y6EQN $6@S W MZ,]7>:Z.)R9 O5-Q]AJ02P,$% @ 68)L61NB'V6) P
\PT !D !X M;"]W;W)K&ULS5=M;]LV$/XK!ZT8$B"U7OR:S#:0 MV@@:8,6"&&T_#/O 2&>+*R5Z)&6WP'\CI2BR+%BI(,*](LM4GZF^Z!31P-=,Y'KFI<9LKWQ?QREF3/?D%G-
ZLY8J8X:&:N/KK4*6.*=,^%$0 MC/R,\=R;3]W)>[Y)C9WPY],MV^ * MS8%E MA)C8R$8_>UP@4)8).+Q3P7JU6M:Q^;S(_J-"YZ">6 :%U)\YHE)9][$@P37 MK!#F7N[?
8Q70T.+%4FCW"_O*-O @+K216>5,##*>E__L:R5PR;^#:RLL-I^FWL*+D20J!(-?PY "WN3:JH#TU&G@.*\,,VI$U MN^$YRV/.!-Q)S>V.7< -XPH^,5$@G"W1,"
[T.:%_7"WA[,TYO+$@'[@09*RG MQ'H+$<_KB)Y5T82O1#)"K<]Z <7$ 71H,5]<=I]B3&YA\Z)?^CNDZ:UL%$M M;.3P^B_@W6,LF-9\S6/F$O8Z^9NVL]2G@[-7?
KS=UH);DEJ_5>;2B6M03LM>RI;12AK5#KWYK[^$ MH^"W-LTZ CM0L%\KV#^%WDA-("'17$ NK9*44RR316[:HB\A1P[2'F&[>13V MQE-
_UXSJV&@X[@UJHP.V@YKMX+5L!6YH\B\[; M8CJY\/?F8$=@!QJ-:HU&/V<5C[I4L".P P7'M8+C[JMX?)3N42]Z5A*ES;!A M,VJOATG-=/)C*GAR7)SA405/CN@&[70O:
[J7/[)\]9[JMRV:DZM^;^9U!'8@ M4!@\]3;!SUF]%:^.1.P*[5#%1H<8=E_!%>9!45SVAL^*HL5J&+[T)0Z?6J_P M9%_R_RNYPKUL\'G>.U0FH].?8K_1D=OKT >FJ"8U"%R36]
;TT&@RAM&.3!R MZYKT!VFHY7>/*=W*4%D#>K^6TCP.;-]?W_/F_P%02P,$% @ 68)L61<_ M2N&5! AQ0 !D !X;"]W;W)K&ULS5A1<]HX
M$/XK&E_G)IE),#8&0@Z8(=B]9J:99,+T^M"Y!\466%=;XB09F[T%,QSQ3"67D02"9I2D6_]V0A&\G MEF/M.A[I*E:ZPYZ.UWA%%D1]6C\(>+)+E(BFA$G*&1)D.;%FSG7@N-K!6/Q%
MR596VDB'\L3Y5_UP&TVLKIX124BH- 2&GPV9DR312#"/?PM0JQQ3.U;;._3W M)G@(Y@E+,N?)9QJI>&)=62@B2YPEZI%O/Y BH+[&"WDBS7^T+6R[%@HSJ7A:
M.,,,4LKR7_Q<)*+BX+JO.+B%@WNJ0ZJPZ)WJX!4.WJD._<+!A&[GL9Q$^5CA MZ5CP+1+:&M!TPV3?>$.^*-.%LE "WE+P4U.?"+K!FBR),(O0!Q*M*%*6J0
M*@K=EV@!Y1EE"4%\B1X$N53X&07+)7"M>ZH00/WL?GYKH!8**P(U98SNUT1@ M71H2G?E$89K((+?K>C7SF9_NWJL+ MY^=&#WYX]+UD],H:ZQF\WBMXCR1,L)1T24-3
F@6_0.5G9=&9LIC%H99FB50 M,!&Z5S$1:,Y34+Y82]*&H%L6\I3H\JI6VY>/,!*ZA2J3?]<533XMKWY:6H*O MY1J'9&+!2)*(#;&FO__F#+I_U#'6)IC?)EC0$M@>MU[)K=>$/H7%?
H'F6,;H M/>PY1C[(!3IB"8TY%,9PBJC+,,L!*,]?=@1_ KQ7X)GI7N>0(0"EJ6%F-2R MWCSA6Z8(I$$A\@;K81Y,*+J^&X'QF\')OAIF#UV^R6[_4;<6W;^&^B!,<6SJ TV0MZ M44 8]:
RZJC",*SAV2+IB)F8L45QD)1))3)=OK7[5>,0WRL];8+Y;8(%+8'M M\30L>1K^FMO*L$UNVP3SVP0+6@+;X_:JY/:J<0U^Y%*"NH1\Q>@W( ].A]1P M5<=!#M5OD)HW+?PW+8+
<8EBUZ+RB-*,RRM')2@,1AGH;7>IM="RY9SI!"7CM.Y.M"B&K-A MQSN0HSHLMS,\D*0:*]?K./6BY+@OV7 ;LW&FTW&.DD*#B]J'?"P%3X_.@)0I
M7HCSR9ERCXY^EXYWG*D:LU'&>W]'2:NQL?S#L^509V9VZN8Y:FS*Q'I6P!$B5D M"4-U.T/8FT1^ZY4_*+XVUSI/7"F>FF9,<2-H#W2\[5[D$/4-X]3O\'4$L# M!!0 (%F";%EON$(
104 $X: 9 >&PO=V]R:W-H965TW 3 U:= MF+,=V/[W-TY"(*F39>^LT[U ;,]\]GPS'GN2Z8Z+5[DF1*'O"4OE36^MU.;: M<62T)@F6?;XA*8PLN4BP@J98.7(C"(YSI80YONN.G
33M#>;YGV/8C;EF6(T M)8\"R2Q)L'B[)8SO;GI>;]_Q1%=KI3N]=R;:(5&P_&O&!)[CC[1F.UONE->B@F2YPQ]<1WGTAI4*#Q M(LYD_HMVI:S;0U$F%4]*95A!0M/B'W\OB3A2\
8M"GZIX#<5@A:%0:DP:"H, M6Q2&I<+PU!F"4B$X=891J3#*N2_(RIF^QPK/IH+OD-#2@*8?)H MD8D5$6_H$0N5$@$;\7,:I4U>*B88Y1/HDVT[NQQX_?'4V1[3;Y :]J_J0J%!
M*+CJC^I26A46>H%F?->>&0"Y,3"OW@*# \?^2-_48H MFL2"\; 1L:$1S;T:-*+1B!8$+>$XKHP==QJ[/TX[S+WM1OC#^]/$T?@TCDQB M!HZ,:.\Y,J*UN[ANWV>MHU/,?OV!V M.
[K4^A%;9K%W=)G%WO'5@M9&V%%]XG7: MN- [%?&-:KWM=^K_[%:UBA9:19O;0]M[PC]XPO^OLFLYDRV?V40+K:+-;:'5 M?7:HIKS.6J%(-
W1+D"11)JBB]9LK2KF":CIB&92RNJQ6Z_R>NP&7[LO]N,Q8 M3==++4P%(LLEB0 %*H94T7@_8=>UK%QT[?CW)LT"P20U]+UF>C)AC8;-[&3" M\OR6Y'2HE;SN8NF)2-@ D::G,-
=H;2?&3P>[3;30*MK<%EK=&X>"S>NNV&PF M**OEFU6TT"K:W!9:W6>'$[KKN'^IPGJ?0WG3[QF?C((N9-F>C((O<].)2V MY*0+QGK/H3SR.N_S^KZ(O@*!-
&/*LW=ABL"I&#&WE!L<,52O^5E3--*>2S1 M#EC5+HG@,D9AJP#M+R3"F22Y9TJJ=SQC>B G_'*/VS<%C'/TZCHA8I5_9)" MGZ6J>%=3]58?,F[SU_>-_COO^MXS](?
ZPX>A_Z,WO@Z!3-/(!$;R;R7.84G% MEY8'+%8TE8B1)2S/[8_!9Z+X>%$T%-_D+]M?N%(\R1_7! -36@#&EQP8+QMZ M@NH3TNQO4$L#!!0 (%F";%F-8#-M! , .@(9 >&PO=V]R:W-H
M965T)58.9;9+VW^\84D83E_5B-V##>5_YQC;'3"9"/J@-@:"/&<_5U-EH M75QXGDHVD%'EB@)R?+,2,J,:NW+MJ4("32M1QKW0]P=>1EGNQ)/JV:\)2V+4
MG.5P*XDJLXS*IRO@8C=U N?YP1U;;[1YX,63@JYA ?]^N)78\QJ7E&60*R9R M(F$U=2Z#B]G8Q%?&"#%^ M[SV=9D@C;+>?W3]5N6,N2ZI@)O@/ENK-U!DY)
(45+;F^$[O/L,^G;_P2P55U M);LZ=N []"F5%ME>C 09R^L[?=S7H24(>J\(PKT@?*L@V@NB*M&:K$IK3C6- M)U+LB#31Z&8:56TJ-6;#K#PE<$64+@D\C^0 MT]
[%OFL6SZ'!.5!)8]>RCU,N\D];'(/*[^H,_=VSG.F$BY4*8'\O%PJ+?$K M^V7+LS;NV8W-RKM0!4U@ZN#24B"WX,3OWP4#_Z,MZ_JD]](&45.#],L]KI;M MN5B=EPH([@V2:I:O"0=
<&H3_+8VM"+7SH'(VN\4V[@4NSNNVG=QQ4#1T!TW0 M"^A>]WKA)X)I7$*+*834_V*LC8:MX4/?'1XP6H(B=VQG[#>,_4[&RTR4N58D M+8%H00JL*Y@^S5/L/ EIQ>T?
DXR/2FH)>A5WT. ..G&OUN=JW=&BJ(ZFI=!X MT%7-#?Z*@#0!^'XEA'[NF-.N^;F)_P!02P,$% @ 68)L63ZJ?3EI @ M]04 !D !X;"]W;W)K&ULK53;;A,Q$/T5RU30 M2B5[;:C*9J4V
<%#I:A1X0'QX.Q.$JN^++:3E+]G[-VN$K$M"/&2]67.F7/& MF2GVVCS8#8 CCU(H.Z$;YYJK*++5!B2S(]V PIN5-I(YW)IU9I.L#K X@*:(T MCL>19%S1L@AGNL$5S
WQ&ZE9.;G#0B]G]"$/AW<\?7&^8.H+!JVA@6X M^V9NAU$T;>DOO%C)R>G)$3PA6YY4+@*]@B3O^CF@W4<6QWJ(YV5WH'!YQV2 MFO^N(CY0T4K]0U K-
3IH2C\0;YE9HPHB8(6P>/3N@A+3#IEVXW03^G2I'79] M6&YP+H/Q 7B_TMH];7SK]Y.^_ 502P,$% @ 68)L66-5P,4? @ I00 M !D !X;"]W;W)K&ULC51-C],P$/TKEI$02%"G
M:7:!DD1J=T'+85=5*^ .+C))+'6L8/M-,N_QQ]I*%*WXA)[!'EOWDQFG Y2 M/>H&P*'GE@N=X<:8;DF(+AIHJ9()#H2]J:1]J;&FJHGN%-#2@UI.XBBZ)BUE M N>I/]NH/6]X4S
1B'=MRU5O]? Y9#A.3X>;%G=&'= \K2C->S ?.TVREID M8BE9"T(S*9""*L.K^7*=.'_O\(W!H$_VR6&RE_+1&5_*#$=.$' HC&.@=CG M#7#NB*R,7R,GGD(ZX.G^R/[9YVYSV5,--
Y)_9Z5I,OP>HQ(JVG.SE<,=C/E< M.;Y"=PCD5=Y20_-4 MR0$IYVW9W,:GZM%6'!/NI^R,LK?,XDR^@]J6V* M=%(9)FKT%CU0I:@K%GIU M"X8RKE^GQ-A@#D**D7@=B.-
GB#^@>RE,H]$G44+Y+YY8D9/2^*AT'5\DW$$W M0XOH#8JC.$$ZZ+[NY@JL/"\B_^NP(_57AME^^7GN;0#6W*>ST@ S; M(=&@#H*SER_FU]""UJ326RMB3U_Z-L]*"0K9*?
2_2.K=JR$/J> MASQ.R>%4 #EIG194[0=$HT+VPH0NFDZG&5R%UOOK'@;XGJJ:"8TX5!8:S=[9 MN"H,13",['PC[J6Q;>VWC7U'0#'D>U]):8Z&"S"]3/D?4$L#!!0 (%F" M;%EZXNJ3J <
$,I 9 >&PO=V]R:W-H965T(=]N'H@^,Q=AJ9=$KT;D4_?A2 MEU@7CIBDU>8AL>0S0YT9$HL:S;=LB@9+4Z*>]?IXD3L91PE_#I% MV7ZJ9>G3.8_%P^D(CYYOW$3KC FC+4^R2"0H
MY7>GHS-\"%":&Q2(7R/^D#4^HYS*K1!_Y1>7X>G(RI^(QWPE',7#/YN=G[Q\+\HK,+5?]E@%HF&@_, &I#(@70.[QX!6 M!O2U(]B5@?W:$9S*H* ^+;D7@?.99(N35#R@-$<=35F O
MDY78YY)%Z+ MUYM3B,[_&SWXSZ.W@D$/LX86_NBK9\UE4A:M?/'_?]7@Z%+R;?8'E/G2MPW[MSBOC<;9C*WXZ4J4OX^D]'RU^_ '/K)^@L _IS!_263"0LU:"[$.";)/W1;5<
MP8576LX*RWP?N5^XKC51L^J^&5<<-7/M"6ZC?!U%B#V?S-NP (!9EMN M4@Z M!Y*.D>19^*##3V8'IS+C>;OA*)*LHCLH%INIRA_LQ1'XVY#H;TID_I+-@(&>MQ+B'
MQ+C&*5AM@+=<53^N=KSB2K)'>.6YP#SKKI4+'41)8_Z4 =1!+IG,K<9/9Z4& MNH5')A2>EMZ!O6=D_XL2LA5G)F4:W>XENU6Z00J4B&2LYJQ,A5(:G^($LE5 M^"48%T]
[MC'UNK7F D+9W;7L RB,O8G;"0< F\\;2[X5C_DA'O,79D-)$O%' M)>O>H02+B'"I1NG,;IC==C.M0=4=;4[#700MKTN*H!0=E_NL54K1\O(UN=J M0:VJDI3K0K;-Q<#?
Q0U0\5G:@SC6A'2(RA5LCNKQ =04)HK6#/2GMM#O"&9 ML9%X\&T?R:=QW1^$2,W^/-=E%*J\@^2QOF2U*0Z M!WE!T!$ITV)L!*12:+BNN5ZY6GLU0"M H>[F^U%A7):C]\- MA.
[)Q=WY%$#C>7T;,JX5,#;JMZ+VQ2++D.(:1ME.9"S.CA3M)!-Q%!9!R8JH MA+Q]$PP*!=9H=S9? "A'JPD B&CQ#0"4VU?^<*TZL5EV7JGQTR*] FM-BQ9J]URJ[9EL#Q6H[2BH8DV
&1WD^^#GK18 "#:)TYQ MK4ZQ69Y>/<\.?IOO"F;!%;)@\)2-K19GQW3W@9XF-=?SIZ;3#Y;;.M%2HV MZJS%5]5G9]$Z8;DH#7D:W;/\"@\"5+E$J0\>YGRBQ#_94A009I1L1H3JDVY
MUG[8+/X^RPU/05ZZV++TQ0RH07W^ZJ QU7K M?7]UUX45F6O-)8#"NL@%4+/9Q)HW?[J1T$VHVRMU:EV'S<)N5DJQ_N=@;L@3?_X A8P8"FZRO?I%9TQ*SHWNR(6=@5"
[I)NS?=!%!76KH!D*7S!=3_:L8)'J9]"6*1*M*"KS]?/VW<1E&+[!J-B M'.^M)PZ#>O,'!180753:O0FI-24Q:\KZ8+TZ8,W0/VBY3]?12N7H(\M/@.23 M^C*]CU;P$8-YA#>G8-#3U4&]!4-
Y:^>JEKK$_HY'X,2HM]^]<]G*G)@5 M^"N.PXFN@[$]UUHK"$:U8W,?@=EXKF]>.HQZ=N]N7D-W0;\%0WMHYJGL(XGW/*FEI4-ZI4OK1L=:FFI7E$J*=2'='MX M #36FW@(I34" 80B?
5T\K7L::NYISN(8B;Z#"K/MF_\5/Z0W?U!OP5#>VEFH M6RU*OF,=I(/V58-Z\P?U%@SEK9VFQFLMY@;L-76A]#!K+5.L5P8 1K'V;RP(MYMJ:A()@GC-QX*.PDORT\5+8EJ?
KXFV\#*W$/I'EFSZ'NX&ULM5A=;]LV%/TKA%H4 M+;#IVY*=V08,'6Z)X MSKWW4#RXYO1 V3>>("3 CY1D?&8D0N17EL7C!*60FS1'F7RRI2R%0MZRG<5S
MAN"F!*7$T%PAE8,\'V:0O9XC0@]S S'. [?H-#/=[PGP!X-Y03IG V0[\"A:<(\$!S#9@"7D"5GL6 M)U);#N@6K)A\YYAX+!]__+['>8F_?P1_RG%84AQ)WT=(0$SX!TGZ>1V!]V_ M@+<
9^ 6$R)7G4\M(6LH,K'B.M_K*E_WB7PGX)9F(N'@8[9!FR[>DK4W KA' M :Y=)>$:Y2;P[%^ :[O^0#[+Y\.] 7BDAD#&X%2_L^0]!6W/\Q=.- 5SV&,9H:T&([8 S+F[]XX@?W;D&XZ
MR2)-9!U-_4937\4^_XL*2 L-\60:A4Z*-&%S3[,PY'GF_)E>FCKH0QRJ1[] MF,$X#,RPB=FI=-14.GI&I7&QY_/VGL_;>QX=]_R0%A5_V,G+M"?MSYDL%6+2 M1IQ-
B91)OW#Q@T:20"E)S]0X^!>L]VR'8RG5)QAC@J4P:QD6QVCP_5 &N'17 MZ22+-)%UA T;8<-7=*I0IZ8ZR2)-9!U-QXVFXY]RJG%_=TZ\4;GFZ$R)@4ECT[=;'^?,JY1IOW#Y'?O4S-F7
MN]4BDR9%9%.O="DU\Z5;2BM;I(NMJVJK179>T:IJ+$^_02\P/2&OF.LE_5X%YU@'9BCMG3HC_)-H,S MPU*G^M)7X-
1;.^KF>D$(H")!;+!*G3WS4BM;I(NMJ]NI4W=&K^E)FEKJ6EB= M;)$NMJZPIW[?43?_^M)06]3C1SO?%LMU5$NUB3H_4OR)T_9T*D#=Y3-J X;
M"GO_0[U>.UE/:B=OGYN0UJ[9:AV'I8CMRF-%#F*ZST1U,-2,-D>7B_+ [FS\ MVKE:5@>0)YKJ//06RG^ &0<$;26E;8;RI675$6-U(VA>'KK=4R%H6EXF"&X0 M*R;(YUM*Q?&F"- <],[_
U!+ P04 " !9@FQ9? O/6R\# D$P #0 M 'AL+W-T>6QEUY-B9X[*67S_?.$T_\&6,AXTN%8U]3\ZYQ_8--@QKLQ+L9LZ8"9:ED'5&
MYL94'*PGLY92>LS53%ID4+IDAK;U,.PKC2C>0VD4H3]7B\)2\HE&0WEHKPJ M31U,U4*:C"1=*'"WSWE&HN0]"9S<6.4L(W%-T*_(R;/PZK1DP3T5&1E3P2>:
ZN@)1V4^+>QP9-.'ZF37FA5\V?2716< 4X]P=5I58O51\)DLF1O\ MLQ..AG3-"^9*\P>;#4IE:@-,D^">:<.GVY&?FE:W;&G6Y;0L<,_] _3\=^=Y MQB335&R;MK7_FF?YQ8[CBW]EN?
FMLF_8Z['=5E^[R?-#,)D<@LF#J,G!(9A, M7Z7)L-W MTX).V>$+AK 62PCW^!D)S9)@\F"'\-EVYOS/&?RT5'!RALZL7\" M[.C;YW-6T(4PMQV8D4W[*\OYHDR[IZYA(MJG-
NTO,+PHZ0Z"-A>7.5NR?-QV M]6S2- /;L%G;"PC[R%5S^1&,XS _ AB6!W. <1P+R_,_C6> CL=AF+>!%QF@ MG '*<2P?,FX^6!X_)[67?Z1I&L=)WH>[QU,,;F+4G@QZ^&>0,&E@7G
MQ#&L*N8->X-Q)$TQ!&K17Z-)@LQ. A__^F!O21RGJ1\!S.\@CC$$WD8-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 (
%F";%G&P=V]R:V)O;K&ULQ9K?C]HX$(#_%2M/6ZD]2&+8 M'RJ5*'#7E2BL"NIK91(#5A.;LPW;W;^^3E+N)KMT="]S>0IQ0O)E[.2;P4N1N+Z4O MBU[2[P][I5 Z^O#^?
*P'VX,KQLO,*Z-#8]7P5C?:B6&76%,4HBIL-7Z7U*GO5O*H@UV+C MZA8O-E]$!E%PWXXX%99Y^L]ZN.+P'B28>=F]>C-GZKPTDZ%EW]97-M/D"!2-D[%;8^[$E
(T19+J:SQ6HV9>'7:CF_GX[78>7C>#Y> M3&8,0"8(9-(AY+<$0*8(9-H)Y&H=%I]G"P#)$4C>(60KD@,$O5M+6P:HC8=4J&.(
M)3.7PDD']:3"9Q,0VF4JK3J'#9KN^R3S7<@$PE@+;:H5-$PG,;9%l+J@.78 M@[1LM1=60C+,(3&Q)9^'Y F1VO#?FRN1)WGJ78/8_Z(J05BRE+Y:J>FAR'9<5
MQAW;8Q!S1DPLC7OM5!Y&X=J*O+YYK16AA^L^AXR8,F)B9Z!B:R5;">:,A-@9 M."9,MQ),(@FU1%IJ8U>AKBND>P/QT!*%V"J-XRYB819)B"V"RJX]!C&E),1* M>2V[BY'$I)
(02^6WUFM((2:FE>3_ULK%0&)^28C]@C]O8.648(9)NBQ+6K53 M@DDFZ50R0S@W@DDF[50RUQ 3DTQ*+!D<\P9B8K))B66#8]Y"3'1&C%@^&.:W MND[^!Q.33TI=SZ"8,
<3$!)02"PB=@FC/@F("2HD%A&/"=#+%+)026^A%.OF. MK<)!\V,AJUZ?&XB)62@EMM KS(4E2S5[&KJ823%2EFH9380K^RWW840QE^
M,/I%1<8Q"W'JZ;%+F'4CF_TXP.*68Q;BQ!;"DW9X"W',0KS+B;16(LFP)B8A;BU"]H ML)E*=@4Q,0MQ8@N]+BI;(H*8F(4XL84N88(G/7R[B5EH0&RA2YACY^2O,0 Q M,0L-
FB\7SI\KY'*KM,P7X10NM&>BR!XLJQ;-&Q<^J"9#M\>BF(2VI9X;D9^_ M?CA_N?'A)U!+ P04 " !9@FQ9H9?JE,D! "@'@ &@ 'AL+U]R96QS
M+W=O/@@*FC1NNWB\7%FU_:')EV6_#EVSW#7K&'0RF8;^YXSJ9?9SYFAQ[N)? M)K:KU7897]OEYR$>\R^#PU?;[](FQER-%DV_CGE>A=/^?CJ%ZT'&E\G5Z.UC
M7O5O'U*%TD$*05H^R"#(R@BOJK01Z^JM!'HKZJT$>BOJK01Z^IM!'H;ZFT$>AOJ;01ZVV"SA$!O0[W-0&]#O8U M;T.]C4:00[V-0&]#O8U
;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\?;'83 MZ.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^A=H]XU@=XUZEW_I]XIG_UW7VSI;#)^VUGRO6U5
MUGZ2+$.P#XSY;$F5]JFQ5,>1N7&5#O'1+9C5V4HOB(G!8,0R4P>J0S\T-9+I M^(GF>EV&WO,VOO:%J2>)H](GONI,:N__CG:W--*%_4QG[5_H*>?4$L! A0#% @ 68)L M60=!36*! L0
! (! &1O8U!R;WS+V%P<"YX M;6Q02P$"% ,4 " !9@FQ9[< 6/^X K @ $0 @ &O M 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " !9@FQ9F5R<(Q & "< M)P $P @ ', 0
>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 M Q0 (%F";%FQX+) W 4 -T> 8 " @0T(!X;"]W M)K&PO=V]R:W-H965T&UL M4$L! A0#% @ 68)L6;%%Z&11 P %PL !@ ("!/!4 M
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 68)L M6:3=8\F[@]P< !@ ("!E"4 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ 68)L61BY"0S\'P QF, !@ M ("!,SP
'AL+W=O&UL4$L! A0#% @ 68)L60&PO=V]R:W-H965T&UL4$L! A0#% @ 68)L6:R!]\$*! ?@D !D M ("!@7T 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 68)L64_P8M9:!P
8!4 !D ("!$(D 'AL M+W=O&PO=V]R:W-H965TH^K0P((H& 9 " M@6>3 !X;"]W;W)K&UL4$L! A0#% @ 68)L M67)LV! %P *4D !D ("!X94 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ 68)L66>L'B3(! \ P M !D ("!F[< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 68)L65*TD*W9 @ - 8 !D M ("!H<8 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @
68)L6:,J9*E&! R!D !D ("!K], 'AL+W=O M&PO=V]R:W-H965T!0, ,X' 9 " @?O> M !X;"]W;W)K&UL4$L! A0#% @ 68)L66_> MX&BO @ =P8 !D ("!-^('AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ 68)L649GXF9) P 3PX !D M ("!A^X 'AL+W=O&PO M=V]R:W-H965T4^:0@4 M -(? 9 " @<#Z !X;"]W;W)K&UL4$L! A0#% @ 68)L60B1N#>C!0 E"0 !D ("!
M.0 ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 68)L6&PO=V]R:W-H965T&UL4$L! A0#% @ 68)L61NB'V6) M P \PT !D ("!@",! 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ 68)L68U@,VT$ P Z @ !D M ("!B#$! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 68)L67KBZI.H!P 0RD !D ("!N3D! M 'AL+W=O&PO=V]R:W-H965T : " M 8I.
0!X;"]? 3 " 8M0 0!;0V]N=&5N=%]4>7!E <&UL4$L%!@ [#L % '!]2 0 $! end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created for the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()

{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 276 270 1 true 72 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://www.surgerypartners.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 9952158 - Disclosure - Organization and Summary of Accounting Policies Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies Organization and Summary of Accounting Policies Notes 9 false false R10.htm 9952159 - Disclosure - Acquisitions, Disposals and Deconsolidations Sheet http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidations Acquisitions, Disposals and Deconsolidations Notes 10 false false R11.htm 9952160 - Disclosure - Long-Term Debt Sheet http://www.surgerypartners.com/role/LongTermDebt Long-Term Debt Notes 11 false false R12.htm 9952161 - Disclosure - Leases Sheet http://www.surgerypartners.com/role/Leases Leases Notes 12 false false R13.htm 9952162 - Disclosure - Derivatives and Hedging Activities Sheet http://www.surgerypartners.com/role/DerivativesandHedgingActivities Derivatives and Hedging Activities Notes 13 false false R14.htm 9952163 - Disclosure - Earnings Per Share Sheet http://www.surgerypartners.com/role/EarningsPerShare Earnings Per Share Notes 14 false false R15.htm 9952164 - Disclosure - Other Current Liabilities Sheet http://www.surgerypartners.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 15 false false R16.htm 9952165 - Disclosure - Commitments and Contingencies Sheet http://www.surgerypartners.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 9952166 - Disclosure - Segment Reporting Sheet http://www.surgerypartners.com/role/SegmentReporting Segment Reporting Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 9954471 - Disclosure - Organization and Summary of Accounting Policies (Policies) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies Organization and Summary of Accounting Policies (Policies) Policies http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies 20 false false R21.htm 9954472 - Disclosure - Organization and Summary of Accounting Policies (Tables) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables Organization and Summary of Accounting Policies (Tables) Tables http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies 21 false false R22.htm 9954473 - Disclosure - Long-Term Debt (Tables) Sheet http://www.surgerypartners.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.surgerypartners.com/role/LongTermDebt 22 false false R23.htm 9954474 - Disclosure - Leases (Tables) Sheet http://www.surgerypartners.com/role/LeasesTables Leases (Tables) Tables http://www.surgerypartners.com/role/Leases 23 false false R24.htm 9954475 - Disclosure - Derivatives and Hedging Activities (Tables) Sheet http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables Derivatives and Hedging Activities (Tables) Tables http://www.surgerypartners.com/role/DerivativesandHedgingActivities 24 false false R25.htm 9954476 - Disclosure - Earnings Per Share (Tables) Sheet http://www.surgerypartners.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.surgerypartners.com/role/EarningsPerShare 25 false false R26.htm 9954477 - Disclosure - Other Current Liabilities (Tables) Sheet http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://www.surgerypartners.com/role/OtherCurrentLiabilities 26 false false R27.htm 9954478 - Disclosure - Segment Reporting (Tables) Sheet http://www.surgerypartners.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.surgerypartners.com/role/SegmentReporting 27 false false R28.htm 9954479 - Disclosure - Organization and Summary of Accounting Policies - Narrative (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails Organization and Summary of Accounting Policies - Narrative (Details) Details 28 false false R29.htm 9954480 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) Details 29 false false R30.htm 9954481 - Disclosure - Organization and Summary of Accounting Policies - Revenues by Sources (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails Organization and Summary of Accounting Policies - Revenues by Sources (Details) Details 30 false false R31.htm 9954482 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails Organization and Summary of Accounting Policies - Income Taxes (Details) Details 31 false false R32.htm 9954483 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details) Details 32 false false R33.htm 9954484 - Disclosure - Organization and Summary of Accounting Policies - Non-Controlling Interests - Redeemable (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails Organization and Summary of Accounting Policies - Non-Controlling Interests - Redeemable (Details) Details 33 false false R34.htm 9954485 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details) Details 34 false false R35.htm 9954486 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details) Sheet http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails Organization and Summary of Accounting Policies - Variable Interest Entities (Details) Details 35 false false R36.htm 9954487 - Disclosure - Acquisitions, Disposals and Deconsolidations - Acquisitions (Details) Sheet http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails Acquisitions, Disposals and Deconsolidations - Acquisitions (Details) Details 36 false false R37.htm 9954488 - Disclosure - Acquisitions, Disposals and Deconsolidations - Disposals and Deconsolidations (Details) Sheet http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails Acquisitions, Disposals and Deconsolidations - Disposals and Deconsolidations (Details) Details 37 false false R38.htm 9954489 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details) Sheet http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails Long-Term Debt - Schedule of Long-Term Debt (Details) Details 38 false false R39.htm 9954490 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 39 false false R40.htm 9954491 - Disclosure - Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details) Sheet http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details) Details 40 false false R41.htm 9954492 - Disclosure - Leases - Schedule of Lease Expense and Cash Flow Information (Details) Sheet http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails Leases - Schedule of Lease Expense and Cash Flow Information (Details) Details 41 false false R42.htm 9954493 - Disclosure - Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details) Sheet http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details) Details 42 false false R43.htm 9954494 - Disclosure - Derivatives and Hedging Activities - Narrative (Details) Sheet http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails Derivatives and Hedging Activities - Narrative (Details) Details 43 false false R44.htm 9954495 - Disclosure - Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) Sheet http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) Details 44 false false R45.htm 9954496 - Disclosure - Derivatives and Hedging Activities - Schedule of Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details) Sheet http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails Derivatives and Hedging Activities - Schedule of Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details) Details 45 false false R46.htm 9954497 - Disclosure - Earnings Per Share - Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share (Details) Sheet http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails Earnings Per Share - Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share (Details) Details 46 false false R47.htm 9954498 - Disclosure - Other Current Liabilities (Details) Sheet http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables 47 false false R48.htm 9954499 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.surgerypartners.com/role/CommitmentsandContingencies 48 false false R49.htm 9954500 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.surgerypartners.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 49 false false R50.htm 9954501 - Disclosure - Segment Reporting - Schedule of Segment Revenue and Operating Income (Details) Sheet http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails Segment Reporting - Schedule of Segment Revenue and Operating Income (Details) Details 50 false false R51.htm 9954502 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) Sheet http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) Details 51 false false All Reports Book All Reports sgry-20240930.htm sgry-20240930.xsd sgry-20240930_cal.xml sgry-20240930_def.xml sgry-20240930_lab.xml sgry-20240930_pre.xml sgry-20240930_g1.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sgry-20240930.htm": { "nsprefix": "sgry", "nsuri": "http://www.surgerypartners.com/20240930", "dts": { "inline": { "local": ["sgry-20240930.htm"] }, "schema": { "local": ["sgry-

20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["sgry-20240930_cal.xml"] }, "definitionLink": { "local": ["sgry-20240930_def.xml"] }, "labelLink": { "local": ["sgry-20240930_lab.xml"] }, "presentationLink": { "local": ["sgry-20240930_pre.xml"] } }, "keyStandard": 240, "keyCustom": 30, "axisStandard": 22, "axisCustom": 0, "memberStandard": 30, "memberCustom": 39, "hidden": { "total": 17, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 12 }, "contextCount": 276, "entityCount": 1, "segmentCount": 72, "elementCount": 555, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 814, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.surgerypartners.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LaborAndRelatedExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, "R5": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, "R6": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, "R9": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies", "longName": "9952158 - Disclosure - Organization and Summary of Accounting Policies", "shortName": "Organization and Summary of Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidations", "longName": "9952159 - Disclosure - Acquisitions, Disposals and Deconsolidations", "shortName": "Acquisitions, Disposals and Deconsolidations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.surgerypartners.com/role/LongTermDebt", "longName": "9952160 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.surgerypartners.com/role/Leases", "longName": "9952161 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivities", "longName": "9952162 - Disclosure - Derivatives and Hedging Activities", "shortName": "Derivatives and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.surgerypartners.com/role/EarningsPerShare", "longName": "9952163 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilities", "longName": "9952164 - Disclosure - Other Current Liabilities", "shortName": "Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.surgerypartners.com/role/CommitmentsandContingencies", "longName": "9952165 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.surgerypartners.com/role/SegmentReporting", "longName": "9952166 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":

"us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Organization and Summary of Accounting Policies (Policies)", "shortName": "Organization and Summary of Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables", "longName": "9954472 - Disclosure - Organization and Summary of Accounting Policies (Tables)", "shortName": "Organization and Summary of Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.surgerypartners.com/role/LongTermDebtTables", "longName": "9954473 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.surgerypartners.com/role/LeasesTables", "longName": "9954474 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables", "longName": "9954475 - Disclosure - Derivatives and Hedging Activities (Tables)", "shortName": "Derivatives and Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.surgerypartners.com/role/EarningsPerShareTables", "longName": "9954476 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables", "longName": "9954477 - Disclosure - Other Current Liabilities (Tables)", "shortName": "Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.surgerypartners.com/role/SegmentReportingTables", "longName": "9954478 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails", "longName": "9954479 - Disclosure - Organization and Summary of Accounting Policies - Narrative (Details)", "shortName": "Organization and Summary of Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-3", "name": "sgry:NumberOfSurgicalFacilitiesOwned", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "sgry:NumberOfSurgicalFacilitiesOwned", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails", "longName": "9954480 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)", "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-106", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-106", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails", "longName": "9954481 - Disclosure - Organization and Summary of Accounting Policies - Revenues by Sources (Details)", "shortName": "Organization and Summary of Accounting Policies - Revenues by Sources (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, "R31": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails", "longName": "9954482 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)", "shortName": "Organization and Summary of Accounting Policies - Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails", "longName": "9954483 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)", "shortName": "Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, "R33": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails", "longName": "9954484 - Disclosure - Organization and Summary of Accounting Policies - Non-Controlling Interests - Redeemable (Details)", "shortName": "Organization and Summary of Accounting Policies - Non-Controlling Interests - Redeemable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, "R34": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails", "longName": "9954485 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)", "shortName": "Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-154", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-154", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails", "longName": "9954486 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)", "shortName": "Organization and Summary of Accounting Policies - Variable Interest Entities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "sgry:VariableInterestEntityNumberOfFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name":

"sgry:VariableInterestEntityNumberOfFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, R36": { "role": "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails", "longName": "9954487 - Disclosure - Acquisitions, Disposals and Deconsolidations - Acquisitions (Details)", "shortName": "Acquisitions, Disposals and Deconsolidations - Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-181", "name": "sgry:NumberOfNonControllingInterestsAcquired", "unitRef": "surgical_facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R37": { "role": "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails", "longName": "9954488 - Disclosure - Acquisitions, Disposals and Deconsolidations - Disposals and Deconsolidations (Details)", "shortName": "Acquisitions, Disposals and Deconsolidations - Disposals and Deconsolidations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R38": { "role": "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "longName": "9954489 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)", "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "sgry:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R39": { "role": "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "longName": "9954490 - Disclosure - Long-Term Debt - Narrative (Details)", "shortName": "Long-Term Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R40": { "role": "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails", "longName": "9954491 - Disclosure - Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)", "shortName": "Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "sgry:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "sgry:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R41": { "role": "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails", "longName": "9954492 - Disclosure - Leases - Schedule of Lease Expense and Cash Flow Information (Details)", "shortName": "Leases - Schedule of Lease Expense and Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, R42": { "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails", "longName": "9954493 - Disclosure - Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)", "shortName": "Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R43": { "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "longName": "9954494 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)", "shortName": "Derivatives and Hedging Activities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R44": { "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "longName": "9954495 - Disclosure - Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)", "shortName": "Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssetNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssetNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, R45": { "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails", "longName": "9954496 - Disclosure - Derivatives and Hedging Activities - Schedule of Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)", "shortName": "Derivatives and Hedging Activities - Schedule of Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, R46": { "role": "http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails", "longName": "9954497 - Disclosure - Earnings Per Share - Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share (Details)", "shortName": "Earnings Per Share - Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-251", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R47": { "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails", "longName": "9954498 - Disclosure - Other Current Liabilities (Details)", "shortName": "Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "sgry:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "sgry:CostReportLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R48": { "role": "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails", "longName": "9954499 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SelfInsuranceReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:SelfInsuranceReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, R49": { "role": "http://www.surgerypartners.com/role/SegmentReportingNarrativeDetails", "longName": "9954500 - Disclosure - Segment Reporting - Narrative (Details)", "shortName": "Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true, "unique": true } }, R50": { "role": "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails", "longName": "9954501 - Disclosure - Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)", "shortName": "Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } }, R51": { "role": "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails", "longName": "9954502 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)", "shortName": "Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "first":

true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "sgry-20240930.htm", "unique": true } } }, "tag": { "sgry_A2017SeniorSecuredCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "A2017SeniorSecuredCreditFacilityMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior secured revolving credit facility", "label": "2017 Senior Secured Credit Facility [Member]", "documentation": "2017 Senior Secured Credit Facility [Member]" } } }, "auth_ref": [] }, "sgry_A2017TermLoanMaturing2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "A2017TermLoanMaturing2024Member", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior secured term loan", "verboseLabel": "Senior secured term loan", "label": "2017 Term Loan, Maturing 2024 [Member]", "documentation": "2017 Term Loan, Maturing 2024 [Member]" } } }, "auth_ref": [] }, "sgry_A2023DisposalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "A2023DisposalsMember", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2023 Disposals", "label": "2023 Disposals [Member]", "documentation": "2023 Disposals" } } }, "auth_ref": [] }, "sgry_A2024RefinancingTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "A2024RefinancingTermLoansMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Refinancing Term Loans", "label": "2024 Refinancing Term Loans [Member]", "documentation": "2024 Refinancing Term Loans" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r102", "r720"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r869"] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r18", "r19", "r120", "r212", "r544", "r583", "r584"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } } }, "auth_ref": ["r776"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r115", "r720", "r969"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r594", "r857", "r858", "r859", "r860", "r914", "r972"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r789"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r789"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r789"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r789"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r822"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r748", "r758", "r768", "r800"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r751", "r761", "r771", "r803"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r823"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r789"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r796"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r752", "r762", "r772", "r796", "r804", "r808", "r816"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r814"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "sgry_AncillaryServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "AncillaryServicesMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails", "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Ancillary Services", "terseLabel": "Ancillary Services", "label": "Ancillary Services [Member]", "documentation": "Ancillary Services [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r265"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r29"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r29"] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r8", "r19", "r844", "r845", "r846"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"], "lang": { "en-us": { "role": {
"totalLabel": "Total assets", "verboseLabel": "Assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r154", "r165", "r211", "r239", "r270", "r276", "r294", "r298", "r311", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r451", "r455", "r491", "r541", "r618", "r682", "r683", "r720", "r739", "r900", "r901", "r930"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "verboseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "sgry_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [
"http://www.surgerypartners.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Right-of-use Assets and Liabilities Related to Leases", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r206", "r216", "r239", "r311", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r451", "r455", "r491", "r720", "r900", "r901", "r930"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r811"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r812"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r807"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r810"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r809"] }, "ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r808"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r808"] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [
"http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Organization and Summary of Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r135"] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r329", "r330", "r331", "r332", "r333", "r447", "r705", "r706"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r54", "r55", "r329", "r330", "r331", "r332", "r333", "r447", "r705", "r706"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r447"] }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Recognized non-controlling interests", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date." } } }, "auth_ref": ["r57"] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Start-up costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": ["r53"] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationIntegrationRelatedCosts", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }
}, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction and integration costs", "label": "Business Combination, Integration Related Costs", "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." }
} }, "auth_ref": [] }, "sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.surgerypartners.com/20240930", "localname": "BusinessCombinationIntegrationRelatedCostsAndMergerCosts", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction, integration and acquisition costs", "label": "Business Combination, Integration Related Costs, And Merger Costs", "documentation": "Business Combination, Integration Related Costs, And Merger Costs" } } }, "auth_ref": [] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr":
"debit", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Intangible assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
"documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r56"] },
"sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVentures": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr":

"debit", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments and advances to affiliates", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest, fair value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": ["r11"] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net loss on fair value of non-controlling interest", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss", "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r87", "r88"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r25", "r208", "r670"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r25", "r132", "r238"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r132"] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount estimated to be reclassified as a reduction to interest expense over next 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": ["r86"] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r787"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r784"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r782"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r788"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r788"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.surgerypartners.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r140", "r343", "r344", "r662", "r888", "r893"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r727", "r728", "r729", "r731", "r732", "r733", "r736", "r857", "r858", "r860", "r914", "r968", "r972"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in USD per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r114"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r114", "r606"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r114"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (shares)", "periodStartLabel": "Beginning Balance (shares)", "periodEndLabel": "Ending Balance (shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r114", "r606", "r624", "r972", "r973"] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 127,127,901 and 126,593,727, respectively", "label": "Common Stock, Value, Outstanding", "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares." } } }, "auth_ref": ["r114", "r606"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r793"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r792"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r794"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r791"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"], "lang": { "en-us": {

```
"role": { "totalLabel": "Comprehensive loss attributable to Surgery Partners, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r20", "r224", "r226", "r234", "r538", "r553", "r555" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Comprehensive income attributable to non-controlling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r61", "r72", "r224", "r226", "r233", "r537", "r553", "r554" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive (loss) income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r72", "r148", "r224", "r226", "r232", "r536", "r553" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r32", "r33", "r89", "r90", "r304", "r661" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r32", "r33", "r89", "r90", "r304", "r586", "r661" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r32", "r33", "r89", "r90", "r304", "r661", "r831" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by service type as a proportion of total revenues (percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r32", "r33", "r89", "r90", "r304" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r32", "r33", "r89", "r90", "r304", "r661" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r176", "r188", "r242", "r451", "r452", "r455", "r456", "r521", "r663", "r834", "r837", "r838", "r899", "r902", "r903" ] },
"srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r176", "r188", "r242", "r451", "r452", "r455", "r456", "r521", "r663", "r834", "r837", "r838", "r899", "r902", "r903" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r163", "r176", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r242", "r270", "r278", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r350", "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r359", "r682", "r683", "r835", "r836", "r900", "r901" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r163", "r176", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r242", "r270", "r278", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r350", "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r359", "r682", "r683", "r835", "r836", "r900", "r901" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r62", "r674" ] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interests\u2014Redeemable", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r167" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r58", "r65", "r67" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "All other", "terseLabel": "All other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } },
"auth_ref": [ "r13", "r293", "r294", "r295", "r296", "r299", "r865" ] }, "sgry_CostReportLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "CostReportLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost report liabilities", "label": "Cost Report Liabilities, Current", "documentation": "Cost Report Liabilities, Current" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r349", "r897" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r349", "r897", "r898" ] }, "sgry_CreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "CreditFacilityMember", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Member]", "documentation": "Credit Facility" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.surgerypartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r136", "r304" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure
```

[Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r15", "r104", "r105", "r155", "r156", "r242", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r689", "r690", "r691", "r692", "r693", "r718", "r854", "r889", "r890", "r891", "r926", "r927"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "sgry_DebtInstrumentBasisSpreadOnVariableRateFloor": { "xbrltype": "percentItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DebtInstrumentBasisSpreadOnVariableRateFloor", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread on variable rate, floor", "label": "Debt Instrument, Basis Spread On Variable Rate, Floor", "documentation": "Debt Instrument, Basis Spread On Variable Rate, Floor" } } }, "auth_ref": [] }, "sgry_DebtInstrumentCallPremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DebtInstrumentCallPremiumPercentage", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, call premium percentage", "label": "Debt Instrument, Call Premium Percentage", "documentation": "Debt Instrument, Call Premium Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r15", "r156", "r378"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Original balance of debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r361", "r500", "r501", "r690", "r691", "r718"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r107", "r362"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r242", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r689", "r690", "r691", "r692", "r693", "r718", "r854", "r926", "r927"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r15", "r242", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r689", "r690", "r691", "r692", "r693", "r718", "r854", "r889", "r890", "r891", "r926", "r927"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r15", "r50", "r51", "r91", "r144", "r145", "r242", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r689", "r690", "r691", "r692", "r693", "r718", "r854", "r926", "r927"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: unamortized debt issuance costs and discounts", "terseLabel": "Debt issuance costs and discount", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r367", "r379", "r499", "r500", "r501", "r690", "r691", "r718"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized fair value discount", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": ["r905", "r925", "r926", "r927"] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r430", "r431"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r4", "r173", "r856"] }, "sgry_DeferredPremiumCap1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DeferredPremiumCap1Member", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred premium cap", "label": "Deferred Premium Cap 1 [Member]", "documentation": "Deferred Premium Cap 1" } } }, "auth_ref": [] }, "sgry_DeferredPremiumCap2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DeferredPremiumCap2Member", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred premium cap", "label": "Deferred Premium Cap 2 [Member]", "documentation": "Deferred Premium Cap 2" } } }, "auth_ref": [] }, "sgry_DeferredPremiumCap3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DeferredPremiumCap3Member", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred premium cap", "label": "Deferred Premium Cap 3 [Member]", "documentation": "Deferred Premium Cap 3" } } }, "auth_ref": [] }, "sgry_DeferredPremiumCap4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DeferredPremiumCap4Member", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred premium cap", "label": "Deferred Premium Cap 4 [Member]", "documentation": "Deferred Premium Cap 4" } } }, "auth_ref": [] }, "sgry_DeferredPremiumCap5Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DeferredPremiumCap5Member", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred premium cap", "label": "Deferred Premium Cap 5 [Member]", "documentation": "Deferred Premium Cap 5" } } }, "auth_ref": [] }, "sgry_DeferredPremiumCapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "DeferredPremiumCapMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred premium cap", "label": "Deferred Premium Cap [Member]", "documentation": "Deferred Premium Cap" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r270", "r281", "r298", "r682", "r683"] }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotionalAmount", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, notional amount", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": ["r650", "r653", "r655", "r657", "r909", "r910", "r911"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r596", "r598", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r619", "r620", "r621", "r622", "r631", "r632", "r633", "r634", "r637", "r638", "r639", "r640", "r650", "r652", "r656", "r658", "r727", "r729", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923"] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss recognized in income", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r912"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [

"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r78",
"r80", "r81", "r152", "r596", "r598", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r619", "r620", "r621", "r622", "r631", "r632", "r633", "r634", "r637", "r638", "r639",
"r640", "r650", "r652", "r656", "r658", "r673", "r727", "r729", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923"] }, "us-
gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure
[Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivities"], "lang": { "en-
us": { "role": { "terseLabel": "Derivatives and Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The
entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets,
liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": ["r151", "r462", "r470"] }, "us-
gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit",
"calculation": { "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } },
"presentation": ["http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps", "label": "Derivative
Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional
amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or
normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r217"] }, "us-
gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotionalAmount",
"presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"],
"lang": { "en-us": { "role": { "terseLabel": "Derivative liability, notional amount", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount
used to calculate payments on the derivative liability." } } }, "auth_ref": ["r651", "r653", "r654", "r657", "r909", "r910", "r911"] }, "us-gaap_DerivativeLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label":
"Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r470"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Current notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } },
"auth_ref": ["r910", "r911"] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable",
"presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]",
"label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of
derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r10", "r73", "r74",
"r76", "r77", "r79", "r80", "r82", "r84", "r85", "r470"] }, "us-gaap_DerivativeVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DerivativeVariableInterestRate", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Variable interest rate of derivative instrument (percent)", "label": "Derivative, Variable Interest Rate", "documentation": "Variable interest rate in
effect as of the balance sheet date related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and
Hedging Activities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
} } }, "auth_ref": ["r10", "r73", "r74", "r77", "r83", "r241", "r256"] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Derivatives in cash flow hedging relationships", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument
designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r10"] }, "us-gaap_DisaggregationOfRevenueLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation
of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r392", "r695", "r696", "r697", "r698",
"r699", "r700", "r701"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisaggregationOfRevenueTable", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails"], "lang":
{ "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about
disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref":
["r392", "r695", "r696", "r697", "r698", "r699", "r700", "r701"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal
Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r204"] }, "us-
gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain",
"presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of,
including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-
gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposed
of by Sale", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals
classified as discontinued operations." } } }, "auth_ref": ["r5", "r12"] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax
gain (loss) on disposal", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the
sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": ["r339", "r853", "r884"] },
"sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed": { "xbrltype": "integerItemType", "nsuri": "http://www.surgerypartners.com/20240930",
"localname": "DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of
interests sold", "label": "Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed", "documentation": "Disposal Group, Not Discontinued Operation,
Number Of Businesses Disposed" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal
Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r705", "r706"] },
"dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or
other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFiscalYearFocus", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year
Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also
provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.surgerypartners.com/role/Cover"],
"lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-
K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the
reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": {
"terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } }
}, "auth_ref": ["r743"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentTransitionReport", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report",
"label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r775"] },
"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of
document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } }
}, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total
Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } }
}, "auth_ref": ["r786"] }, "sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.surgerypartners.com/20240930", "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortization", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Adjusted
EBITDA", "label": "Earnings Before Interest Taxes Depreciation And Amortization", "documentation": "Earnings Before Interest Taxes Depreciation And Amortization" } } },
"auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract",
"lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",

"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in USD per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r235", "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r260", "r262", "r263", "r264", "r269", "r445", "r449", "r472", "r473", "r539", "r556", "r675"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in USD per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r235", "r248", "r249", "r250", "r251", "r252", "r253", "r260", "r262", "r263", "r264", "r269", "r445", "r449", "r472", "r473", "r539", "r556", "r675"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r29", "r30", "r266"] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders:", "verboseLabel": "Net loss per share attributable to common stockholders:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r257", "r265", "r267", "r268"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r434", "r708"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (benefits) related to vesting of restricted stock awards", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": ["r826", "r907", "r908"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r105"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r741"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r741"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r741"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r825"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r741"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r741"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r741"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r741"] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r780"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r821"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r821"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r821"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component

[Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r201", "r228", "r229", "r230", "r243", "r244", "r245", "r247", "r252", "r254", "r256", "r271", "r312", "r313", "r338", "r382", "r439", "r440", "r442", "r443", "r444", "r446", "r448", "r449", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r492", "r494", "r495", "r496", "r497", "r498", "r502", "r505", "r520", "r552", "r579", "r580", "r581", "r594", "r643"] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Loss on sale of equity method investment", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": ["r848", "r849", "r853"] }, "us-gaap_EquityMethodInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsMember", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments [Member]", "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r790"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r748", "r758", "r768", "r800"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r745", "r755", "r765", "r797"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r369", "r490", "r690", "r691"] }, "us-gaap_EstimatedInsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimatedInsuranceRecoveries", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Estimated insurance recoveries", "label": "Estimated Insurance Recoveries", "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts." } } }, "auth_ref": ["r842"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r796"] }, "sgry_FacilitiesAmbulatorySurgeryCentersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "FacilitiesAmbulatorySurgeryCentersMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Facilities, Ambulatory Surgery Centers", "label": "Facilities, Ambulatory Surgery Centers [Member]", "documentation": "Facilities, Ambulatory Surgery Centers [Member]" } } }, "auth_ref": [] }, "sgry_FacilitiesSurgicalHospitalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "FacilitiesSurgicalHospitalsMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Facilities, Surgical Hospitals", "label": "Facilities, Surgical Hospitals [Member]", "documentation": "Facilities, Surgical Hospitals [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r479", "r480", "r481", "r482", "r483", "r484", "r487", "r713"] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r479", "r480", "r481", "r482", "r483", "r484", "r487", "r713"] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r87", "r88"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r369", "r394", "r395", "r396", "r397", "r398", "r399", "r474", "r475", "r476", "r477", "r478", "r485", "r486", "r488", "r522", "r523", "r524", "r690", "r691", "r702", "r703", "r704", "r711", "r714"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r369", "r690", "r691"] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": ["r369", "r690", "r691"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r369", "r394", "r399", "r475", "r476", "r486", "r523", "r690", "r691", "r702", "r703", "r704", "r711"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r369", "r394", "r395", "r396", "r397", "r398", "r399", "r474", "r475", "r476", "r477", "r478", "r485", "r486", "r488", "r522", "r523", "r524", "r690", "r691", "r702", "r703", "r704", "r711", "r714"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r6"] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Federal Funds Effective Swap Rate", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": ["r913"] }, "sgry_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total finance lease costs", "label": "Finance Lease, Cost", "documentation": "Finance Lease, Cost" } } }, "auth_ref": [] }, "sgry_FinanceLeaseCost1Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "FinanceLeaseCost1Abstract", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease costs:", "label": "Finance Lease, Cost1 [Abstract]", "documentation": "Finance Lease, Cost1 [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails": { "parentTag": "sgry_FinanceLeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": ["r509", "r515", "r719"] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating cash outflows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": ["r511", "r517"] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 2.0 }, "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "sgry_LeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease obligations", "totalLabel": "Total finance lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r507", "r519"] }, "us-gaap_FinanceLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityAbstract", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities:", "label": "Finance Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability",

"weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r507"] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": ["r508"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r507"] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": ["r508"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financing cash outflows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r510", "r517"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "sgry_LeaseRightOfUseAsset", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease assets", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r506"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails": { "parentTag": "sgry_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of leased assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r509", "r515", "r719"] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": ["r508"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r328", "r329", "r330", "r331", "r333", "r334", "r335", "r336", "r532", "r533", "r666"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r328", "r329", "r330", "r331", "r333", "r334", "r335", "r336", "r666"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r785"] }, "sgry_GainLossOnDispositionOfAssetsAndDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "GainLossOnDispositionOfAssetsAndDeconsolidation", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 1.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Net loss on disposals, consolidations and deconsolidations", "negatedTerseLabel": "Net loss on disposals, consolidations and deconsolidations", "label": "Gain (Loss) On Disposition Of Assets And Deconsolidation", "documentation": "Gain (Loss) On Disposition of Assets And Deconsolidation" } } }, "auth_ref": [] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Litigation settlements", "terseLabel": "(Loss) gain on litigation settlement", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": ["r682", "r894"] }, "sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Litigation settlements and regulatory change impact", "label": "Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact", "documentation": "Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on debt extinguishment", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r4", "r46", "r47"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r125", "r628"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Goodwill, beginning of period", "periodEndLabel": "Goodwill, end of period", "verboseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r209", "r317", "r534", "r683", "r688", "r712", "r720", "r874", "r881"] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions, including post acquisition adjustments", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": ["r320", "r688"] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": ["r316", "r327", "r688"] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "GoodwillRollForward", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Goodwill, Written off Related to Sale of Business Unit", "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r322", "r688"] }, "sgry_GovernmentRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "GovernmentRevenueMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Government", "label": "Government Revenue [Member]", "documentation": "Government Revenue [Member]" } } }, "auth_ref": [] }, "sgry_HealthcareOrganizationPatientServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "HealthcareOrganizationPatientServiceMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total patient service revenues", "label": "Healthcare Organization, Patient Service [Member]", "documentation": "Healthcare Organization, Patient Service [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r10", "r461"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r10"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": ["r240", "r433"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in earnings of unconsolidated affiliates", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r4", "r121", "r159", "r270", "r283", "r298", "r310", "r548"] }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in earnings of unconsolidated affiliates, net of distributions received", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities." } } }, "auth_ref": ["r4"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r705", "r706"] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r7", "r12", "r17", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r139"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax (expense) benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r166", "r174", "r255", "r256", "r270", "r284", "r298", "r432", "r434", "r441", "r558", "r708"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r227", "r428", "r429", "r435", "r436", "r437", "r438", "r588"] }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationDispositionOfBusiness", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Effective income tax rate reconciliation, disposition of business, amount", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation." } } }, "auth_ref": ["r907", "r908"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] },
"sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Medicare accelerated payments and deferred governmental grants", "label": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants", "documentation": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and divestitures:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other operating assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r752", "r762", "r772", "r796", "r804", "r808", "r816"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r814"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r744", "r820"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r744", "r820"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r744", "r820"] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangible assets, net", "label": "Intangible Assets, Net (Including Goodwill)", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets." } } }, "auth_ref": ["r872"] }, "sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "InterestExpenseImpactOfChangeInLetterOfProtectionRegulation", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional interest expense for Florida LOP regulation change", "label": "Interest Expense, Impact Of Change In Letter Of Protection Regulation", "documentation": "Interest Expense, Impact Of Change In Letter Of Protection Regulation" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "negatedTerseLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r682", "r850", "r864"] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest payable", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r105"] }, "us-gaap_InterestRateCapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCapMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate caps (2)", "label": "Interest Rate Cap [Member]", "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount." } } }, "auth_ref": ["r668"] }, "sgry_InterestRateCapOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "InterestRateCapOneMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap", "label": "Interest Rate Cap One [Member]", "documentation": "Interest Rate Cap One" } } }, "auth_ref": [] }, "sgry_InterestRateCapTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "InterestRateCapTwoMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap", "label": "Interest Rate Cap Two [Member]", "documentation": "Interest Rate Cap Two" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": ["r668", "r734", "r735"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r213", "r671", "r720"] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Investments in and advances to affiliates", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": ["r843"] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Salaries and benefits", "label": "Labor and Related Expense", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": ["r847"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r514", "r719"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.surgerypartners.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense and Cash Flow Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r929"] }, "sgry_LeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "LeaseLiability", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Lease, Liability", "documentation": "Lease, Liability" } } }, "auth_ref": [] }, "sgry_LeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "LeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total leased assets", "label": "Lease, Right-Of-Use Asset", "documentation": "Lease, Right-of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": ["http://www.surgerypartners.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": ["r504"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r513"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.surgerypartners.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r504"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding letters of credit", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r15", "r104", "r105", "r106", "r109", "r110", "r111", "r112", "r239", "r311", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r452", "r455", "r456", "r491", "r605", "r676", "r739", "r900", "r930", "r931"] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": ["http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r119", "r158", "r547", "r720", "r855", "r871", "r924"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r106", "r207", "r239", "r311", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r452", "r455", "r456",

```
"r491", "r720", "r900", "r930", "r931" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding balance on debt", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r103", "r108", "r349" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other litigation costs", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r833" ] }, "sgry_LoanAmortizationRate": { "xbrltype": "percentItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "LoanAmortizationRate", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan amortization rate", "label": "Loan Amortization Rate", "documentation": "Loan Amortization Rate" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.surgerypartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r15", "r156", "r368", "r380", "r690", "r691", "r718", "r938" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 2.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, less current maturities", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r15", "r542" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 1.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt", "verboseLabel": "Less: current maturities", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r105" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r141" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15", "r889", "r890", "r891" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r45", "r889", "r890", "r891" ] }, "sgry_ManagementRightsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "ManagementRightsAgreementMember", "presentation": [ "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management Rights Agreement", "label": "Management Rights Agreement [Member]", "documentation": "Management Rights Agreement" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r788" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r788" ] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidations" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions, Disposals and Deconsolidations", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r92", "r147" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r199", "r200", "r345", "r346", "r347", "r348", "r400", "r427", "r478", "r530", "r577", "r578", "r585", "r597", "r598", "r646", "r647", "r648", "r649", "r659", "r664", "r665", "r687", "r694", "r707", "r714", "r715", "r716", "r722", "r904", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests\u2014non-redeemable", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r118", "r157", "r239", "r311", "r350", "r353", "r354", "r355", "r359", "r360", "r491", "r546", "r608" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to non-controlling interests\u2014non-redeemable holders", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r146" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r807" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r815" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r789" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r237" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r237" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
```

gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r132", "r133", "r134"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Surgery Partners, Inc.", "verboseLabel": "Net loss attributable to Surgery Partners, Inc.", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r123", "r134", "r161", "r205", "r222", "r225", "r230", "r239", "r246", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r261", "r311", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r445", "r449", "r473", "r491", "r551", "r626", "r641", "r642", "r737", "r900"] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Net income attributable to non-controlling interests", "negatedLabel": "Net income attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r71", "r149", "r222", "r225", "r252", "r255", "r256", "r550", "r846"] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to non-controlling interests\u2014redeemable", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref": ["r122"] }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity." } } }, "auth_ref": ["r16", "r149", "r150"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and disposal of shares of non-controlling interests, net", "label": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net", "documentation": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r788"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r752", "r762", "r772", "r796", "r804"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r779"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r778"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r796"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r815"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r815"] }, "sgry_NoncashInterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "NoncashInterestIncomeExpenseNet", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash interest expense, net", "label": "Noncash Interest Income (Expense), Net", "documentation": "Noncash Interest Income (Expense), Net" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncash consideration", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future." } } }, "auth_ref": ["r26", "r27", "r28"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interests\u2014 Non-Redeemable", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r59", "r382", "r857", "r858", "r859", "r860", "r972"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r10"] },
"sgry_NotesPayableAndSecuredLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "NotesPayableAndSecuredLoansMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes payable and other secured loans", "label": "Notes Payable and Secured Loans [Member]", "documentation": "Notes Payable and Secured Loans [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfBusinessesAcquired", "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of business entities acquired", "label": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of interest rate swaps held", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": ["r75", "r76"] }, "sgry_NumberOfNonControllingInterestsAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "NumberOfNonControllingInterestsAcquired", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of non-controlling interests in in-development de novo surgical facilities acquired", "label": "Number Of Non-Controlling Interests Acquired", "documentation": "Number Of Non-Controlling Interests Acquired" } } }, "auth_ref": [] }, "sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of non-controlling interests in surgical facilities acquired", "label": "Number Of Non-Controlling Interests In Surgical Facilities Acquired", "documentation": "Number Of Non-Controlling Interests In Surgical Facilities Acquired" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r683", "r863"] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of states in which entity operates", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "sgry_NumberOfSurgicalFacilitiesOwned": { "xbrltype": "integerItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "NumberOfSurgicalFacilitiesOwned", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of surgical

```
facilities owned", "label": "Number of Surgical Facilities Owned", "documentation": "Number of Surgical Facilities Owned" } } }, "auth_ref": [] },
"sgry_NumberOfSurgicalFacilitiesOwnedConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname":
"NumberOfSurgicalFacilitiesOwnedConsolidated", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Number of surgical facilities owned, consolidated", "label": "Number Of Surgical Facilities Owned, Consolidated", "documentation":
"Number of Surgical Facilities Owned, Consolidated" } } }, "auth_ref": [] }, "sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest": { "xbrltype": "integerItemType", "nsuri":
"http://www.surgerypartners.com/20240930", "localname": "NumberOfSurgicalFacilitiesOwnedMajorityInterest", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of surgical
facilities owned, majority interest", "label": "Number Of Surgical Facilities Owned, Majority Interest", "documentation": "Number of Surgical Facilities Owned, Majority
Interest" } } }, "auth_ref": [] }, "us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
"xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "OCI,
Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in
statement of income or comprehensive income that includes reclassification from accumulated other comprehensive income (AOCI) for gain (loss) recognized in other
comprehensive income (OCI) from discontinuance of cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r459", "r460" ] },
"sgry_OperatingAndFinanceLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname":
"OperatingAndFinanceLeaseExpense", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease expense", "label":
"Operating And Finance Lease, Expense", "documentation": "Operating And Finance Lease, Expense" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }
}, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Cost of
revenues", "label": "Operating Costs and Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses
which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order":
1.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total
operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses
which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label":
"Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "label":
"Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r164", "r677",
"r862", "r864", "r866", "r867", "r868" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails": { "parentTag":
"us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of
remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of
remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r516", "r719" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": {
"role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } },
"auth_ref": [ "r928" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability",
"crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag":
"sgry_LeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel":
"Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating
lease." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilityAbstract", "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease liabilities:", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "us-
gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-
gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails",
"http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "verboseLabel": "Right-of-use operating lease
liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified
as current." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position
[Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r508" ]
}, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag":
"us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 },
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "us-
gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel":
"Right-of-use operating lease liabilities", "terseLabel": "Long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted
obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash outflows
from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to
condition and location necessary for its intended use." } } }, "auth_ref": [ "r512", "r517" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "sgry_LeaseRightOfUseAsset",
"weight": 1.0, "order": 1.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order":
2.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel":
"Right-of-use operating lease assets", "terseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use
underlying asset under operating lease." } } }, "auth_ref": [ "r506" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating
Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn
revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r299", "r682", "r683"
] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of
Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } },
"presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets",
"label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r215", "r720" ] }, "us-gaap_OtherAssetsNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other
Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r210" ] }, "us-
gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative
activity, net of tax of $0", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax
and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [
"r218", "r219", "r552" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "lang": { "en-us": { "role": {
```

"terseLabel": "Derivative activity, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r220"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in OCI (effective portion)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r218", "r219", "r457", "r458", "r463"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss reclassified from accumulated OCI into income (effective portion)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r172", "r219", "r221"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of accumulated OCI related", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r459"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r9", "r14", "r223", "r226", "r231", "r252", "r492", "r493", "r498", "r535", "r552", "r844", "r845"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Other operating expenses", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": ["r124", "r557", "r682"] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": ["http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Total", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [
"r105", "r720"] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities Disclosure [Abstract]", "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": ["http://www.surgerypartners.com/role/OtherCurrentLiabilities"], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": ["r105", "r110", "r887"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r110"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r126"] }, "us-gaap_OtherNonrecurringIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringIncomeExpense", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonrecurring (Income) Expense", "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature." } } }, "auth_ref": ["r127"] }, "sgry_OtherPatientServiceRevenueSourcesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "OtherPatientServiceRevenueSourcesMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Patient Service Revenue Sources [Member]", "documentation": "Other Patient Service Revenue Sources [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r788"] }, "sgry_OtherServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "OtherServicesMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Other service revenues", "label": "Other Services [Member]", "documentation": "Other Services [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r750", "r760", "r770", "r802"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r753", "r763", "r773", "r805"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [
"r753", "r763", "r773", "r805"] }, "sgry_PayFixedSwapOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "PayFixedSwapOneMember", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pay-fixed swap", "label": "Pay-fixed Swap One [Member]", "documentation": "Pay-fixed Swap One Member" } } }, "auth_ref": [] }, "sgry_PayFixedSwapThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "PayFixedSwapThreeMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pay-fixed swap", "label": "Pay-fixed Swap Three [Member]", "documentation": "Pay-fixed Swap Three Member" } } }, "auth_ref": [] }, "sgry_PayFixedSwapTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "PayFixedSwapTwoMember", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pay-fixed swap", "label": "Pay-fixed Swap Two [Member]", "documentation": "Pay-fixed Swap Two Member" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r777"] }, "srt_PayablesToCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PayablesToCustomers", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.surgerypartners.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amounts due to patients and payors", "label": "Broker-Dealer, Payable to Customer", "documentation": "Amount payable to customer by broker-dealer." } } }, "auth_ref": ["r839"] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": ["r827", "r851"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r24"] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to non-controlling interest holders", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": ["r130"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails",
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for

acquisitions, net of cash acquired", "terseLabel": "Total cash consideration, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r22"] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of equity investments", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": ["r22"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r129"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r787"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r787"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r779"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r796"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r789"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r778"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r780"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r824"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r779"] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r489"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in USD per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r113", "r381"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r113", "r606"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r113", "r381"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r113", "r606", "r624", "r972", "r973"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r113", "r543", "r720"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r214", "r314", "r315", "r672"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r841"] }, "sgry_PrivateInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "PrivateInsuranceMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Private insurance", "label": "Private Insurance [Member]", "documentation": "Private Insurance [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Borrowings of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r23", "r589"] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": ["r828", "r852"] }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsToMinorityShareholders", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds related to ownership transactions with non-controlling interest holders", "label": "Proceeds from (Payments to) Noncontrolling Interests", "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails", "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of equity investments", "label": "Proceeds from Sale of Equity Method Investments", "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": ["r21"] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails", "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposals of facilities and other assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r128"] }, "sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "ProceedsFromTerminatedDerivativeInstrumentOperatingActivities", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain on termination", "label": "Proceeds from Terminated Derivative Instrument, Operating Activities", "documentation": "Proceeds from Terminated Derivative Instrument, Operating Activities" } } }, "auth_ref": [] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Source", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": ["r137"] }, "us-gaap_ProductInformationLineItems": { "xbrltype":

"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." }
} }, "auth_ref": ["r182", "r183", "r184", "r185", "r186", "r187", "r198", "r301", "r531", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r669", "r695", "r721", "r722",
"r723", "r725", "r726", "r840", "r895", "r896", "r906", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953",
"r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967"] }, "srt_ProductsAndServicesDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } },
"auth_ref": ["r182", "r183", "r184", "r185", "r186", "r187", "r198", "r301", "r531", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r669", "r695", "r721", "r722", "r723",
"r725", "r726", "r840", "r895", "r896", "r906", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954",
"r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0,
"order": 3.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": {
"terseLabel": "Professional and medical fees", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and
accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } },
"auth_ref": ["r682", "r737", "r970", "r971"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss",
"crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0, "order": 1.0 }, "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 },
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel":
"Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of
income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r205", "r222", "r225", "r236", "r239", "r246", "r252", "r255", "r256",
"r311", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r445", "r449", "r450", "r453", "r454", "r473", "r491", "r540", "r549", "r593", "r626", "r641",
"r642", "r709", "r710", "r738", "r846", "r900"] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated depreciation
on property and equipment", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation":
"Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": ["r829", "r832",
"r886"] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr":
"debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }
}, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Property and
equipment, net of accumulated depreciation of $558.8 and $454.4, respectively", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after
Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance
lease right-of-use asset." } } }, "auth_ref": ["r832", "r885"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance
Disclosure [Table]" } } }, "auth_ref": ["r777"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label":
"Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r777"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RangeAxis", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum,
maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r177", "r178", "r179", "r180", "r181", "r199", "r200", "r345", "r346", "r347", "r348", "r393",
"r400", "r423", "r424", "r425", "r427", "r478", "r525", "r529", "r530", "r577", "r578", "r585", "r597", "r598", "r646", "r647", "r648", "r649", "r659", "r664", "r665", "r687",
"r694", "r707", "r714", "r715", "r716", "r717", "r722", "r729", "r892", "r904", "r915", "r933", "r934", "r935", "r936", "r937"] }, "srt_RangeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]",
"label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic
average, and median." } } }, "auth_ref": ["r177", "r178", "r179", "r180", "r181", "r199", "r200", "r345", "r346", "r347", "r348", "r393", "r400", "r423", "r424", "r425", "r427",
"r478", "r525", "r529", "r530", "r577", "r578", "r585", "r597", "r598", "r646", "r647", "r648", "r649", "r659", "r664", "r665", "r687", "r694", "r707", "r714", "r715", "r716",
"r717", "r722", "r729", "r892", "r904", "r915", "r933", "r934", "r935", "r936", "r937"] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label":
"Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing
receivable." } } }, "auth_ref": ["r306", "r307", "r308", "r309", "r870"] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
"presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"], "lang": { "en-
us": { "role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "label": "Reclassification Adjustment out of
Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r230"] }, "us-
gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "label": "Reclassification Adjustment out of
Accumulated Other Comprehensive Income on Derivatives [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r230"] }, "us-
gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails",
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income
[Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r230"] }, "us-
gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingTables"], "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Reconciliation of Assets from Segment to Consolidated", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text
Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated
assets." } } }, "auth_ref": ["r42", "r43"] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Revenue and Operating Income", "label":
"Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from
reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after
income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r41", "r43"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of
Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r745", "r755", "r765", "r797"] },
"sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.surgerypartners.com/20240930", "localname": "RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit",
"presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails"], "lang": { "en-us": {
"role": { "negatedTerseLabel": "Distributions to non-controlling interest \u2014redeemable holders", "label": "Redeemable Noncontrolling Interest, Decrease From
Distributions To Noncontrolling Interest Holders", "documentation": "Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders" }
} }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0
} }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Non-controlling interests\u2014redeemable", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Redeemable
Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are
redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon
occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership)
regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": ["r48", "r49",

"r142", "r143"] }, "sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and disposal of shares of non-controlling interests, net\u2014redeemable", "label": "Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests", "documentation": "Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests" } } }, "auth_ref": [] }, "sgry_RedeemableNoncontrollingInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "RedeemableNoncontrollingInterestRollForward", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNonControllingInterestsRedeemableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interests - Redeemable [Roll Forward]", "label": "Redeemable Noncontrolling Interest [Roll Forward]", "documentation": "Redeemable Noncontrolling Interest [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rollforward of Non-Controlling Interests - Redeemable", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r131", "r590"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r746", "r756", "r766", "r798"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r747", "r757", "r767", "r799"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r754", "r764", "r774", "r806"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Restricted shares", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r29"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Retained deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r116", "r146", "r545", "r582", "r584", "r591", "r607", "r720"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Retained Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r201", "r243", "r244", "r245", "r247", "r252", "r254", "r256", "r312", "r313", "r338", "r439", "r440", "r442", "r443", "r444", "r446", "r448", "r449", "r464", "r466", "r467", "r469", "r471", "r502", "r505", "r579", "r581", "r594", "r972"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r162", "r163", "r270", "r277", "r278", "r292", "r298", "r301", "r303", "r304", "r391", "r392", "r531"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r175", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r667"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": ["r518", "r719"] }, "sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract", "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Obligations [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Obligations" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r518", "r719"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r815"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r815"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails",
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r304", "r830"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r54", "r55", "r447"] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amounts and Fair Values of Long-Term Debt", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": ["r79"] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [
"http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r10", "r73", "r74", "r76", "r77", "r79", "r80", "r82", "r84"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.surgerypartners.com/role/EarningsPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Numerator and Denominator of

Basic and Diluted Earnings per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r861"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Rollforward of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r688", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883"] }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "presentation": ["http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Interest Rate Swaps", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Information [Table]", "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r38", "r39", "r40"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Information by Reportable Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r38", "r39", "r40"] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities [Table]", "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": ["r63", "r64", "r66", "r68", "r69", "r451", "r452", "r455", "r456", "r526", "r527", "r528"] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": ["r31", "r32", "r33", "r34", "r89", "r153"] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r913"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r740"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.surgerypartners.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r742"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r162", "r163", "r164", "r165", "r270", "r273", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r304", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r337", "r341", "r342", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r679", "r682", "r683", "r688", "r724", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967"] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total cash purchases of property and equipment", "label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": ["r270", "r287", "r298", "r682", "r683"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.surgerypartners.com/role/SegmentReporting"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r165", "r270", "r272", "r273", "r274", "r275", "r276", "r288", "r290", "r291", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r678", "r680", "r681", "r682", "r684", "r685", "r686"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails", "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract", "presentation": ["http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Adjusted EBITDA:", "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReserve", "crdr": "credit", "presentation": ["http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Professional, general and workers' compensation insurance reserve", "label": "Self Insurance Reserve", "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": ["r110"] }, "sgry_SelfPayRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SelfPayRevenueMember", "presentation": ["http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRevenuesbySourcesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Self-pay", "label": "Self-Pay Revenue [Member]", "documentation": "Self-Pay Revenue [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "sgry_SeniorUnsecuredNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SeniorUnsecuredNotesDue2025Member", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "6.750% senior unsecured notes due 2025", "label": "Senior Unsecured Notes Due 2025 [Member]", "documentation": "Senior Unsecured Notes Due 2025 [Member]" } } }, "auth_ref": [] }, "sgry_SeniorUnsecuredNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SeniorUnsecuredNotesDue2027Member", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails", "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "10.000% senior unsecured notes due 2027", "label": "Senior Unsecured Notes, Due 2027 [Member]", "documentation": "Senior Unsecured Notes, Due 2027 [Member]" } } }, "auth_ref": [] }, "sgry_SeniorUnsecuredNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SeniorUnsecuredNotesDue2032Member", "presentation": ["http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails", "http://www.surgerypartners.com/role/LongTermDebtScheduleofLongTermDebtDetails",

```
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "7.250% senior unsecured notes due 2032", "label": "Senior Unsecured Notes Due 2032 [Member]", "documentation": "Senior Unsecured Notes Due 2032" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r162", "r163", "r164", "r165", "r203", "r270", "r273", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r304", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r337", "r340", "r341", "r342", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r679", "r682", "r683", "r688", "r724", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r114", "r117", "r118", "r201", "r228", "r229", "r230", "r243", "r244", "r245", "r247", "r252", "r254", "r256", "r271", "r312", "r313", "r338", "r382", "r439", "r440", "r442", "r443", "r444", "r446", "r448", "r449", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r492", "r494", "r495", "r496", "r497", "r498", "r502", "r505", "r520", "r552", "r579", "r580", "r581", "r594", "r643" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r243", "r244", "r245", "r271", "r505", "r531", "r587", "r595", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r619", "r620", "r621", "r622", "r623", "r625", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r643", "r730" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r243", "r244", "r245", "r271", "r305", "r505", "r531", "r587", "r595", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r619", "r620", "r621", "r622", "r623", "r625", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r643", "r730" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r749", "r759", "r769", "r801" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation (shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r9", "r113", "r114", "r146" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r52", "r113", "r114", "r146" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Surgery Partners, Inc. stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r114", "r117", "r118", "r138", "r608", "r624", "r644", "r645", "r720", "r739", "r855", "r871", "r924", "r972" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r59", "r60", "r70", "r201", "r202", "r229", "r243", "r244", "r245", "r247", "r252", "r254", "r312", "r313", "r338", "r382", "r439", "r440", "r442", "r443", "r444", "r446", "r448", "r449", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r492", "r494", "r498", "r503", "r520", "r580", "r581", "r592", "r608", "r624", "r644", "r645", "r660", "r738", "r855", "r871", "r924", "r972" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SuppliesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SuppliesExpense", "crdr": "debit", "calculation": {
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplies", "label": "Supplies Expense", "documentation": "Amount of expense associated with supplies that were used during the current accounting period." } } }, "auth_ref": [ "r160" ] }, "sgry_SurgicalFacilitiesAndAnesthesiaPracticeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilitiesAndAnesthesiaPracticeMember", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Facilities and Anesthesia Practice", "label": "Surgical Facilities And Anesthesia Practice [Member]", "documentation": "Surgical Facilities And Anesthesia Practice" } } }, "auth_ref": [] }, "sgry_SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilitiesMember", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails",
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Facilities and In-Development De Novo Surgical Facilities", "label": "Surgical Facilities and In-Development De Novo Surgical Facilities [Member]", "documentation": "Surgical Facilities and In-Development De Novo Surgical Facilities" } } }, "auth_ref": [] }, "sgry_SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilitiesAndInDevelopmentDeNovoSurgicalFacilityMember", "presentation": [ "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Facilities And In-Development De Novo Surgical Facility", "label": "Surgical Facilities And In-Development De Novo Surgical Facility [Member]", "documentation": "Surgical Facilities And In-Development De Novo Surgical Facility" } } }, "auth_ref": [] }, "sgry_SurgicalFacilitiesAndPhysicianPracticesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilitiesAndPhysicianPracticesMember", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Facilities and Physician Practices", "label": "Surgical Facilities And Physician Practices [Member]", "documentation": "Surgical Facilities And Physician Practices" } } }, "auth_ref": [] }, "sgry_SurgicalFacilityEquityMethodInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilityEquityMethodInvestmentMember", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Facility, Equity Method Investment", "label": "Surgical Facility, Equity Method Investment [Member]", "documentation": "Surgical Facility, Equity Method Investment" } } }, "auth_ref": [] }, "sgry_SurgicalFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilityMember", "presentation": [ "http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Facility", "label": "Surgical Facility [Member]", "documentation": "Surgical Facility" } } }, "auth_ref": [] }, "sgry_SurgicalFacilityServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname": "SurgicalFacilityServicesMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
"http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical
```

```
Facility Services", "label": "Surgical Facility Services [Member]", "documentation": "Surgical Facility Services [Member]" } } }, "auth_ref": [] },
"sgry_SurgicalFacilityWithARetainedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname":
"SurgicalFacilityWithARetainedInterestMember", "presentation": [
"http://www.surgerypartners.com/role/AcquisitionsDisposalsandDeconsolidationsDisposalsandDeconsolidationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical
Facility With A Retained Interest", "label": "Surgical Facility With A Retained Interest [Member]", "documentation": "Surgical Facility With A Retained Interest" } } },
"auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } },
"auth_ref": [ "r795" ] }, "sgry_TermRateBasedSecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.surgerypartners.com/20240930", "localname": "TermRateBasedSecuredOvernightFinancingRateSOFRMember", "presentation": [
"http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Rate Based Secured Overnight Financing Rate
(SOFR)", "label": "Term Rate Based Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Term Rate Based Secured Overnight Financing Rate (SOFR)" } }
}, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder
Return Amount" } } }, "auth_ref": [ "r787" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total
Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r794" ] }, "ecd_TradingArrAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang":
{ "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r814" ] }, "ecd_TradingArrByIndTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r816" ] },
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.surgerypartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of
an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label":
"Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r817" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement
Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r818" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r818" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r816" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r816" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r819" ] },
"ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" }
} }, "auth_ref": [ "r817" ] }, "sgry_UndesignatedDerivativeActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname":
"UndesignatedDerivativeActivity", "crdr": "credit", "presentation": [
"http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Undesignated derivative activity", "label": "Undesignated Derivative Activity", "documentation": "Undesignated Derivative Activity" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label":
"Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r813" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" ], "lang": { "en-
us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of
estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r35", "r36", "r37", "r168", "r169",
"r170", "r171" ] }, "sgry_VariableAndShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.surgerypartners.com/20240930", "localname":
"VariableAndShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails": {
"parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.surgerypartners.com/role/LeasesScheduleofLeaseExpenseandCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable and short-term
lease costs", "label": "Variable And Short-Term Lease, Cost", "documentation": "Variable And Short-Term Lease, Cost" } } }, "auth_ref": [] }, "us-
gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation":
[ "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable
Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r451", "r452", "r455", "r456",
"r526", "r527", "r528" ] }, "sgry_VariableInterestEntityNumberOfFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.surgerypartners.com/20240930",
"localname": "VariableInterestEntityNumberOfFacilities", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
facilities included in VIE", "label": "Variable Interest Entity, Number Of Facilities", "documentation": "Variable Interest Entity, Number of Facilities" } } }, "auth_ref": [] }, "us-
gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [
"http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable
Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity
has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the
entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that
could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary
beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r63", "r451", "r452", "r455", "r456" ] }, "us-gaap_VariableRateAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [
"http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]",
"documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark
interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted
and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r783" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": {
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails": { "parentTag":
null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Diluted (shares)", "totalLabel": "Diluted (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation":
"The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of
issuance of shares or units in the period." } } }, "auth_ref": [ "r259", "r264" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "calculation": {
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails": { "parentTag":
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Basic (shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after
adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period
that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r258", "r264" ] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [
"http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.surgerypartners.com/role/EarningsPerShareScheduleofReconciliationofNumeratorandDenominatorofBasicandDilutedEarningsperShareDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Weighted average common shares outstanding:", "verboseLabel": "Weighted average common shares outstanding:", "label": "Weighted Average
Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding
and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r781" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230",
"Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r3": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
```

"45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(3)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Paragraph": "2AA", "Subparagraph": "(a)", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r142": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r281": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",

"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Rule 15c3-1", "Number": "240", "Section": "15c3-1", "Publisher": "SEC" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r877": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r938": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 70 0001638833-24-000147-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001638833-24-000147-xbrl.zip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

"